Genetically modified organisms for production of psychotropic alkaloids
Through genetic engineering and modification technology of fungal cells, the problem of low alkaloid yield of psychotropic drugs has been solved, and a significant increase in alkaloid yield and industrial production has been achieved, providing an effective treatment plan for mental health disorders.
Patent Information
- Application Number
- CN202280092993.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-12-31
- Filing Date
- 2022-12-30
- Publication Date
- 2024-11-19
AI Technical Summary
Prior art is difficult to effectively produce psychotropic alkaloids such as psilocybin and N,N-dimethyltryptamine, and these alkaloids are produced in trace amounts only by a limited number of fungal species, leading to the challenge of treating mental health disorders. .
Through genetic engineering of fungal cells, genetic modification technology is used to enhance the expression of PsiD gene and hygromycin resistance gene, inhibit or eliminate the expression of psilocybin phosphatase, increase the expression of L-tryptophan decarboxylase, and thus change the organism Synthetic pathways to increase the yield of psilocybin and its derivatives.
Significantly increasing the yield of psilocybin and other psychotropic alkaloids, providing a low-cost source of alkaloids, enhancing the availability of therapeutic uses, and achieving industrial production of these rare alkaloids.
Smart Images

Figure CN118984868A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 63 / 295,735 filed on December 31, 2021, U.S. Provisional Application No. 63 / 295,739 filed on December 31, 2021, U.S. Provisional Application No. 63 / 295,742 filed on December 31, 2021, and U.S. Provisional Application No. 63 / 295,723 filed on December 31, 2021, the entire contents of each of which are hereby incorporated by reference in their entirety.
[0003] background
[0004] The World Health Organization estimates that more than 400 million people in the United States suffer from mental health disorders, such as severe depression, anxiety, obsessive-compulsive disorder, and addiction. Although there is no generally effective treatment or cure for mental health disorders, certain alkaloids produced by fungi have shown promising results in achieving positive therapeutic outcomes. Psychotropic alkaloids such as psilocybin, N,N-dimethyltryptamine (DMT), and dephosphorylated psilocybin have promising therapeutic properties for treating mental health disorders (including severe depression, anxiety, obsessive-compulsive disorder, and addiction). Unfortunately, the feasibility of industrial production of such alkaloids has not yet been achieved. Psychotropic alkaloids are only produced in trace amounts by a limited number of fungal species. Therefore, the synthetic production of fungus-derived alkaloids is currently a challenge. Therefore, there is a need for providing compositions, methods, devices, and systems for the production of enhanced therapeutically relevant fungus-derived alkaloids.
[0005] Incorporated by Reference
[0006] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. Unless otherwise indicated, the publications, patents, and patent applications mentioned in this specification are incorporated herein by reference in their entirety.
[0007] Brief Description
[0008] The present disclosure relates to non-natural organisms having biosynthetic pathways that are genetically engineered to produce one or more desired alkaloids compared to comparable wild-type organisms. The present disclosure also relates to methods for preparing genetically modified organisms that are rich in one or more alkaloids compared to comparable non-genetically modified organisms. The genetically modified organisms described herein can have a biochemical phenotype with pharmaceutically relevant alkaloids and pharmaceutically relevant alkaloid combinations that can be used to treat certain diseases and conditions, including mental health disorders. In addition, the genetically modified organisms disclosed herein can promote the industrial production of alkaloids by providing an effective and low-cost source from which alkaloids can be isolated, thereby increasing the availability of originally rare alkaloids for therapeutic purposes.
[0009] In some embodiments, the engineered fungal cell comprises a first genetic modification and a second genetic modification, wherein the first genetic modification results in reduced expression of a PsiD gene product; and the second genetic modification results in increased expression of a protein encoded by a hygromycin resistance gene. In some embodiments, the first genetic modification comprises a modification of a promoter operably linked to the PsiD gene. In some embodiments, the first genetic modification comprises a genetic modification that induces a frameshift in the PsiD gene, such that when the PsiD gene is transcribed and translated, the protein expressed by the PsiD gene comprising the genetic modification has reduced or no function compared to a protein expressed by a comparable PsiD gene that does not comprise the genetic modification. In some embodiments, the first genetic modification comprises excision of the PsiD gene. In some embodiments, the excision is a CRISPR excision. In some embodiments, the second genetic modification comprises a first exogenous polynucleotide comprising a hygromycin resistance gene. In some embodiments, the first exogenous polynucleotide is stably incorporated into the genome of the engineered fungal cell. In some embodiments, the first exogenous polynucleotide is not stably incorporated into the genome of the engineered fungal cell. In some embodiments, the first exogenous polynucleotide is not incorporated into the genome of the engineered fungal cell. In some embodiments, the first exogenous polynucleotide is contained in a plasmid present in the engineered fungal cell. In some embodiments, the first exogenous polynucleotide is operably connected to a promoter. In some embodiments, the promoter is a CaMV 35S promoter. In some embodiments, the first exogenous polynucleotide is operably connected to a promoter. In some embodiments, the promoter is a CaMV 35S promoter. In some embodiments, the engineered fungal cell further comprises a second exogenous polynucleotide comprising an indoleethylamine N-methyltransferase (INMT) gene. In some embodiments, the engineered fungal cell comprises an increased amount of alkaloids compared to comparable wild-type fungal cells. In some embodiments, the alkaloid is N,N-dimethyltryptamine (DMT). In some embodiments, the increased amount of alkaloids is determined by spectrophotometry. In some embodiments, the engineered fungal cell further comprises a second exogenous polynucleotide comprising an INMT gene. In some embodiments, the engineered fungal cell comprises an increased amount of an alkaloid compared to a comparable wild-type fungal cell. In some embodiments, the alkaloid is N,N-dimethyltryptamine. In some embodiments, the increased amount of the alkaloid is determined spectrophotometrically. In some embodiments, the engineered fungal cell further comprises a second exogenous polynucleotide comprising an INMT gene. In some embodiments, the engineered fungal cell comprises an increased amount of an alkaloid compared to a comparable wild-type fungal cell. In some embodiments, the alkaloid is N,N-dimethyltryptamine. In some embodiments, the increased amount of the alkaloid is determined spectrophotometrically.In some embodiments, the engineered fungal cell further comprises a second exogenous polynucleotide comprising an INMT gene. In some embodiments, the engineered fungal cell comprises an increased amount of alkaloids compared to comparable wild-type fungal cells. In some embodiments, the alkaloid is N,N-dimethyltryptamine. In some embodiments, the increased amount of alkaloids is determined by spectrophotometry. In some embodiments, the engineered fungi belongs to Basidiomycota. Wherein the composition, the engineered fungal cell or both further comprise a monoamine oxidase inhibitor. In some cases, the monoamine oxidase can be monoamine oxidase A, monoamine oxidase B or a combination of these. In some embodiments, the alkaloids are separated and purified. In some embodiments, the engineered fungal cell is contained in a fungus or a portion thereof.
[0010] In one aspect, the present disclosure relates to a composition comprising a non-naturally occurring organism, such as a genetically modified fungal cell, engineered to produce a desired alkaloid in greater amounts than a corresponding naturally occurring fungal cell. The engineered fungal cell can comprise a modification that inhibits or eliminates expression of a psilocybin phosphatase in the engineered fungal cell, compared to a comparable fungal cell without the modification. Advantageously, by inhibiting or eliminating expression of a psilocybin phosphatase, the engineered fungal cell can produce an increased amount of one or more desired alkaloids, compared to a comparable fungal cell without the modification that inhibits or eliminates expression of the psilocybin phosphatase. For example, without being bound by any one embodiment, by inhibiting or eliminating expression of a psilocybin phosphatase, the engineered fungal cell can possess an altered biosynthetic pathway in which the conversion of psilocybin to dephosphorylated psilocin is significantly reduced or eliminated. By reducing the conversion of psilocybin to dephosphorylated psilocybin, the engineered fungal cells can provide greater amounts of psilocybin or a derivative or precursor of psilocybin compared to comparable wild-type fungal cells in which a substantial portion of the biosynthesized psilocybin is converted to dephosphorylated psilocybin. Thus, provided herein are methods and compositions for making and using engineered fungal cells that are enriched for one or more otherwise rare alkaloids in the psilocybin pathway.
[0011] In one aspect, the present disclosure provides a composition comprising an engineered fungal cell comprising a genetic modification that results in an at least 6-fold increase in expression of an alkaloid or a precursor thereof compared to a comparable fungal cell not comprising the genetic modification. The engineered fungal cell may comprise a genetic modification that results in an at least 6-fold increase in expression of an mRNA encoding an L-tryptophan decarboxylase in the engineered fungal cell compared to a comparable fungal cell not comprising the genetic modification, thereby resulting in a higher yield of one or more alkaloids. In some cases, the fungal cell is from the division Basidiomycota. In some embodiments, the fungal cell is a mycelial cell. In some embodiments, the fungal cell may be a mycelium cell, which is a portion of a fungal hyphae comprising more than one such mycelial cell. In some cases, upregulation of L-tryptophan decarboxylase (e.g., by upregulation of a PsiD gene) results in an increase in expression of one or more of tryptamine or 4-hydroxytryptamine compared to wild-type mycelium. By increasing the expression of L-tryptophan decarboxylase, the engineered mycelium can also produce increased amounts of many alkaloids that appear in the downstream biosynthetic pathways of tryptamine and / or 4-hydroxytryptamine, such as psilocybin, dephosphorylated psilocybin, baeocystin, norbaeocystin, aeruginascin, tryptamine or N,N-dimethyltryptamine. Thus, the genetically modified fungal cells described herein can produce an entourage of many alkaloids, the combination of which can enhance therapeutic effects.
[0012] The present disclosure also provides compositions and methods for genetically modifying organisms to increase the production of new or rare alkaloids.
[0013] In one aspect, the present disclosure provides a gene editing system for enhancing the expression of psychotropic alkaloids in fungal cells. The system comprises an endonuclease and at least one guiding polynucleotide, or one or more nucleic acids encoding an endonuclease and at least one guiding polynucleotide, wherein the guiding polynucleotide is bound to a nucleic acid encoding or regulating a gene that regulates the production of psychotropic alkaloids in fungal cells. The system further comprises an agent that increases the incorporation of an endonuclease or at least one guiding polynucleotide, or one or more nucleic acids encoding an endonuclease or at least one guiding polynucleotide into the fungal cell compared to the incorporation of the agent without the agent. In some embodiments, the fungal cell is a fungal protoplast. In some embodiments, the system comprises one or more nucleic acids encoding a gene editing system. In some embodiments, the one or more nucleic acids comprise non-replicating DNA. In some embodiments, the system comprises an endonuclease and at least one guiding polynucleotide in the form of an active ribonucleoprotein. In some embodiments, the reagent comprises a non-ionic surfactant, a lipid nanoparticle, or an agent that depolymerizes microtubules. In some embodiments, the reagent comprises:
[0014] In some embodiments, the agent has a molecular weight of 647 g / mole. In some cases, n can be: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
[0015] On the other hand, the present disclosure provides a gene editing system for genetically modifying fungal cells, wherein the system comprises an endonuclease and at least one guide polynucleotide, or one or more nucleic acids encoding the endonuclease and at least one guide polynucleotide, wherein the guide polynucleotide comprises a sequence that can bind to a gene comprising a sequence comprising one of SEQ ID NOs: 29-87, wherein the binding of the guide polynucleotide to the gene in the fungal cell results in a genetic modification that regulates the production of one or more alkaloids. In some embodiments, the guide polynucleotide comprises a sequence complementary to an alkaloid synthase gene. In some embodiments, the guide polynucleotide is combined with one of the gene sequences listed in Table 1 or Table 2. In some embodiments, the gene sequence includes the gene sequence in Table 1 or Table 2. In some embodiments, the gene sequence includes any one of SEQ ID NOs: 1-19, 67, 90-99, or 151. In some embodiments, the gene sequence has 95% identity to any one of SEQ ID NOs: 1-19, 67, 90-99, or 151. In some embodiments, the gene sequence has 99% percent identity to any one of SEQ ID NOs: 1-19, 67, 90-99, or 151. In some embodiments, the gene sequence is any one of SEQ ID NOs: 1-19, 67, 90-99, or 151.
[0016] On the other hand, the present disclosure provides a gene editing system for genetically modifying fungal cells, wherein the system comprises an endonuclease and at least one guide polynucleotide, or one or more nucleic acids encoding the endonuclease and at least one guide polynucleotide, wherein the guide polynucleotide comprises a sequence that can be bound to a gene comprising a sequence comprising one of SEQ ID NOs: 29-87, wherein the binding of the guide polynucleotide to the gene in the fungal cell results in a genetic modification that regulates the production of one or more alkaloids. In some embodiments, the guide polynucleotide comprises a sequence in Table 9-Table 16. In some embodiments, the guide polynucleotide is combined with a sequence listed in Table 9-Table 16. In some embodiments, the guide polynucleotide is combined with a sequence selected from the group consisting of SEQ ID NOs: 29-87. In some embodiments, the guide polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOs: 29-87.
[0017] On the other hand, the present disclosure provides a gene editing system for genetically modifying fungal cells, the system comprising at least one nucleic acid sequence encoding a guide polynucleotide that binds to a nucleic acid involved in the expression or regulation of a psychotropic alkaloid, wherein at least one nucleic acid sequence is operably linked to a first gene promoter, and a nucleic acid sequence encoding an endonuclease operably linked to a second gene promoter, wherein the second gene promoter is different from the first gene promoter; wherein when the gene editing system is expressed in a fungal cell, the gene editing system introduces genetic modification into the genome of the fungal cell. The first gene promoter and the second gene promoter may have different promoter activities. In some embodiments, the first gene promoter is a U6 gene promoter. In some embodiments, the second gene promoter is a GDP gene promoter.
[0018] On the other hand, the present disclosure provides a gene editing system for multiple genetic engineering of fungal cells, the system comprising a vector encoding at least two guide polynucleotides and an endonuclease, each of which is bound to a nucleic acid encoding or regulating a gene that regulates the production of a psychotropic alkaloid in a fungal cell. When the at least two guide polynucleotides and the endonuclease are expressed in a fungal cell, the at least two guide polynucleotides and the endonuclease introduce the genetic modification regulating alkaloid expression into the genome of the fungal cell. In some embodiments, the vector is a bacterial vector. In some embodiments, the vector comprises a border sequence that promotes bacteria to incorporate at least a portion of the vector into the fungal cell.
[0019] In another aspect, the present disclosure provides a kit comprising a gene editing system for genetically modifying fungal cells as described herein. In some cases, the kit may comprise a container. The kit may comprise reagents for delivering the gene editing system into the fungal cells. The kit may also comprise instructions.
[0020] On the other hand, the present disclosure provides a method for genetically modifying fungal cells. The method includes introducing a gene editing system as described herein into a fungal cell. In some embodiments, the method also includes expressing the gene editing system in the fungal cell, wherein compared to a fungal cell without the gene editing system, the expression of the gene editing system in the fungal cell produces a genetic modification that results in an increase in the production of one or more psychotropic alkaloids.
[0021] In one aspect, the present disclosure provides a composition comprising an engineered fungal cell comprising a first genetic modification (e.g., in a PsiD gene) that results in increased expression of L-tryptophan decarboxylase in the engineered fungal cell compared to a comparable fungal cell without the genetic modification, and a second genetic modification that results in decreased expression of psilocybin phosphatase in the engineered fungal cell compared to a comparable fungal cell without the second genetic modification. In some embodiments, the fungal cell is from the phylum Basidiomycota.
[0022] In one aspect, the present disclosure provides an engineered fungus comprising a genetic modification (e.g., in a PsiD gene) that results in increased expression of an L-tryptophan decarboxylase, wherein the increased expression of the L-tryptophan decarboxylase results in increased alkaloid production in the fungus, which in turn results in the engineered fungus, or a portion thereof, changing from a first color to a second color upon exposure to air, e.g., due to an oxidation reaction of one or more alkaloids. The second color is visually distinct from a corresponding portion of a comparable non-engineered fungus upon equivalent exposure to air. The second color can include a blue coloration that is different from the blue coloration of a wild-type fungus.
[0023] In one aspect, the present disclosure provides a method comprising introducing an exogenous nucleic acid (e.g., a PsiD gene) encoding an L-tryptophan decarboxylase into a fungal cell, growing the fungal cell into a mycelial mass, and expressing the L-tryptophan decarboxylase in the mycelial mass, wherein the presence of the exogenous nucleic acid causes the mycelial mass to express the L-tryptophan decarboxylase in an amount greater than that of a comparable mycelial mass without the exogenous nucleic acid, which in turn results in higher expression of one or more alkaloids, such as psilocybin, by the mycelial mass. For example, in some embodiments, expression of the exogenous nucleic acid results in at least a 6-fold increase in expression of the L-tryptophan decarboxylase in the mycelial mass compared to a comparable wild-type mycelial mass. Advantageously, unregulated expression of the L-tryptophan decarboxylase in the mycelial mass results in increased production of one or more psychotropic or non-psychotropic alkaloids, such as psilocybin, by the genetically modified mycelial mass compared to a comparable wild-type mycelium. In some embodiments, one or more psychotropic alkaloids can be isolated directly from the mycelial mass before it produces mushrooms, thereby allowing for a faster, more cost-effective method of harvesting the one or more psychotropic alkaloids.
[0024] In one aspect, the present disclosure provides a method comprising obtaining a genetically modified organism comprising a genetic modification, wherein the genetic modification results in increased expression of L-tryptophan decarboxylase, e.g., by upregulating a PsiD gene or introducing an exogenous PsiD gene, compared to a comparable organism without the genetic modification, and detecting from tissue of the genetically modified organism a change from a first color to a second color upon exposure to air, wherein the second color is visually different from tissue of the comparable organism when equally exposed to air. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] The novel features of the present disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure may be obtained by reference to the following detailed description and its accompanying drawings, which set forth illustrative embodiments in which the principles of the present disclosure are utilized, wherein:
[0027] Figure 1 Diagram depicts the alkaloid biosynthetic pathway of a genetically modified organism having a genetic modification that upregulates expression of tryptophan decarboxylase.
[0028] Figure 2 Schematic diagram of the biosynthetic pathway carried by an organism engineered to produce psilocybin. The organism contains a genetic modification that inhibits psilocybin phosphatase.
[0029] Figure 3 An additional alkaloid biosynthetic pathway of a genetically modified organism is illustrated. The organism comprises a genetic modification that upregulates expression of tryptophan decarboxylase and a genetic modification that downregulates expression of psilocybin phosphatase.
[0030] Figure 4 The PsiD-encoding plasmid is shown.
[0031] Figure 5 A PCR gel confirming PsiD genetic modification of fungal cells is shown. "C+" indicates a lane loaded with a positive control. "C-" indicates a lane loaded with a negative control. "wt" indicates a lane from a PCR run performed on wild-type fungal material. The absence of signal in the "wt" lane and the positive signal in lanes 1-16 indicate integration of the PsiD transgene into the genome of the fungal cells.
[0032] Figure 6Shown are image captures of electrophoretic gels confirming upregulation of PsiD in transgenic mycelia. The gel is from cDNA analysis of PsiD mRNA expression in mycelia transformed with the GT6 plasmid. The upper gel is from cDNA analysis (RT-PCR) of total mRNA expressed in transgenic mycelia. The lower gel is from cDNA analysis of PsiD mRNA expressed in transgenic mycelia, where no reverse transcriptase was added during the RT-PCR assay, thus confirming that the PsiD signal observed in the upper gel is from expressed mRNA and not contaminating DNA.
[0033] Figure 7 Images of non-transgenic wild-type mycelia (control) and transgenic mycelia expressing elevated levels of PsiD.
[0034] Figure 8 The transgenic mycelial mass is shown during primordium formation.
[0035] Figure 9 Images showing side-by-side comparisons of PsiD transgenic fungi compared to wild-type fungi.
[0036] Figure 10 The biosynthetic pathway is schematically depicted. The pathway shows alkaloids that are upregulated upon increased PsiD expression.
[0037] Figure 11 Shown are the alkaloid concentrations measured in PsiD transgenic fungi and wild-type fungi as measured by LC-MS. The Y-axis shows the area counts as detected by LC-MS. The X-axis identifies the samples.
[0038] Figure 12 Shown are the levels of psilocybin and dephosphopsilin in PsiD transgenic fungi compared to wild-type fungi as measured by LC-MS.
[0039] Figures 13A-13D Shown are the amounts of certain alkaloids measured in transgenic and wild-type fungi by LC-MS. The Y-axis shows the area counts as detected by LC-MS. The X-axis identifies the sample.
[0040] Figure 14 Shown are the contents of various alkaloids in PsiD transgenic fungi compared to wild-type fungi as measured by LC-MS.
[0041] Figure 15 Illustration of some of the alkaloids formed from dephosphorylated psilocybin.
[0042] Figure 16A and Figure 16BLC-MS data for quinones and quinone dimers are shown. Samples 1771 and 1772 are from transgenic fungi. Sample 1773 is from a comparable wild-type control.
[0043] 17A to 17D The relative amounts of alkaloids in PsiD transgenic fungi compared to wild-type fungi are shown. The Y-axis shows area counts as detected by LC-MS. The X-axis identifies the samples. Samples 1771 and 1772 are from transgenic fungi. Sample 1773 is from a comparable wild-type control. Figure 17A The relative amounts of serotonin are shown. Figure 17B The relative amount of 4-hydroxytrimethyltryptamine is shown. Figure 17C The relative amounts of aeruginascin are shown. Figure 17D It shows 17A to 17C Graph of the data.
[0044] 18A to 18C A genetically modified fungal cell with phenotypic blue coloration is shown. Figure 18A Blue transgenic fungal cells with enhanced expression of PsiD and PsiK are shown. Figure 18B Shown are mycelial masses composed of transgenic cells overexpressing PsiD (with blue coloration) compared to wild-type mycelial masses (no coloration). Figure 18C Shown is a mycelial mass composed of transgenic cells with enhanced PsiD and PsiK expression, which was cultured to primordium formation after 7 days, with visible pinheads showing growth from the mycelium appearing after 5 days.
[0045] Figure 19 A plasmid map for the construction of a microhomology end joining map for double-strand breaks (DSBs) in DNA is shown. The plasmid includes a guiding Cas enzyme and a hygromycin resistance gene as a DNA repair template. Arrows show the points of DSB microhomology integration.
[0046] Figure 20 A graphic representation of genes from the psilocybin cluster of six psilocybin-producing fungal species is shown. Genes are coded in grayscale according to the annotated legend.
[0047] Figure 21A and Figure 21B The biosynthetic pathway for β-carbolines is shown. The construction of the β-carboline core requires a Pictet-Spengler cyclization process. Figure 21A A pathway from bacteria is shown for the production of β-carboline scaffolds from L-tryptophan. Figure 21B A related pathway from plants is shown, involving the condensation of tryptamine and secologanin to produce tetrahydro-β-carboline compounds.
[0048] Figure 22 Diagram illustrating the methyl transfer steps during the biosynthesis of N,N-dimethyl-L-tryptophan and psilocybin by TrpM and PsiM, respectively.
[0049] Figure 23 Shown is a comparison of PsiM gene products from four different psilocybin-producing fungal species.
[0050] Figure 24 Shown is a sequence alignment comparing the PsiH and PsiH2 gene products from four different psilocybin-producing fungi.
[0051] Figure 25 Shown are phylogenetic trees generated for the PsiH and PsiH2 genes from four psilocybin-producing fungi.
[0052] Figure 26 Schematic diagram of a cloning system used in genetic engineering.
[0053] Figure 27 A schematic diagram to guide oligonucleotide design is shown.
[0054] Figure 28 An alignment of the three U6 promoters used in the cloning system is shown.
[0055] Figures 29A-29F Analytical analysis of optimized genetically engineered fungi of two strains (39.9 and 39.6) are shown, where the analysis was run in triplicate.
[0056] Figure 30A-Figure 30B Shown is a graphical representation of Psilocybe cubensis INMT (PcINMT) expression in 24 independent cell lines transformed into genetically engineered mycelia using a PcINMT plasmid optimized for Psilocybe cubensis. Expression is measured in arbitrary units.
[0057] Figure 31A-Figure 31B An image showing the molecular ladder of Psilocybe cubana INMT ( Figure 31A ). Figure 31B Shown are graphical representations of PcINMT expression in selected transgenic copy lines.
[0058] Figures 32A-32C Shown are analytical representations of TrpM expression using genetically engineered fungi containing various primer sequences. Figure 32A An image of a molecular ladder evaluating TrpM expression is shown. Figure 32B and Figure 32CShown are graphical representations of TrpM expression, including TrpM expression from a strain containing multiple copies of the transgene (TrpM-03).
[0059] Details
[0060] The present disclosure relates to organisms and preparation and use methods thereof that can be used to produce one or more genetically modified alkaloids. In particular, the present disclosure relates to organisms that have significantly different characteristics compared to comparable wild-type organisms present in nature through genetic modification. Therefore, the genetically modified organisms of the present disclosure are not naturally occurring. The genetically modified organisms of non-naturally occurring described herein can be used to produce alkaloids with desired characteristics through one or more genetic modifications. One or more genetic modifications can provide new or enhanced biosynthetic pathways that cause the production of one or more desired alkaloids. One or more desired alkaloids prepared by the genetically modified organisms described herein can be produced in an amount that can not be present in comparable wild-type organisms. Therefore, the present disclosure provides genetically modified organisms that are richer in desired alkaloids than comparable organisms present in nature.
[0061] According to the present disclosure, the organism of genetic modification can be designed to comprise the biosynthetic pathway that produces one or more desired alkaloids.For example, the biosynthetic pathway can be engineered to produce the desired alkaloid of the amount that raises or the alkaloid combination of expectation.Alkaloid may be desired because of its useful biological properties.For example, without limiting the scope of the present disclosure, the alkaloid of expectation can show antiproliferation, antibacterial, antiviral, anticancer, insecticide, anti-metastasis or anti-inflammatory effects.Therefore, the organism of genetic modification produced by method described herein can have the biosynthetic pathway that causes production to have the alkaloid of known or suspected useful properties.In some embodiments, the desired alkaloid compound can comprise tryptophan derivative compound.In some embodiments, alkaloid can comprise tryptamine derivative compound.
[0062] Tryptamine-derived compounds comprise a large group of monoamine alkaloids derived from the amino acid tryptophan. Some tryptamine-derived compounds can be found in trace amounts in naturally occurring organisms, including some plants, fungi, microorganisms, and amphibians. For example, psilocybin and dephosphorylated psilocybin are tryptamine-derived compounds found in some fungal species, such as Psilocybin edulis. Recently, some of these compounds have garnered attention for their therapeutic potential. For example, clinical studies have revealed positive results with tryptamine-derived compounds in the treatment of existential anxiety, nicotine addiction, major depressive disorder, and other psychiatric illnesses and disorders. However, due to the cost and rarity of naturally occurring tryptamine-derived compounds, clinical research and widespread access to clinically relevant tryptamine-derived compounds remain limited. While some synthetic methods for producing tryptamine derivatives have been developed, such methods typically rely on the continuous production of one derivative at a time, which is inefficient and expensive. Furthermore, reports indicate that administration of a single derivative has failed to achieve the same positive clinical outcomes as administration of fungal extracts containing a range of diverse tryptamine-derived compounds. The enhanced clinical effects of alkaloid combinations, sometimes referred to as the entourage effect, cannot be achieved using current synthetic methods. Therefore, there remains a need for methods to produce rare and / or novel biologically derived alkaloids (eg, tryptamine-derived compounds) using a unified engineering approach.
[0063] The present disclosure helps address this need with genetically modified organisms (e.g., modified by upregulating PsiD genes or introducing exogenous PsiD genes) and methods for preparing genetically modified organisms that possess a biochemical phenotype enriched for desired tryptamine-derived compounds. The present disclosure also provides methods for modulating the production of specific compounds in genetically modified organisms. For example, the methods described herein can be implemented to upregulate or downregulate the expression of one or more compounds with high specificity. Thus, the methods described herein can be used to tailor the biosynthetic pathways of an organism to produce genetically modified organisms that can produce increased amounts of certain compounds of interest, such as psilocybin. Because production occurs in a genetically modified organism, a production method is provided that can be optimized, customized, and controlled in any desired manner. The present disclosure also provides for the efficient production of alkaloids and makes it possible to scale up the production method to an industrial scale. For example, production of one or more alkaloids in the genetically modified organisms described herein can utilize large-scale bioreactors or production systems to provide consistent, inexpensive, and high-level production. Furthermore, the alkaloids produced by the methods described herein can be used or formulated into selected compositions, such as pharmaceutical compositions, and even provided in single dosage forms.
[0064] Any gene described herein can independently have about following sequence identity percentage: 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%.Any gene described herein can independently have up to following sequence identity percentage: 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%.Any gene described herein can independently have at least following sequence identity percentage: 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.9%.
[0065] The present disclosure provides gene editing systems, compositions and methods for genetically modifying organisms to produce alkaloids. The present disclosure provides a gene editing system, and when expressed in an organism, the gene editing system causes genetic modification, which causes the production of one or more desired alkaloids that increase. The result of the genetic modification introduced by the system, composition or method described herein is a genetically modified organism with significantly different characteristics compared to comparable wild-type organisms present in nature. Therefore, the system, composition and method of the present disclosure can produce non-naturally occurring genetically modified organisms. The non-naturally occurring genetically modified organisms described herein can be used to produce alkaloids with desired characteristics by one or more genetic modifications. In particular, the system, composition and method described herein can produce genetically modified organisms with new or enhanced biosynthetic pathways that cause the production of one or more desired alkaloids. One or more desired alkaloids as described herein can be new in nature or produced in an amount that cannot be present in comparable wild-type organisms.
[0066] The present disclosure also relates to gene editing systems and methods that can accurately modify the genetic material in eukaryotic cells, which makes it possible to achieve a wide range of high-value applications in medicine, pharmaceuticals, drug discovery, agriculture, basic research and other fields. Basically, the genome editing system and method provided herein can introduce or remove one or more nucleotides at a specific position in the eukaryotic genome. The genome editing system also allows exogenous nucleic acids (sometimes referred to as donor sequences) to be incorporated into an organism with the ability to be expressed by the organism. Therefore, the present disclosure provides a gene editing system and method thereof, which allows the targeted editing of an organism, such as deletion, insertion, mutation or replacement of a specific nucleic acid sequence to produce a genetically modified organism. The organism genetically modified by the gene editing system, composition or method described herein can provide a source of new or rare drugs (such as one or more fungus-derived alkaloids). The organism can be a fungal cell from the phylum Basidiomycota. The fungal cell can be a fungal protoplast.
[0067] The present disclosure further relates to compositions and methods for carrying out genome engineering with gene editing systems (e.g., gene editing systems based on CRISPR enzymes). The present disclosure provides compositions and methods that can be used for genetically modifying organisms (such as fungal protoplasts) with gene editing systems. In some embodiments, the present disclosure relates to the following findings: Cas endonucleases can be used in combination with guidance polynucleotides and donor sequences for fungal kingdoms (fungal kingdom), to provide an option toolbox, from which selection and selection can result in the genetic modification of biosynthetic pathways for the genetic modification of new or rare alkaloid compounds. In some embodiments, the present disclosure provides codon optimization tools for genetically modifying fungal cells with CRISPR systems. In some embodiments, the alkaloids produced are new alkaloids with significant clinical value in nature.
[0068] In some embodiments, the present disclosure provides a platform of compositions and methods involving gene editing systems that have particular applicability to organisms that already possess biosynthetic pathways for producing clinically relevant compounds. Thus, in some embodiments, the present disclosure provides a drug discovery platform that can generate genetic modifications that result in altered biosynthetic pathways that result in the production of new compounds that are useful for drug discovery.
[0069] The present disclosure also provides certain sequences of endonucleases that can be used for targeting polynucleotide guidance. This sequence can be used to design a gene editing system targeting gene involved in alkaloid production to edit the guidance polynucleotide. Targeted editing described herein can be used to create a new biosynthetic pathway for producing one or more desired alkaloids in vivo. For example, a biosynthetic pathway can be engineered to produce an elevated amount of desired alkaloid or desired alkaloid combination using a gene editing system.
[0070] The alkaloid produced by the organism of genetic modification described herein may be desirable due to its useful biological properties.For example, without limiting the scope of the present disclosure, the alkaloid of expectation can show antiproliferation, antibacterial, antiviral, anticancer, insecticide, anti-metastasis or anti-inflammatory effects.Therefore, the organism of genetic modification produced by method described herein can have the biosynthetic pathway that causes production of the alkaloid with known or suspected useful properties.In some embodiments, the alkaloid compound of expectation can comprise tryptophan derivative compound.In some embodiments, alkaloid can comprise tryptamine derivative compound.
[0071] The present disclosure also provides compositions and methods with a gene editing system, which can be used for fungal cells to produce genetically modified fungal cells with a biochemical phenotype rich in one or more desired alkaloids. The present disclosure also provides compositions and methods for regulating the production of specific alkaloids in genetically modified fungal cells. For example, the method described herein can be implemented to raise or lower the production of one or more alkaloids with high specificity using a gene editing system guided by one or more nucleic acids. Therefore, the method described herein can be used to customize the biosynthetic pathways of fungal cells to produce genetically modified fungal cells that can produce some alkaloids of interest that can produce an increased amount. Because production is carried out in genetically modified fungal cells, a production method that can be optimized, customized, and controlled in any desired manner is provided.
[0072] For the purpose of illustration and description, the following discussion of the present disclosure has been presented. The following is not intended to limit the present invention to one or more forms disclosed herein. Although the description of the present disclosure has included the description of one or more embodiments and certain variations and modifications, after understanding the present disclosure, other variations and modifications are also within the scope of the present disclosure, such as within the skill and knowledge of those skilled in the art. It is intended to obtain the right to include alternative embodiments within the scope allowed, including claiming those alternative, interchangeable and / or equivalent structures, functions, scopes or steps, regardless of whether such alternative, interchangeable and / or equivalent structures, functions, scopes or steps are disclosed herein.
[0073] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0074] Although various features of the present disclosure may be described in the context of a single embodiment, these features may also be provided individually or in any suitable combination. Conversely, although the present disclosure may be described in the context of different embodiments herein for clarity, various aspects and various embodiments may be implemented in a single embodiment.
[0075] definition
[0076] As used herein, "alkaloid" and "psychoactive alkaloid" are used interchangeably and refer to any of a class of nitrogen-containing organic compounds of plant or fungal origin that have a physiological effect on a subject, such as a human subject. In some embodiments, the alkaloid may include a tryptophan-derived alkaloid. In some embodiments, the alkaloid may include a tryptamine-derived alkaloid. Exemplary alkaloids can include psilocybin, dephosphorylated psilocybin, norpsilocin, tryptamine, 4-hydroxytryptamine, N,N-dimethyltryptamine, norpsilocybin, nordimethylpsilocybin, serotonin, melatonin, melanin, N-acetyl-serotonin, 4-hydroxy-L-tryptophan, 5-hydroxy-L-tryptophan, 7-hydroxy-L-tryptophan, 4-phosphoryloxy-N,N-dimethyltryptamine, serotonin, aeruginascin, 2-(4-hydroxy-1H-indol-3-yl)-N,N,N-trimethylethan-1-amine, 4-phosphoryloxy-N,N-dimethyltryptamine, ketamine, N-acetylserotonin, 3,4-methylenedioxymethamphetamine, β-carboline, or any derivative or any analog thereof.
[0077] As used herein, "biosynthetic pathway" refers to a multi-step, enzyme-catalyzed process in which a substrate can be converted into a compound (e.g., an alkaloid) in a living organism (e.g., a genetically modified organism). In biosynthesis, e.g., alkaloid biosynthesis, a substrate can be modified and, in some cases, converted into another compound, such as a tryptophan-derived alkaloid, via a biosynthetic pathway.
[0078] As used herein, "cell" refers to a biological cell. Some non-limiting examples include: prokaryotic cells, eukaryotic cells, bacterial cells, archaeal cells, cells of unicellular eukaryotic organisms, protozoan cells, cells from plants, algal cells, fungal cells, fungal protoplasts, animal cells, etc. Sometimes a cell is not derived from a natural organism; for example, a cell can be produced synthetically, sometimes referred to as an artificial cell.
[0079] As used herein, "Cas9" refers to an RNA-guided nuclease comprising a Cas9 protein or a fragment thereof (e.g., a protein comprising an active, inactive, or partially active DNA cleavage domain of Cas9 and / or a gRNA binding domain of Cas9). Cas9 nucleases are sometimes also referred to as casn1 nucleases or CRISPR (clustered regularly interspaced short palindromic repeats) associated nucleases. An exemplary Cas9 is Streptococcus pyogenes Cas9 (spCas9).
[0080] As used herein, "disease" or "disorder" refers to any condition that damages or interferes with the normal function of a cell, tissue, or organ. Exemplary disorders include severe anxiety and addiction.
[0081] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount sufficient to achieve or at least partially achieve a desired effect. For example, an effective amount can include an amount that reduces the symptoms of a disease or condition or disorder (such as a mental health disorder) when administered to a subject. In other cases, an effective amount can include an amount that prevents an unwanted disease or condition or disorder (e.g., a mental health disorder) when administered to a subject.
[0082] The terms "exogenous nucleic acid," "exogenous nucleic acid sequence," or "exogenous polynucleotide" refer to nucleic acids or genetic material that originates from outside a cell or organism and is transferred into a cell or organism. Exogenous nucleic acids can be produced synthetically. Exogenous nucleic acids can be produced naturally, for example, from a different organism of the same species or from a different organism of a different species. An exogenous nucleic acid can be another copy of a nucleic acid similar to the endogenous nucleic acid into which the exogenous nucleic acid is incorporated.
[0083] As used herein, "excipient" includes both functional and non-functional ingredients in a pharmaceutical composition. An excipient can be an inactive substance that serves as a vehicle or medium for the alkaloids or other compounds disclosed herein.
[0084] As used herein, "expression" includes any step involved in producing a polypeptide in a host cell, e.g., producing RNA in a cell or organism, including but not limited to transcription, translation, post-translational modification, and secretion. Expression can also refer to the process by which information from a nucleic acid (e.g., an exogenous nucleic acid comprising a gene) is used to synthesize a functional gene product capable of producing a final product.
[0085] As used herein, the term "functional mushroom" refers to fungal species, derivatives, extracts, and mixtures thereof that have nutritional and / or health benefits. Functional mushrooms include medicinal mushrooms and adaptogenic mushrooms. Examples of functional mushrooms include, but are not limited to, reishi mushrooms and lion's mane mushrooms.
[0086] As used herein, the term "gene" refers to the corresponding nucleotide sequence of nucleic acid (e.g., DNA, such as genomic DNA or cDNA) and its encoding gene product (such as RNA transcript). The term used as mentioned herein includes interleaved non-coding regions and regulatory regions. In some applications, the term encompasses transcribed sequences, including 5' and 3' untranslated regions (5'-UTR and 3'-UTR), exons and introns, and in some genes, the transcribed region can contain an "open reading frame" encoding a polypeptide. In some applications of the term, "gene" only includes the coding sequence (e.g., "open reading frame" or "coding region") necessary for encoding a polypeptide. In some cases, a gene does not encode a polypeptide, such as ribosomal RNA genes (rRNA) and transfer RNA (tRNA) genes. In some cases, the term "gene" not only includes transcribed sequences, but in addition, also includes non-transcribed regions, including upstream and downstream regulatory regions, enhancers and promoters. A gene can refer to an "endogenous gene" or a natural gene in its natural location in the genome of an organism. A gene can refer to an "exogenous gene" or a non-natural gene.
[0087] As used herein, the term "gene editing" and its grammatical equivalents refer to a genetic engineering method or genetic modification that inserts, replaces, or removes one or more nucleotides from the genome of a cell or organism. For example, gene editing can be performed using a nuclease (e.g., a naturally occurring nuclease or an artificially engineered nuclease).
[0088] As used herein, the term "gene knockout" or "knockout" refers to any genetic modification that reduces the expression of the gene being "knocked out." Reduced expression includes no expression. The genetic modification can include genomic disruption.
[0089] As used herein, the terms "genetically modified," "genetically engineered," "transgenic," "genetically modified," "non-naturally occurring," and their grammatical equivalents refer to one or more changes in a nucleic acid (e.g., a nucleic acid within the genome of an organism) and can be used interchangeably. For example, genetic modification can refer to an alteration, addition, and / or deletion of one or more genes. A genetically modified cell can also refer to a cell with an added, deleted, and / or altered gene.
[0090] As used herein, the term "genetic disruption" or "disruption" and its grammatical equivalents can refer to the process of altering a gene by, for example, deletion, insertion, mutation, rearrangement, or any combination thereof. For example, a gene can be disrupted by knockout. Disrupting a gene can partially reduce or completely inhibit the expression (e.g., mRNA and / or protein expression) of a gene. Disruption can also include inhibitory techniques such as shRNA, siRNA, microRNA, dominant negative, or any other means of inhibiting gene or protein function or expression.
[0091] As used herein, "guide RNA" or "gRNA" refers to a polynucleotide that is specific for a target sequence and can form a complex with a polynucleotide-programmable nucleotide-binding domain protein (e.g., Cas9 or Cpf1).
[0092] As used herein, the term "nucleotide" generally refers to a base-sugar-phosphate combination. A nucleotide can be composed of three subunit molecules: a nucleobase, a five-carbon sugar (ribose or deoxyribose) and a phosphate group consisting of one to three phosphates. The four nucleobases in DNA can include guanine, adenine, cytosine, and thymine; in RNA, uracil can be used instead of thymine. Nucleotides can include synthetic nucleotides. Nucleotides can include synthetic nucleotide analogs. Nucleotides can be monomeric units of a nucleic acid sequence, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).
[0093] As used herein, the term "phenotype" and its grammatical equivalents refer to a combination of observable characteristics or properties of an organism, such as its morphology, development, biochemical or physiological characteristics, phenology, behavior, and behavioral products. Depending on the context, the term "phenotype" can sometimes refer to a combination of observable characteristics or properties of a population.
[0094] As used herein, the term "plant" includes whole plants and any progeny, cells, tissues, or parts of plants. The plant classes that can be used in the present disclosure are generally as broad as the classes of higher and lower plants suitable for mutagenesis, including angiosperms (monocots and dicots), gymnosperms, ferns, and multicellular algae. Thus, "plant" includes dicots and monocots.
[0095] As used herein, "protoplasts" refers to isolated cells whose cell walls have been removed. Protoplasts can be produced by stripping the cell wall from plant, bacterial or fungal cells by mechanical, chemical or enzymatic means.
[0096] As used herein, the terms "protein", "peptide" and "polypeptide" are used interchangeably to refer to a series of amino acid residues connected to each other by peptide bonds between the α-amino group and the carboxyl group of adjacent residues. The terms "protein", "peptide" and "polypeptide" refer to polymers of amino acids (including modified amino acids (e.g., phosphorylated amino acids, glycosylated amino acids, glycosylated amino acids, etc.) and amino acid analogs) regardless of their size or function. "Protein" and "polypeptide" are typically used to refer to relatively large polypeptides, while the term "peptide" is typically used to refer to small polypeptides, but the use of these terms in the art overlaps. When referring to gene products and fragments thereof, the terms "protein", "peptide" and "polypeptide" are used interchangeably herein.
[0097] The term "transgenic" refers to a gene or genetic material derived from outside the organism that can be transferred into an organism. A transgenic can include a section or continuous segment of nucleic acid encoding a gene product artificially introduced into an organism. The gene or genetic material may come from different species. The gene or genetic material may be synthetic. When a transgenic is transferred into an organism, the organism can then be referred to as a transgenic organism. The transgenic can retain its ability to produce RNA or polypeptides (e.g., proteins) in a transgenic organism. The transgenic can include a polynucleotide encoding a protein or a fragment thereof (e.g., a functional fragment). The polynucleotide of the transgenic can be an exogenous polynucleotide. A fragment of a protein (e.g., a functional fragment) can include at least or at least approximately 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99% of the amino acid sequence of the protein.
[0098] As used herein, "transgenic organism" generally refers to a recombinant organism in which a desired DNA sequence or genetic locus within the genome of the organism is modified by insertion, deletion, substitution or other manipulation of the nucleotide sequence.
[0099] As used herein, the term "transgenic plant" refers to a plant, or any subsequent generation of progeny plants derived therefrom, wherein the DNA of the plant or its progeny contains an introduced exogenous DNA segment that is not naturally present in non-transgenic plants of the same line. A transgenic plant may additionally contain sequences that are native to the transformed plant, but in which the "exogenous" gene has been altered, for example, by the use of one or more heterologous regulatory elements or other elements, so as to alter the level or pattern of expression of the gene.
[0100] As used herein, a gene sequence may be referred to as "unmasked" when the sequence does not include any linker or promoter sequences.
[0101] As used herein, " vector " or " plasmid " is a polynucleotide (for example, DNA or RNA), and can be used as a carrier to carry genetic material into a cell, where the genetic material can be replicated and / or expressed. In some embodiments, the vector is an Agrobacterium transformation vector. In some cases, the vector is, for example, a yeast artificial chromosome, a phagemid, a bacterial artificial chromosome, a virus or linear DNA (for example, a linear PCR product), or can be used for transferring a polynucleotide sequence to another cell. The vector (or part thereof) can be present in the target cell transiently (i.e., not integrated into the genome) or stably (i.e., integrated into the genome). In some embodiments, the vector can also include a selection marker or a reporter gene.
[0102] Mention that the sequence identity percentage between two nucleotide sequences refers to when comparing, and this nucleotide percentage is identical when comparing two sequences.This comparison and homology or sequence identity percentage can be determined using software programs known in the art, such as those described in Section 7.7.18 of Current Protocols in Molecular Biology (FM Ausubel et al., ed., 1987) Supplement 30, and the document is incorporated by reference.Preferred comparison is determined by Smith-Waterman homology search algorithm using affine gap search, wherein the gap opening penalty is 12, and the gap extension penalty is 2, and module matrix (BLOSUM matrix, BLOSUM) is 62.Smith-Waterman homology search algorithm is disclosed in Smith&Waterman (1981) Adv.Appl.Math.2:482-489, which is incorporated by reference.
[0103] As used herein, "substantially pure" means sufficiently homogeneous to appear free of readily detectable impurities as determined by standard analytical methods used by those skilled in the art to assess such purity, such as thin layer chromatography (TLC), gel electrophoresis, and high performance liquid chromatography (HPLC), or sufficiently pure so that further purification does not detectably alter the physical and chemical properties of the substance, such as enzymatic activity and biological activity. Methods for purifying compounds to produce substantially chemically pure compounds are known to those skilled in the art. However, substantially chemically pure compounds can be mixtures of stereoisomers. In such cases, further purification may increase the specific activity of the compound. In some embodiments, the compositions of the present disclosure are substantially pure.
[0104] As used herein, "wild type" or "wild-type organism" refers to an organism that has a genotype or phenotype as a typical organism of its species as found in nature.
[0105] Unless otherwise indicated, structures depicted herein are also intended to include all isomeric (e.g., enantiomeric, diastereomeric, geometric (or conformational)) forms of the structure; for example, R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of this disclosure.
[0106] Although various features of the present disclosure may be described in the context of a single embodiment, these features may also be provided individually or in any suitable combination. Conversely, although the present disclosure may be described in the context of different embodiments herein for clarity, various aspects and various embodiments may be implemented in a single embodiment.
[0107] Overview
[0108] Genetically modified organisms
[0109] In some embodiments, the genetically modified organism provided herein is a multicellular organism. In some embodiments, the genetically modified organism is a unicellular organism. In some embodiments, the genetically modified organism is a single plant cell or a single fungal cell. Embodiments described herein also include cell colonies, such as cell colonies from fungal species. For example, in some embodiments, the genetically modified organism comprises a genetically modified fungal cell colony that forms a mycelium mass together. In some embodiments, the genetically modified organism as described herein is a fungus. For example, in some cases, the genetically modified organism provided herein is a fungal cell. In some cases, the fungus or fungal cell is from Basidiomycota. In some cases, Basidiomycota fungi or fungal cell can be from Psilocybe, Conocybe, Gymnopilus, Panaeolus, Pluteus or Stropharia. In some cases, the fungus or fungal cell is from tropical purple-brown naked umbrella (Gymnopilus dilepis). In some cases, the fungus or fungal cell is from Pluteus salicinus. In some cases, the fungus or fungal cell is from Psilocybe edulis. In some cases, the fungus or fungal cell is from Panaeolus cyanescens. In some cases, the fungus or fungal cell is from Pleurotus nebrodensis. In some cases, the fungal cell is mycelium or mycelial cells. In some embodiments, the fungal cell is aerial mycelium. In some embodiments, the protoplast is separated from the mycelium or mycelial mass. In some embodiments, the fungal cell is aerial mycelium. In some cases, the fungal cell is a fungal protoplast. In some embodiments, the mycelial mass is present and comprises the fungal cell.
[0110] In some embodiments, the genetically modified organism described herein is a plant. For example, in some embodiments, the genetically modified organism is from the genus Cannabis. In some cases, the genetically modified organism described herein is a bacterium. In some cases, the bacterium is Agrobacterium.
[0111] In some embodiments, the genetically modified organisms described herein include Mitragynas peciosa (commonly known as kratom). Kratom is a tropical evergreen tree in the coffee family, native to Southeast Asia. Kratom is native to Thailand, Indonesia, Malaysia, Myanmar, and Papua New Guinea and has been used in herbal medicine since at least the 19th century. Kratom has opioid properties and some stimulant-like effects. In some embodiments, the compositions and methods described herein are used to produce genetically modified kratom with increased opioid or stimulant-like properties.
[0112] In some embodiments, the genetically modified organism can be a eukaryotic organism. In some embodiments, the genetically modified organism described herein can be a fungus. In some embodiments, the genetically modified organism can be phylum basidiomycota.
[0113] In some embodiments, the genetically modified organism can be a eukaryotic organism. In some embodiments, the genetically modified organism described herein can be a fungus. In some embodiments, the genetically modified organism can be the phylum basidiomycota. In some embodiments, the genetically modified organism can be from a genus selected from: Copelandia, Gymnopilus, Inocybe, Copelandia, Pholiotina, Psilocybe and Psilocybe. In some embodiments, the genetically modified organism described herein can be a multicellular organism. In some cases, the genetically modified organism can be a unicellular organism. For example, in certain embodiments, the organism can be a single plant cell or a single fungal cell. Embodiments described herein also include cell colonies, such as cell colonies from fungal species. For example, in some embodiments, the genetically modified organism comprises a genetically modified fungal cell colony that together forms a mycelium mass.
[0114] In some embodiments, the present disclosure provides genetically modified organisms that have been genetically modified, for example, by upregulating a PsiD gene or introducing an exogenous PsiD gene, to enhance the conversion of L-tryptophan or 4-hydroxy-L-tryptophan to tryptamine. For example, a genetically modified organism can include a genetic modification that results in increased expression of L-tryptophan decarboxylase compared to a comparable wild-type organism. In further embodiments, the present disclosure provides genetically modified cells or organisms that include a genetic modification that inhibits or minimizes one or more pathways that consume 4-hydroxy-L-tryptophan or tryptophan, thereby enhancing the formation of tryptamine and optionally downstream derivatives of tryptophan-derived alkaloids such as psilocybin and dephosphorylated psilocybin. In some cases, this enhancement is achieved by introducing or upregulating a gene associated with the expression or activity of a tryptophan decarboxylase. Thus, the genetically modified organisms described herein can be used to produce increased amounts of tryptophan-derived alkaloids (e.g., psilocybin) compared to a comparable wild-type organism.
[0115] In some embodiments, the present disclosure provides genetically modified organisms that have been genetically modified to inhibit the conversion of psilocybin to dephosphorylated psilocybin. For example, in some embodiments, the present disclosure provides genetically modified organisms that have been modified to reduce or eliminate the expression of an alkaline phosphatase (e.g., psilocybin phosphatase), which can dephosphorylate psilocybin, thereby converting psilocybin to dephosphorylated psilocybin. By inhibiting or eliminating the activity of alkaline phosphatase, the genetically modified organism can contain a higher concentration of psilocybin compared to a comparable wild-type organism (i.e., a comparable organism without the genetic modification). In some embodiments, additional modulation of PsiRs can affect the production of alkaloid synthesis.
[0116] In some embodiments, the PsiR is introduced as an exogenous nucleotide. The order of psilocybin-producing gene clusters varies across fungal species, with respect to their transcriptional regulators (e.g., PsiRs). This diversity in composition may indicate the existence of alternative pathways for psilocybin production and / or additional biosynthetic pathways capable of producing non-naturally occurring alkaloids outside the psilocybin scaffold. Some psilocybin-producing mushrooms are known to contain the transcriptional regulator PsiR, although its location varies, as discussed above. PsiR is a basic helix-loop-helix (bHLH) transcriptional regulator expressed in the fruiting body. bHLHs are known to bind to a consensus hexanucleotide sequence in DNA called the E-box (CANNTG (SEQ ID NO: 150)). Other genes in the psilocybin biosynthetic gene cluster that also contain an E-box motif in their promoters are PsiD, PsiH, PsiM, and PsiT2. PsiT1 has two E-box motif regions. Interestingly, PsiP contains four E-box motifs (500 base pairs upstream of the ATG). PsiL and PsiK lack this promoter region. When fungi contain multiple PsiP genes, the genes or their protein expression products mentioned herein may be numbered to distinguish them, for example, PsiP1 and PsiP2.
[0117] In some embodiments, the genetically modified organism may comprise one or more genetic modifications. In some embodiments, the genetically modified organism may comprise a genetic modification that results in modulation of a psilocybin biosynthetic enzyme. For example, in some embodiments, the genetically modified organism may comprise a genetic modification that results in increased expression of L-tryptophan decarboxylase compared to a comparable wild-type organism, and a genetic modification that results in decreased expression or activity of an alkaline phosphatase (e.g., psilocybin phosphatase). In various embodiments, the genetically modified organism may comprise a genetic modification that results in increased expression of L-tryptophan decarboxylase compared to a comparable wild-type organism, and a genetic modification that results in increased expression of 4-hydroxytryptamine kinase compared to a comparable wild-type organism. In some embodiments, the genetically modified organism may comprise a genetic modification that results in increased expression of L-tryptophan decarboxylase compared to a comparable wild-type organism, such as by upregulating a PsiD gene or introducing an exogenous PsiD gene, a genetic modification that results in increased expression of serotonin kinase compared to a comparable wild-type organism, and a genetic modification that results in decreased expression of psilocybin phosphatase compared to a comparable wild-type organism. Additionally, in other embodiments, the genetically modified organism may further comprise a genetic modification that results in increased expression of a methyltransferase, such as a methyltransferase encoded by PsiM. The genetically modified organism may further comprise a genetic modification that results in increased expression of a P450 monooxygenase compared to a comparable wild-type organism.
[0118] In some embodiments, the genetically modified organisms described herein can comprise one or more genetic modifications that result in any of the following: (a) increased tryptophan decarboxylation, (b) increased tryptamine 4-hydroxylation, (c) increased 4-hydroxytryptamine O-phosphorylation, (d) increased psilocybin via continuous N-methylation, or (e) decreased expression of psilocybin phosphatase compared to a control organism without the genetic modification. The genetically modified organisms can also include any one or more genetic modifications described in WO 2021 / 067626, which is incorporated by reference in its entirety.
[0119] For example, in some embodiments, the genetically modified organism comprises a genetic modification that results in the following in the genetically modified organism: (i) upregulated expression of a tryptophan decarboxylase gene, a psilocybin-related hydroxylase gene, a psilocybin-related N-methyltransferase gene, or a psilocybin-related phosphotransferase gene, compared to a comparable control organism without the genetic modification; (ii) reduced synthesis of non-psilocybin tryptamines; and / or (iii) increased production of tryptophan. Advantageously, as a result of the genetic modification, the genetically modified organism can produce an increased amount of a compound, such as, for example, a compound selected from the group consisting of:
[0120]
[0121] In some embodiments, the systems, compositions and methods of the present disclosure can produce genetically modified organisms, wherein the genetically modified organisms include genetic modifications that cause the genetically modified organisms to exhibit a phenotype that is visually different from the phenotype of comparable wild-type organisms. For example, in some embodiments, the phenotype includes a blue coloration. Phenotypes can be measured using methods known in the art, for example, a spectrophotometer can be used to measure the phenotype including a blue coloration. The spectral reflectance of the genetically modified organism in the wavelength region of 400nm to 525nm (blue region) can be high, and the spectral reflectance for wavelengths longer than 550nm can be low. In contrast, comparable wild-type organisms can be described as having a spectral reflectance that is substantially lower than that of the genetically modified organism in the wavelength region of 400nm to 525nm. In some embodiments, the genetically modified organism is a mycelium mass comprising a blue phenotype. In some embodiments, the genetically modified organism includes a fungus with a blue phenotype. In some embodiments, the phenotypic difference can include a change in the color of the fungus or its part relative to the color of the fungus or its part before the genetic alteration or modification of the fungus or its part. In some embodiments, the phenotypic distinction can include a change in the color, shape, length, mass, thickness, density of the fungus or part thereof, or any combination thereof, relative to the color, shape, length, mass, thickness, density of the fungus or part thereof before the genetic alteration or modification of the fungus or part thereof. In some embodiments, the fungus can include or can be a mature fungus, a fruiting body, a mycelial mass, a protocell, or any combination thereof. In other embodiments, a portion of the genetically modified organism comprises a blue phenotype, for example, an internal portion of the tissue when exposed to air. Due to the association between the blue phenotype and increased alkaloid content, in some embodiments, the blue phenotype is used as a reporter of alkaloid content (e.g., psilocybin).
[0122] In some embodiments, the present disclosure relates to the discovery that increased expression of L-tryptophan decarboxylase in a fungus or fungal cell can alter the phenotype of the fungus or fungal cell. In some embodiments, the present disclosure relates to methods for assessing whether a fungal organism has been genetically modified or the extent to which a fungal organism expresses an alkaloid, such as psilocybin or dephosphorylated psilocybin, based on the organism's blue coloration.
[0123] In some embodiments, the genetically modified organism may comprise a genetic modification that results in an up-regulation or down-regulation of a gene product. For example, a gene product encoded by any one of the genes described in Table 1 or Table 2, or a gene product comprising a sequence that is at least, for example, 65%, 75%, 85%, 90%, 95%, 99% or 100% identical to one of the sequences listed in Table 1 or Table 2. In some cases, the genetically modified organism comprises a genetic modification that results in an increase in the expression of a gene product (e.g., one or more gene products identified in Table 3). Tables 1 and 2 provide a list of exemplary genes that can be up-regulated or down-regulated in the genetically modified organisms described herein. The length and number of introns in the psilocybin biosynthesis genes of P. cubensis and P. cyanescens. If two values are present in a cell, the first value refers to the corresponding gene of P. cubensis and the second value refers to the corresponding gene of P. cyanescens. The values for the PsiR and PsiT1 genes of P. coli and the PsiT2 gene of P. gloeosporioides were predicted using the Augustus algorithm. Table 2 provides a list of exemplary genes and gene sequences encoding gene products that can be up-regulated or down-regulated in the genetically modified organisms described herein. Table 3 provides a list of exemplary polypeptides that can be up-regulated or down-regulated in the genetically modified organisms described herein. In some embodiments, the gene product has a sequence comprising SEQ ID NOs: 17-28. In some embodiments, the gene product has a sequence comprising SEQ ID NOs: 17-28.
[0124] Table 1 shows exemplary genes that can be upregulated or downregulated in genetically modified organisms. The length and number of introns for psilocybin biosynthesis genes from P. cochinchinensis and P. leucocephalus are shown. If two values are present in a cell, the first value refers to the corresponding gene from P. cochinchinensis and the second value to the corresponding gene from P. leucocephalus. The values for the PsiR and PsiT1 genes from P. cochinchinensis and the PsiT2 gene from P. leucocephalus were predicted using the Augustus algorithm. An exemplary intron sequence is: gtttgtctctcgcttgcataccacccagcagctcactgatgtcgacttgtag (SEQ ID NO.: 450).
[0125] Table 1. Exemplary genes encoding gene products that can be up-regulated or down-regulated in genetically modified organisms.
[0126]
[0127] Table 2. Exemplary genes and gene sequences encoding gene products that can be up-regulated or down-regulated in the genetically modified organisms described herein.
[0128]
[0129]
[0130]
[0131]
[0132]
[0133]
[0134]
[0135]
[0136]
[0137]
[0138]
[0139]
[0140]
[0141]
[0142]
[0143]
[0144]
[0145]
[0146]
[0147]
[0148]
[0149]
[0150]
[0151]
[0152]
[0153] Table 3. Exemplary polypeptides that can be up-regulated, down-regulated, or expressed by exogenously introduced genes in the genetically modified organisms described herein.
[0154]
[0155]
[0156]
[0157]
[0158]
[0159] Methods for genetic modification
[0160] The present disclosure provides systems, compositions and methods for genetically modifying cells of an organism to produce one or more desired alkaloids. Exemplary cells include fungal cells, such as fungal protoplasts. In some embodiments, the genetic modification is produced using a gene editing system.
[0161] Gene editing (also referred to as genome editing) system refers to a group of technologies that give the ability to change the DNA of an organism. Many genome editing systems are based on bacterial nucleases. The systems, compositions and methods described herein utilize genome editing systems to perform targeted editing in the genome of an organism, and thereby produce one or more alkaloids of interest. For this reason, genome editing systems as used herein can have programmable nucleases. In some embodiments, the genome editing system includes zinc finger nucleases (ZFNs). Zinc finger nucleases are artificial endonucleases that can include designed zinc finger proteins (ZFPs) fused to cleavage domains, such as FokI restriction enzymes. In some embodiments, the genome editing system includes transcription activator-like effector nucleases (TALENs). TALENs are restriction enzymes that can be engineered to cut specific DNA sequences. They are formed by fusing TAL effector DNA binding domains with DNA cleavage domains (nucleases that cut DNA chains). Transcription activator-like effectors (TALEs) can be engineered to bind to virtually any desired DNA sequence, so when combined with nucleases, DNA can be cut at specific positions. In some embodiments, the genome editing system is a meganuclease. In some embodiments, the gene editing system is used to incorporate exogenous nucleic acids into fungi, wherein the incorporation of the exogenous nucleic acids results in genetic modifications that modulate alkaloid production. In some embodiments, the exogenous nucleic acid comprises a sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to one of the sequences listed in Table 2. In some embodiments, the nucleic acid comprises a sequence comprising a sequence selected from the group consisting of: SEQ ID NO. 1-19, 67, 90-99 and 151. In some embodiments, the gene editing system is a CRISPR system, such as a CRISPR-Cas9 endonuclease system.
[0162] CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) may refer to a family of DNA repeat sequences present in the genomes of certain bacteria.
[0163] In some embodiments, the guide RNA binds to a gene comprising a target sequence set forth in Table 9-Table 16 and SEQ ID NOs: 29-87. In some embodiments, the guide RNA binds to a gene comprising a target sequence set forth in Table 9-Table 16 and SEQ ID NOs: 29-87. In some embodiments, the guide RNA is within about 100 bases, about 75 bases, about 50 bases, about 25 bases, about 5 bases, or 1 base of a sequence comprising one of SEQ ID NOs: 29-87. In some embodiments, the guide RNA binds to a gene at a locus that at least partially overlaps with a sequence comprising one of SEQ ID NOs: 29-87. In some embodiments, at least one guide polynucleotide comprises a targeting sequence that is complementary to one of SEQ ID NOs: 29-87. In some embodiments, at least one guide polynucleotide comprises a targeting sequence that binds to one of SEQ ID NOs: 29-87.
[0164] The identification of the target DNA target region can depend on the protospacer adjacent motif (PAM), which can be located at the 3' end of the 20bp target sequence, for example, see Table 1-Table 9. When the CRISPR complex (e.g., Cas9 and the associated guide RNA) recognizes the target DNA sequence, the CRISPR complex can produce double-strand breaks (DSBs) at the DNA target locus. In some cases, one of the two cellular DNA repair mechanisms, non-homologous end joining (NHEJ) and homologous recombination (HR), can play a role in precise genome editing and gene manipulation. For example, NHEJ can be used, which is sometimes considered to be an error-prone repair mechanism that produces short nucleotide insertions or deletions in close proximity to one or more DSB sites. If these short insertions or deletions are present in the gene coding region, or are present in a part of the promoter that participates in the recruitment of proteins involved in transcription, the function of the endogenous gene (e.g., a gene encoding psilocybin phosphatase) may be destroyed. Therefore, this program can be used to produce genetic mutations. In other embodiments, a homology-independent targeted integration (HITI) strategy can be used that allows for integration of fragments (e.g., exogenous nucleic acids) into the genome via NHEJ repair.
[0165] Various forms of CRISPR systems can be used. In some cases, the CRISPR system can be introduced into the genome of the target organism using Agrobacterium tumefaciens-mediated transformation. When the expression of the Cas protein and the guide RNA can be under the control of a constitutive or inducible promoter. For example, in some embodiments, the Cas protein is under the control of the GDP gene promoter, and the guide RNA is under the control of the U6 gene promoter. In some embodiments, the guide RNA is directly inserted into the downstream of the Psilocybe edulis U6 promoter and directly inserted into the upstream of the guide RNA scaffold sequence. In some cases, the Cas protein is optimized for use in fungal cells.
[0166] In some embodiments, an endonuclease system for genetically modifying an organism described herein comprises a CRISPR enzyme and a guide nucleic acid that hybridizes to a target sequence in or near a gene, or a promoter or enhancer associated with a gene. In some cases, the target sequence can be at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, or at least 22 nucleotides in length.
[0167] The CRISPR enzyme can direct the cleavage of one or both strands at a target sequence (such as within the target sequence and / or within the complement of the target sequence). In some embodiments, the target sequence is at least about 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, or at least 22 nucleotides in length. In some embodiments, the target sequence is at most 17 nucleotides in length. In some aspects, the target can be selected from a sequence comprising about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or up to about 100% homology to any one of the following: SEQ ID NOs: 1 to 18 or 89 to 99. In some embodiments, the target is a psilocybin synthase gene. In some aspects, the target can be selected from a sequence comprising about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or up to about 100% homology to any of SEQ ID NOs: 1 to 19 or 89 to 99. In some embodiments, the target is a psilocybin synthase gene.
[0168] The CRISPR enzyme can be guided by a guidance polynucleotide, which can be DNA or RNA. The guidance polynucleotide can be single-stranded or double-stranded. In some cases, the guidance polynucleotide contains a region of single-stranded region and double-stranded region. The guidance polynucleotide can also form a secondary structure. As used herein, the term "guide RNA (gRNA)" and its grammatical equivalents can refer to an RNA that is specific to the target DNA and can form a complex with the Cas protein. The guide RNA can include a guide sequence or spacer sequence that specifies a target site and guides the RNA / Cas complex to the specified target DNA for cleavage. For example, the guide RNA can target the CRISPR complex to a target gene or part thereof and perform targeted double-strand breaks. The target gene can be a gene listed in Table 1 and Table 2. The site-specific cleavage of the target DNA occurs at a position determined by 1) and 2), 1) the base pairing complementarity between the guide RNA and the target DNA (also referred to as the protospacer) and 2) a short motif in the target DNA called the protospacer adjacent motif (PAM). In some cases, gRNAs can be designed using algorithms that can identify gRNAs located in early exons within co-expressed transcripts.
[0169] The CRISPR system can include a nucleic acid binding domain, such as a guide polynucleotide. The nucleic acid binding domain can include a region that contacts the nucleic acid. The nucleic acid binding domain can include a nucleic acid. The nucleic acid binding domain can include DNA. The nucleic acid binding domain can include single-stranded DNA. Examples of nucleic acid binding domains can include, but are not limited to, a helix-turn-helix domain, a zinc finger domain, a leucine zipper (bZIP) domain, a winged helix domain, a winged helix-turn helix domain, a helix-loop-helix domain, an HMG-box domain, a Wor3 domain, an immunoglobulin domain, a B3 domain, and a TALE domain. The nucleic acid binding domain can be a domain of a CRISPR system protein. The CRISPR system protein can be a eukaryotic CRISPR system or a prokaryotic CRISPR. The CRISPR system protein can bind to RNA or DNA, or to both RNA and DNA. In some embodiments, the CRISPR system protein binds to DNA and cleaves DNA. In some cases, the CRISPR system protein binds to double-stranded DNA and cleaves double-stranded DNA. In some cases, two or more nucleic acid binding domains can be linked together. Linking more than one nucleic acid binding domain together can provide increased polynucleotide targeting specificity. Two or more nucleic acid binding domains can be connected via one or more joints. The joint can be a flexible joint. The length of the joint can include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40 or more amino acids. The joint domain can include glycine and / or serine, and in some embodiments can be composed of glycine and / or serine or can be essentially composed of glycine and / or serine. The joint can be a nucleic acid joint that can include nucleotides. The nucleic acid joint can connect two DNA binding domains together. The length of the nucleic acid joint can be up to 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 or more nucleotides. The length of the nucleic acid linker can be at least 5, 10, 15, 30, 35, 40, 45 or 50 or more nucleotides. The nucleic acid binding domain can be combined with the nucleic acid sequence. The nucleic acid binding domain can be combined with the nucleic acid by hybridization. The nucleic acid binding domain can be engineered (for example, engineered to hybridize with the sequence in the genome). The nucleic acid binding domain can be engineered by molecular cloning techniques (such as directed evolution, site-specific mutation and rational mutagenesis). The CRISPR system can include a nucleic acid cleavage domain. The nucleic acid cleavage domain can be a nucleic acid cleavage domain from any nucleic acid cleavage protein. The nucleic acid cleavage domain can be derived from a nuclease.Suitable nucleic acid cleavage domains include nucleic acid cleavage domains of endonucleases (e.g., AP endonuclease, RecBCD endonuclease, T7 endonuclease, T4 endonuclease IV, Bal 31 endonuclease, endonuclease 1 (endo I), micrococcal nuclease, endonuclease II (endoVI, exo III)), exonucleases, restriction nucleases, endoribonucleases, exoribonucleases, RNAses (e.g., RNAse I, II, or III). The nucleic acid binding domain can be a domain of a CRISPR system protein. The CRISPR system protein can be a eukaryotic CRISPR system or a prokaryotic CRISPR / CasX. The CRISPR system protein can bind to RNA or DNA, or to both RNA and DNA. The CRISPR system protein can cleave RNA, or DNA, or both RNA and DNA. In some embodiments, the CRISPR system protein binds to DNA and cleaves DNA. In some embodiments, the CRISPR system protein binds to double-stranded DNA and cleaves double-stranded DNA. In some embodiments, the nucleic acid cleavage domain can be derived from the Fokl endonuclease.
[0170] The CRISPR system may comprise more than one nucleic acid cleavage domain. The nucleic acid cleavage domains may be linked together. Two or more nucleic acid cleavage domains may be connected via a joint. In some embodiments, the joint may be a flexible joint as described herein. The length of the joint may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40 or more amino acids. In some embodiments, the CRISPR system may comprise more than one nucleic acid cleavage domain. The CRISPR system may introduce double-strand breaks in nucleic acids (e.g., genomic DNA). Double-strand breaks may stimulate the cell's endogenous DNA repair pathways (e.g., homologous recombination and non-homologous end joining (NHEJ) or alternative non-homologous end joining (A-NHEJ)). NHEJ may repair the cleaved target nucleic acid without the need for a homologous template. This may result in the loss of the target nucleic acid. Homologous recombination (HR) can occur with a homologous template. The homologous template can include sequences homologous to the sequences flanking the target nucleic acid cleavage site. After the target nucleic acid is cleaved by the CRISPR system, the cleavage site can be destroyed (e.g., the site may be inaccessible for another round of cleavage of the original nucleic acid using the target nucleic acid and CRISPR / Cas9).
[0171] The present disclosure provides a method for genetically modifying an organism to increase the production of one or more alkaloids. In some embodiments, genetic modification is achieved by introducing exogenous nucleic acid (such as donor sequence) into the cell of an organism. Exemplary cells of an organism include fungal cells. Exemplary fungal cells include protoplasts. Exogenous nucleic acid can encode one or more gene products, and when expressed by the genetically modified organism, compared with comparable wild-type organisms, the gene product causes the genetically modified organism to produce one or more alkaloids of the amount increased. In some cases, one or more genes can be one of the genes listed in Table 1 or Table 2. In some embodiments, one or more genes can include one of the genes selected from the group consisting of SEQ ID NO:1-19,67,90-99 and 151. In some embodiments, one or more genes can include one of the genes with 95% identity to the sequence of the group consisting of SEQ ID NO:1-19,67,90-99 and 151. In some cases, one or more copies of the one or more genes included in Table 1 or Table 2 are provided by exogenous nucleic acid. In some cases, at least 1, 2, 3, 4, 5, 6 or 7 copies of one or more genes are introduced into a genetically modified organism together with exogenous nucleic acid. In some cases, at least a portion of exogenous nucleic acid can be integrated into the genome of an organism. In some embodiments, genetic modification results in an organism expressing the genetic modification of one or more polynucleotides listed in Table 2. In some embodiments, genetic modification results in an organism expressing the genetic modification of one or more polynucleotides listed in Table 2. In some embodiments, genetic modification results in an organism expressing the genetic modification of one or more polynucleotides selected from the group consisting of SEQ ID NO: 1-19, 67, 90-99 and 151. In some embodiments, genetic modification results in an organism expressing the genetic modification of one or more polynucleotides selected from the group consisting of SEQ ID NO: 1-19, 67, 90-99 and 151. For example, exogenous nucleic acid can be inserted into a genomic fracture. In some cases, at least a portion of exogenous nucleic acid includes a sequence homologous to the sequence flanking the target sequence for targeted integration. Methods for introducing exogenous nucleic acids into cells of an organism are generally known to those skilled in the art, but may include the use of homology arms. In other cases, the exogenous nucleic acid may be randomly inserted into the genome of the target organism.
[0172] In some embodiments, exogenous nucleic acid can be integrated into the genome of the genetically modified organism by homologous recombination.Homologous recombination allows site-specific modification in endogenous genes, and therefore can correct hereditary or acquired mutations, and / or can engineer new changes into the genome of the genetically modified organism.
[0173] In some embodiments, exogenous nucleic acid comprises a promoter sequence. Increasing the expression of the gene product of design can be achieved by regulating the promoter region to insert a stronger promoter upstream of the desired gene sequence to synthetically increase expression. In some embodiments, for example, a gene promoter is used, such as the 35S gene promoter.
[0174] In some embodiments, the exogenous nucleic acid may comprise a barcode or watermark sequence, which may be referred to as a "barcode". The barcode may comprise a non-natural sequence. In some embodiments, the barcode may be used to identify transgenic organisms via genotyping. In some embodiments, the exogenous nucleic acid may comprise a selective marker, such as an antibiotic resistance gene. Selective marker genes, also referred to herein as "selective markers", may comprise, for example, a hygromycin resistance gene.
[0175] In some embodiments, for identification purposes, a unique sequence is embedded in the genome of a genetically modified organism described herein using CRISPR methods. In some embodiments, this is referred to as a marker or marker sequence. In some embodiments, this is referred to as a watermark sequence. In some embodiments, this is referred to as an intergenic sequence or a portion thereof. In some embodiments, this is referred to as an intergenic watermark sequence. In some embodiments, this is referred to as barcoding. In some cases, an exogenous nucleic acid may include a barcode. For identification purposes, a unique sequence is embedded in the genome of a genetically modified organism described herein using CRISPR methods. In some embodiments, this is referred to as a marker or marker sequence. In some embodiments, this is referred to as a watermark sequence. In some embodiments, this is referred to as an intergenic sequence or a portion thereof. In some embodiments, this is referred to as an intergenic watermark sequence. In some embodiments, this is referred to as barcoding. A barcode may comprise a non-natural sequence. In some embodiments, a barcode can be used to identify a transgenic organism via genotyping. In some embodiments, an exogenous nucleic acid may include a selective marker, such as an antibiotic resistance gene. A selective marker gene may include, for example, a hygromycin resistance gene. In some embodiments, this can be achieved using resistance vector gene sequences such as those shown in Table 4A. Exemplary terminator sequences are shown in Table 4A and Table 4B. In some embodiments, the terminator sequence comprises a sequence selected from the group consisting of any one of SEQ ID NO: 303 and 460-462. In some embodiments, the terminator sequence comprises a sequence having 95% identity to a sequence selected from the group consisting of any one of SEQ ID NO: 303 and 460-462. In some embodiments, the terminator sequence is a sequence selected from the group consisting of any one of SEQ ID NO: 303 and 460-462.
[0176] Table 4A. Resistance vector and related gene sequences
[0177]
[0178]
[0179] Table 4B. Exemplary terminator sequences
[0180]
[0181]
[0182] In some embodiments, a hygromycin resistance gene is used. In some embodiments, the hygromycin resistance gene sequence is SEQ ID NO.: 302. In some embodiments, the sequence of the coding marker can be incorporated into a genetically modified cell or organism, such as a fungal cell, yeast cell, or plant cell as described herein. In some cases, the marker used as a selection or screening device can work in a regenerative genetically modified organism to produce a compound that will impart resistance to other toxic compounds to the tissue in the organism. In some embodiments, the incorporated sequence of the coding marker can be subsequently removed from the transformed genome. The removal of the sequence of the coding marker can be promoted by the presence of a direct repeat sequence before and after the region encoding the marker. In some embodiments, the marker sequence is followed by a protospacer adjacent motif (PAM) to provide appropriate cutting by a Cas nuclease.
[0183] In some embodiments, the hygromycin resistance gene sequence is SEQ ID NO. 302.
[0184] In some embodiments, for identification purposes, a unique sequence is embedded in the genome of a genetically modified organism described herein using gene editing methods such as CRISPR. In some embodiments, this is referred to as a marker or marker sequence. In some embodiments, this is referred to as a watermark sequence. In some embodiments, this is referred to as an intergenic sequence or a portion thereof. In some embodiments, this is referred to as an intergenic watermark sequence. In some embodiments, this is referred to as a barcode as described above. In some embodiments, the incorporated sequence encoding the marker can be subsequently removed from the converted genome. The removal of the sequence encoding the marker can be facilitated by the presence of direct repeats before and after the region encoding the marker. In some embodiments, the marker sequence is followed by a protospacer adjacent motif (PAM) to provide appropriate cutting by the Cas nuclease.
[0185] In some embodiments, exogenous nucleic acid can be introduced into a genetically modified organism by transformation or transfection.
[0186] After transformation, fungi or other organisms can be selected using dominant selective markers incorporated into, for example, transformation vectors. In certain embodiments, such markers confer antibiotic or herbicide resistance to the transformed fungi or other organisms, and the selection of transformants can be completed by exposing fungi and other organisms to antibiotics or herbicides of appropriate concentrations. In some embodiments, ccdb negative selection markers are used. In some embodiments, ccdb negative selection markers are prepared by transforming ccdb sensitive Escherichia coli strains (such as DH5α). After selecting the transformed fungi or other organisms and growing them to maturity, fungi and other organisms showing the changed proterties are identified. The changed proterties can be any one of those described above. Additionally, the expression level or activity of the polypeptide or polynucleotide described herein can be determined by using northern blotting, RT-PCR, RNA seq or microarray analysis of mRNA expression, or by using immunoblotting or protein blotting or gel shift assay analysis of protein expression.
[0187] Suitable methods for transforming fungi or other cells for use with the present disclosure can include almost any method by which nucleic acids can be introduced into cells, such as by direct delivery of DNA, such as by PEG-mediated protoplast transformation, by desiccation / inhibition-mediated DNA uptake, by electroporation, by agitation with silicon carbide fibers, by Agrobacterium-mediated transformation, and by accelerating DNA-coated particles. By applying techniques such as these, cells of almost any fungal species can be stably transformed and developed into transgenic fungi.
[0188] Agrobacterium-mediated transformation
[0189] Agrobacterium-mediated transfer can be used to introduce exogenous nucleic acids into organisms selected for genetic modification, such as fungal cells. In some cases, exogenous nucleic acids can be introduced into entire fungal tissues, thereby overcoming the need for regenerating complete fungi from protoplasts. Agrobacterium-mediated transformation can be used to integrate one or more vectors into genetically modified organisms, including vectors or sequences encoding gene editing systems such as CRISPR systems or donor sequences.
[0190] The present disclosure includes advances in vectors for Agrobacterium-mediated gene transfer that facilitate the construction of vectors capable of expressing a variety of polypeptide-encoding genes by providing improved gene arrangements and restriction of sites within the vector. In some embodiments, the vector may have a convenient polylinker region flanked by a promoter and polyadenylation sites for direct expression of inserted polypeptide-encoding genes and suitable for the purposes described herein. In addition, Agrobacterium containing both armed and disarmed Ti genes can be used for transformation.
[0191] In some embodiments, fungal cell, yeast cell, plant cell can use electroporation to modify.In order to realize conversion by electroporation, can use fragile tissue, such as suspension culture or embryonic callus of cell, perhaps can directly transform immature embryo or other organized tissue alternatively.In some cases, electroporation can comprise 2 pulses, 3 pulses, 4 pulses, 5 pulses, 6 pulses, 7 pulses, 8 pulses, 9 pulses or 10 times or more pulses.In some embodiments, the protoplast of fungi and / or plant can be used for electroporation conversion.
[0192] Another method for delivering or transforming DNA segments to fungal cells and cells derived from other organisms according to the present invention is microprojectile bombardment. In this method, particles can be coated with nucleic acids and delivered to cells by propulsion. Exemplary particles include particles composed of tungsten, platinum, and preferably gold. It is envisioned that in some cases, DNA precipitation on metal particles is unnecessary for delivering DNA to recipient cells using microprojectile bombardment. However, it is envisioned that particles can contain DNA instead of being coated with DNA. In some embodiments, DNA-coated particles can increase the level of DNA delivery via particle bombardment. For bombardment, cells in the suspension are concentrated on a filter or solid culture medium. Alternatively, immature embryos or other target cells can be arranged on a solid culture medium. The cells that can be bombarded are located at an appropriate distance below the large ejection barrier. In some cases, the starting cell density for genome editing can be changed to optimize editing efficiency and / or cell viability.
[0193] In some embodiments, the fungi, yeast or plant of the present disclosure can be used to produce new plant varieties. In some embodiments, plant development is used to develop new, unique and excellent varieties or hybrids with desired phenotypes. In some embodiments, selection methods (such as molecular marker assisted selection) can be combined with breeding methods to accelerate the process. In some embodiments, the method comprises that (i) any organism comprising an expression cassette provided herein is hybridized with a recipient organism system as a donor to produce an FI colony, and (ii) the offspring is selected to have the expression cassette. Optionally, offspring can be further selected by testing the expression of the gene of interest. In some embodiments, the complete chromosome of the donor organism is transferred. For example, a transgenic organism with an expression cassette can be used as a male or female parent in cross-pollination to produce offspring by receiving transgenic from a donor, thereby producing offspring with an expression cassette. In the method for producing an organism with an expression cassette, protoplast fusion can also be used to transfer transgenic from a donor to a recipient. Protoplast fusion is the induction or spontaneous combination between two or more protoplasts (cells whose cell walls are removed by enzymatic treatment), such as somatic hybridization, to produce single binucleate or multinucleate cells.In some embodiments, can utilize a large number of selections.In a large number of selections, select, gather in the crops the independent plant of expectation, and when there is no offspring test, mix seed to produce the next generation.Due to selection only based on maternal parent, and do not have the control to pollination, therefore a large number of selections are equivalent to the form of random mating and selection.As described herein, the purpose of a large number of selections is to increase the ratio of superior genotype in the colony.
[0194] The present disclosure provides a gene editing system for genetically modified organisms. The gene editing system can be selected from the group consisting of: CRISPR system, TALEN, zinc finger, transposon-based, ZEN, mega nuclease, Mega-TAL and any combination thereof. In some embodiments, the gene editing system is guided to the target of interest by guiding the polynucleotide. In some embodiments, the gene editing system involves an endonuclease or nuclease or a polypeptide encoding a nuclease, which can be from a CRISPR (clustered regularly interspaced short palindromic repeats) system. The endonuclease or nuclease or a polypeptide encoding a nuclease can be Cas or a polypeptide encoding Cas.
[0195] In some embodiments, present disclosure provides genetic modification, it can be related to exogenous nucleic acid being introduced into organism and / or carrying out gene deletion / destruction in organism.In some cases, this can be realized using homologous recombination (HR), wherein the selective marker that gives for example antifungal compound (for example hygromycin or neomycin) resistance can be used for replacement or be integrated in target gene seat.Although some fungi (for example saccharomyces cerevisiae)) may have relatively high HR efficiency, due to low HR efficiency, gene disruption may be difficult for many other fungal organisms.This paper provides efficient, fast, powerful and economical gene manipulation tools, such as CRISPR technology, as described in some embodiments herein, it is optimized for use to fungal organisms.This technology can be used for enhancing gene manipulation and for example one or more exogenous nucleic acids are integrated into the efficiency in fungal cell.
[0196] In some embodiments, homologous recombination can insert an exogenous polynucleotide sequence into the target nucleic acid cleavage site. In some embodiments, the exogenous polynucleotide can comprise any sequence from Table 2. In some embodiments, the exogenous polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOs. 1-19, 67, 90-99, and 151. In some embodiments, the exogenous polynucleotide comprises a sequence that is 95% identical to a sequence selected from the group consisting of SEQ ID NOs. 1-19, 67, 90-99, and 151. The exogenous polynucleotide sequence can be referred to as a donor polynucleotide or donor sequence. In some embodiments of the compositions and methods of the present disclosure, a donor polynucleotide, a portion of a donor polynucleotide, a copy of a donor polynucleotide, or a portion of a copy of a donor polynucleotide can be inserted into the target nucleic acid cleavage site. The donor polynucleotide can be an exogenous polynucleotide sequence. The donor polynucleotide can be a sequence that does not naturally occur at the target nucleic acid cleavage site. The vector can comprise the donor polynucleotide. Modification of target DNA due to NHEJ and / or HR can result in, for example, mutation, deletion, alteration, integration, gene correction, gene replacement, gene tagging, transgene insertion, nucleotide deletion, gene disruption, and / or gene mutation. The process of integrating non-natural nucleic acids into genomic DNA can be referred to as genome engineering.
[0197] The CRISPR system proteins disclosed herein may comprise one or more modifications. Modifications may include post-translational modifications. Modifications of the target nucleic acid may occur at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more amino acids away from the carboxyl terminus or amino terminus of the CRISPR system protein. Modifications of the CRISPR system protein may occur at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more amino acids away from the carboxyl terminus or amino terminus of the CRISPR system protein. Modifications may occur due to modifications of the nucleic acids encoding the CRISPR system proteins. Exemplary modifications can include methylation, demethylation, acetylation, deacetylation, ubiquitination, deubiquitination, deamination, alkylation, depurination, oxidation, pyrimidine dimer formation, transposition, recombination, chain elongation, ligation, glycosylation, phosphorylation, dephosphorylation, adenylation, deadenylation, SUMOylation, deSUMOylation, ribosylation, deribosylation, myristoylation, remodeling, cleavage, redox, hydrolysis, and isomerization. The CRISPR system can comprise a modified form of the wild-type exemplary CRISPR. Modified forms of the wild-type exemplary CRISPR system can include amino acid changes (e.g., deletions, insertions, or substitutions) that reduce the nucleic acid cleavage activity of the CRISPR system.
[0198] The genetic modification of the present disclosure may include substitution, addition and deletion or any combination thereof. In some cases, the CRISPR system can target nucleic acids. The CRISPR system can target DNA. In some cases, the CRISPR system comprises nickase activity. In some embodiments, the CRISPR system is modified to target nucleic acids but has no enzymatic activity (e.g., no endonuclease or nickase activity). In some embodiments, only by targeting a CRISPR system without enzymatic activity to a target nucleic acid, the expression of one or more alkaloids is affected. For example, targeting a CRISPR system without enzymatic activity to a target nucleic acid can prevent or replace the transcription factor that originally existed, thereby affecting the expression of the gene product involved in alkaloid production.
[0199] In some embodiments, the CRISPR system can be active at a temperature suitable for fungal or fungal cell growth and culture, such as, for example, but not limited to, about 20 degrees Celsius to about 35 degrees Celsius, preferably about 23 degrees Celsius to about 32 degrees Celsius, and most preferably about 25 degrees Celsius to about 28 degrees Celsius.
[0200] Thus, the methods and compositions of the present disclosure can be used at temperatures suitable for fungal or fungal cell growth and culture, such as, for example, but not limited to, 20 degrees Celsius to about 35 degrees Celsius, preferably about 23 degrees Celsius to about 32 degrees Celsius, and most preferably about 25 degrees Celsius to about 28 degrees Celsius.
[0201] In some embodiments, the gene editing system is provided on a vector. For example, a non-replicating vector, such as a viral vector. In other embodiments, the gene editing system is provided as a complex, wherein the nucleic acid of the target nucleic acid is pre-associated with the CRISPR / Cas protein. In some embodiments, the gene editing system is provided as part of an expression cassette on a suitable vector, and the vector is configured to express the CRISPR system in a desired host cell (e.g., a fungal cell or a fungal protoplast). The vector can allow transient expression of the CRISPR / Cas protein. Alternatively, the vector can allow the expression cassette and / or the CRISPR system to be stably maintained in the host cell, such as, for example, but not limited to, by integration into the host cell genome, including stably integrated into the genome. In some embodiments, the host cell is an ancestral cell, so as to provide heritable expression of the CRISPR / Cas protein.
[0202] Genetic engineering using homology-directed repair and methods for introducing fungal DNA
[0203] In some embodiments, exogenous nucleic acid can be integrated into the genome of the genetically modified organism described herein by homologous recombination.Homologous recombination allows site-specific modification in endogenous genes, and therefore can correct hereditary or acquired mutations, and / or can engineer new changes into the genome of the genetically modified organism.One method that can cause precise sequence changes at a specific genomic location is by using a homology-directed repair (HDR) method ( Figure 19 ). The designed HDR donor template can contain sequences homologous to specific sequences flanking the cleavage site, referred to herein as "homology arms." In some embodiments, the homology arms are at least: 10-nt, 15-nt, 20-nt, 25-nt, 30-nt, 35-nt, 40-nt, 50-nt, 55-nt, 60-nt, 65-nt, or 70-nt, 80-nt, 90-nt, 100-nt, 110-nt, 120-nt, 130-nt, or 140-nt.
[0204] HDR for self-replicating plasmids and protoplasts
[0205] In some embodiments, HDR is performed using self-replicating plasmids and protoplasts. In some embodiments, the PsiD gene locus is targeted. In some embodiments, targeting the PsiD locus produces a genetically engineered, edited, non-genetically modified Psilocybe edulis fungus. In some embodiments, targeting the PsiD locus during the genetic engineering process results in overexpression of PsiD. In some embodiments, the targeted PsiD gene locus undergoes HDR to produce a genetically edited PsiD fungus that overexpresses PsiD. In some embodiments, this HDR method produces a non-genetically modified fungus containing the genetic modification. The B-AMA1 origin of replication allows the plasmid to replicate in a fungal cell without being integrated into the fungal cell's genome. In some embodiments, the plasmid containing the B-AMA1 origin of replication allows the plasmid to replicate in a fungal cell without being integrated into the fungal cell's genome. In some embodiments, the plasmid containing the B-AMA1 origin of replication further comprises a hygromycin resistance gene sequence. In some embodiments, the plasmid containing the B-AMA1 origin of replication further comprises a Cas endonuclease. In some embodiments, the Cas endonuclease is an SpCas enzyme. In some embodiments, the Cas endonuclease is an optimized SpCas enzyme sequence. In some embodiments, the optimized SpCas enzyme comprises a sequence having about the following percentage of identity with any one of SEQ ID NOs: 640-647: 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%. In some embodiments, the optimized SpCas enzyme comprises the sequence of any one of SEQ ID NOs: 640-647. In some embodiments, the hygromycin resistance cassette and transfected protoplasts can then be selected in the presence of hygromycin until only until HDR is complete. The antibiotic selection is then removed, and the plasmid is no longer part of the protoplast. This produces gene-edited fungi. In some embodiments, the resistance cassette can be reused to target subsequent loci in the genome as needed. In some embodiments, a Golden Gate cloning strategy is used to produce gene-edited fungi. In some embodiments, the plasmid comprises the SpCas9 enzyme. In some embodiments, the plasmid comprises a codon-optimized SpCas9 enzyme. Exemplary Cas endonucleases comprising SpCas9 enzymes are shown in Table 5A. In some embodiments, the Cas endonuclease comprises a sequence selected from the group consisting of SEQ ID NOs: 640-657. Additional exemplary Cas sequences are shown in Table 5B. In some embodiments, the Cas endonuclease comprises a sequence selected from the group consisting of SEQ ID NOs: 640-657 and 203.In some embodiments, the Cas enzyme used is a Ustilagomaydis SpCas9 sequence codon-optimized on the backbone.
[0206] Table 5A. Exemplary sequences comprising SpCas9 for use in HDR methods
[0207]
[0208]
[0209]
[0210]
[0211]
[0212]
[0213]
[0214]
[0215]
[0216]
[0217]
[0218]
[0219]
[0220]
[0221]
[0222]
[0223]
[0224] Table 5B. Exemplary Cas sequences
[0225]
[0226]
[0227] In some embodiments, the HDR cassette and guide RNA for a gene described herein are cloned into a plasmid. In some embodiments, the HDR cassette and guide RNA for a PsiD gene described herein are cloned into a plasmid.
[0228]
[0229] In some embodiments, the repair cassettes described herein are cloned. In some embodiments, primers are used to amplify the PsiD gene for homologous recombination (HR). In some embodiments, the primers are the primers listed in Tables 6A-6C.
[0230] Table 6A. Exemplary primers for left flank HR PsiD amplification-PsiD repair cassette cloning
[0231]
[0232] Table 6B. Exemplary primers for right flank HR PsiD amplification-PsiD repair cassette cloning
[0233]
[0234] In some embodiments, the GPD-intron described herein will be amplified using the primers in Table 6C and the GPD:intron plasmids described herein.
[0235] Table 6C. Exemplary primers for GPD-intron amplification-PsiD repair cassette cloning
[0236]
[0237] In some embodiments, a combination of primers from Tables 6A-6C is used. In some embodiments, the plasmid comprises a tRNA-gRNA-scaffold sequence. In some embodiments, the gRNA comprises a PsiD gene gRNA. In some embodiments, the tRNA sequence comprises: ACTAGATTCCCTTACGCCTTCCATCACCTGTCCGCACCCGGCCCCATCCCGCTTTCAACCCCCCGCTCCGAGCCGGCACCGGAGCACACCCACCCAAACCGGTTCGATGGCGTAGTTG GTTATCGCATCTGTCTAACACACAGAAGGTCCTCAGTTCGAGCCTGGGTCGAATCA. In some embodiments, the gRNA sequence comprises: CTCCCAACACTTGATCATGC. In some embodiments, the scaffold sequence comprises: gtttTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTG GCACCGAGTCGGTGCTTTTTTatgccacaacactggtggtacc. In some embodiments, the tRNA sequence is: ACTAGATTCCCTTACGCCTTCCATCACCTGTCCGCACCCGGCCCCATCCCGCTTTCAACC CCCCGCTCCGAGCCGGCACCGGAGCACACCCACCCAAACCGGTTCGATGGCGTAGTTGGTTATCGCATCTGTCTAACACACAGAAGGTCCTCAGTTCGAGCCTGGGTCGAATCA. In some embodiments, the gRNA sequence is: CTCCCAACACTTGATCATGC. In some embodiments, the scaffold sequence is: gtttTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTG GCACCGAGTCGGTGCTTTTTTatgccacaacactggtggtacc. In some embodiments,The tRNA-gRNA-scaffold sequence contains: ACTAGATTCCCTTACGCCTTCCATCACCTGTCCGCACCCGGCCCCATCCCGCTTTCAACCCCCCGCTCCGAGCCGGCACCGGAGCACACCCACCCAAACCGGTTCGATGGCGTAGTTGGTTATCGCATCTGTCTAACACAC AGAAGGTCCTCAGTTCGAGCCTGGGTCGAATCACTCCCAACACTTGATCATGCgtttTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTatgccacaacactggtggtacc. In some embodiments, the tRNA-gRNA-scaffold sequence is: ACTAGATTCCCTTACGCCTTCCATCACCTGTCCGCACCCGGCCCCATCCCGCTTTCAACCCCCCGCTCCGAGCCGGCACCGGAGCACACCCACCCAAACCGGTTCGATGGCGTAGTTGGTTATCGCATCTGTCTAACACACAGAAGGTCCTCAGTTCGAGCCTGGGTCGAATCACTCCCAACACTTGATCATGCgtttTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTatgccacaacactggtggtacc. In some embodiments, the tRNA-gRNA-scaffold is combined with the HDR repair cassette sequence and the B-AMA1 sequence. In some embodiments,The HDR repair cassette sequence contains: ACTGGATTAGGTTGAAGAACCGGCGATCTGGGCAGACGCGCCACGCTCTGAGTACCTAAGGGTGTACTTAAACTGGATTAGGTTGAAGAACCGGCGATCTGGGCAGACGCGCCACGCTCTGAGTACCTAAGGGTGTACTTAAATTTATCACAGCTTGACGTTTGACCTGGAAGCTTGATTTACGCAAGGTTGGAACTTGCACCCCCCGGTCGAGCATCTCTCTCTAGTCATAGTTTATCTTTGTATAAATGGGGGCCTCAACGCAAGGCCGCAAAACTACTCCCAACTTTTATAACTCATTTCTGCTCCCAACACTTGATCAGAGGTCCGCAAGTAGATTGAAAGTTCAGTACGTTTTTAACAATAGAGCATTTTCGAGGCTTGCGTCATTCTGTGTCAGGCTAGCAGTTTATAAGCGTTGAGGATCTAGAGCTGCTGTTCCCGCGTCTCGAATGTTCTCGGTGTTTAGGGGTTAGCAATCTGATATGATAATAATTTGTGATGACATCGATAGTACAAAAACCCCAATTCCGGTCACATCCACCATCTCCGTTTTCTCCCATCTACACACAACAAGCTCATCGCCGTTTGTCTCTCGCTTGCATACCACCCAGCAGCTCACTGATGTCGACTTGTAGaTGCAGGTGATACCCGCGTGCAACTCGGCGTACGTCGTTTTTATTCGCTGACTTCACCCGCTAATTACTATAACTTGAAAACACAGAGCAATAAGATCACTATGTCCTACTCCCGAGTCTTTGAGAAACATGGGATGGCTCTCTGTCAGCGATGCGGTCTACAGCGAGTTCATAGGAGAGTTGGCTACCCGCGCTTCCAATCGAAATTACTCCAACGAGTTCGGCCTCATGCAACCTATCCAGGAATTCA. In some embodiments,The HDR repair cassette sequence is: ACTGGATTAGGTTGAAGAACCGGCGATCTGGGCAGACGCGCCACGCTCTGAGTACCTAAGGGTGTACTTAAACTGGATTAGGTTGAAGAACCGGCGATCTGGGCAGACGCGCCACGCTCTGAGTACCTAAGGGTGTACTTAAATTTATCACAGCTTGACGTTTGACCTGGAAGCTTGATTTACGCAAGGTTGGAACTTGCACCCCCCGGTCGAGCATCTCTCTCTAGTCATAGTTTATCTTTGTATAAATGGGGGCCTCAACGCAAGGCCGCAAAACTACTCCCAACTTTTATAACTCATTTCTGCTCCCAACACTTGATCAGAGGTCCGCAAGTAGATTGAAAGTTCAGTACGTTTTTAACAATAGAGCATTTTCGAGGCTTGCGTCATTCTGTGTCAGGCTAGCAGTTTATAAGCGTTGAGGATCTAGAGCTGCTGTTCCCGCGTCTCGAATGTTCTCGGTGTTTAGGGGTTAGCAATCTGATATGATAATAATTTGTGATGACATCGATAGTACAAAAACCCCAATTCCGGTCACATCCACCATCTCCGTTTTCTCCCATCTACACACAACAAGCTCATCGCCGTTTGTCTCTCGCTTGCATACCACCCAGCAGCTCACTGATGTCGACTTGTAGaTGCAGGTGATACCCGCGTGCAACTCGGCGTACGTCGTTTTTATTCGCTGACTTCACCCGCTAATTACTATAACTTGAAAACACAGAGCAATAAGATCACTATGTCCTACTCCCGAGTCTTTGAGAAACATGGGATGGCTCTCTGTCAGCGATGCGGTCTACAGCGAGTTCATAGGAGAGTTGGCTACCCGCGCTTCCAATCGAAATTACTCCAACGAGTTCGGCCTCATGCAACCTATCCAGGAATTCA. In some embodiments,The B-AMA1 sequence contains: attaccgatcctcgatctttgtgcaagctagcccgcctcggcagcaacaaagcagccgagcaagaagcagtacttgccttctgaatc gtgaatgggttacgttcttcaccgctgtgatcagcgaatcatgaatcaaatcatgagggcattgctgatcatgaatcaaatcatgagggcatttaaaaa ttcagtctgagtcgtgagtagcaagtcggttctggatcggatggcattcatgaatcacagggtcgtgaatcatgaatgttcaagtccccttttctcgag aggctggtgggatcggtgcgaatcacgaatcatgattgtaattcattgagtgaaggagtttcgcagccacccacagtactagaatcacgaatgacaat. In some embodiments, the B-AMA1 sequence is: attaccgatcctcgatctttgtgcaagctagcccgcctcggcagcaacaaagcagccgagcaagaagcagtacttgccttct gaatcgtgaatgggttacgttcttcaccgctgtgatcagcgaatcatgaatcaaatcatgagggcattgctgatcatgaatcaaatcatgagggcatttaaa aattcagtctgagtcgtgagtagcaagtcggttctggatcggatggcattcatgaatcacagggtcgtgaatcatgaatgttcaagtccccttttctcgag aggctggtggggatcggtgcgaatcacgaatcatgattgtaattcattgagtgaaggagtttcgcagccacccacagtactagaatcacgaatgacaat(SEQ ID NO:648). In some embodiments, the B-AMA1 sequence and the HDR repair cassette and tRNA-gRNA-scaffold are combined by overlapping PCR and inserted into the pMGA entry plasmid. In some embodiments, the pMGA plasmid comprises SEQ ID: 309.
[0238] Microhomology-mediated end joining method
[0239]
[0240] Split-Marker Box Method
[0241] In some embodiments, exogenous nucleic acids can be integrated into the genome of a genetically modified organism by homologous recombination. Homologous recombination allows site-specific modification in endogenous genes and can therefore correct inherited or acquired mutations, and / or homology-directed repair (HDR) can be used to engineer new changes into the genome of a genetically modified organism. In some embodiments, a split cassette HDR approach is used. In some embodiments, the genes described herein are replaced with a hygromycin resistance gene. In some embodiments, the PsiD, PsiH, PsiH2, PsiK, PsiP, PsiP2, TrpE, PsiM, PsiT1, PsiT2 genes, or a portion thereof, or any combination thereof, are excised and the hygromycin resistance gene is introduced, for example, into a plasmid. In some embodiments, the hygromycin resistance gene is not integrated or is not stably integrated into the genome of the engineered fungal cell. In some embodiments, the PsiD gene is replaced with a hygromycin resistance gene. In some embodiments, the PsiH gene is replaced with a hygromycin resistance gene. In some embodiments, the PsiH2 gene is replaced with a hygromycin resistance gene. In some embodiments, the PsiK gene is replaced by a hygromycin resistance gene. In some embodiments, the PsiL gene is replaced by a hygromycin resistance gene. In some embodiments, the PsiM gene is replaced by a hygromycin resistance gene. In some embodiments, the PsiP gene is replaced by a hygromycin resistance gene. In some embodiments, the PsiP2 gene is replaced by a hygromycin resistance gene. In some embodiments, the PsiT1 gene is replaced by a hygromycin resistance gene. In some embodiments, the PsiR gene is replaced by a hygromycin resistance gene. In some embodiments, the PsiT2 gene is replaced by a hygromycin resistance gene. In some embodiments, the hygromycin resistance gene is 35s hygromycin. In some embodiments, one or more cassettes are included in the plasmids described herein. In some embodiments, the cassettes are the cassettes described in Table 7B. In some embodiments, the DNA components of the genes described herein are separated into two cassettes. In some embodiments, these can be referred to as split marker cassettes. In some embodiments, the split marker cassettes are used in conjunction with the in vitro assembled Cas9-guide RNA ribonucleoprotein (Table 7A). In some embodiments, the Cas9 guide RNA ribonucleoprotein is a sequence selected from the group consisting of any one of SEQ ID NOs: 660-663. In some embodiments, the split marker cassette is used in conjunction with in vitro assembled Cas9-guide RNA ribonucleoprotein for rapid and efficient gene deletion. In some embodiments, the cassette is at least 1 kb.In some embodiments, the cassette is at least 1 kilobase (kb), at least 1.1 kb, at least 1.2 kb, at least 1.3 kb, at least 1.4 kb, at least 1.5 kb, at least 1.6 kb, at least 1.7 kb, at least 1.8 kb, at least 1.9 kb or at least 2.0 kb. In some embodiments, a variety of guide RNAs are used. In some embodiments, the first guide RNA is located at the beginning of a gene described herein, and the second guide RNA is placed at the end of the same gene described herein for replacement. In some embodiments, the guide RNA is each independently selected from the guide RNA sequence in Table 7A. In some embodiments, the split marker cassette has the sequence listed in Table 7B. In some embodiments, the upstream homology arm sequence (UHA) can be at least 500 base pairs (bp), at least 550 bp, at least 600 bp, at least 650 bp, at least 700 bp, at least 750 bp, at least 800 bp, at least 850 bp, at least 900 bp, at least 950 bp or at least 1000 bp. In some embodiments, the downstream homology arm sequence (DHA) can be at least 500 base pairs (bp), at least 550bp, at least 600bp, at least 650bp, at least 700bp, at least 750bp, at least 800bp, at least 850bp, at least 900bp, at least 950bp, or at least 1000bp.
[0242] Table 7A. HDR guide RNA sequences
[0243]
[0244] Table 7B. Exemplary Cassettes for HDR Integration of PsiDs
[0245]
[0246]
[0247]
[0248]
[0249]
[0250] In some embodiments, the HDR method includes using a sequence to replace the promoter of a gene described herein with a GPDi promoter. In some embodiments, the GPDi promoter has a sequence comprising: GAGGTCCGCAAGTAGATTGAAAGTTCAGTACGTTTTTAACAATAGAGCATTTTCGAGGCTTGCGTCATTCTGTGTCAGGCTAGCAGTTTATAAGCGTTGAGGATCTAGAGCTGCTGTTCCCGCGTCTCGAATGTTCTCGGTGTTTAGGGGTTAGCAATCTGATATGATAATAATTTGTGATGACATCGATAGTACAAAAACCCCAATTCCGGTCACATCCACCATCTCCGTTTTCTCCCATCTACACACAACAAGCTCATCGCCGTTTGTCTCTCGCTTGCATACCACCCAGCAGCTCACTGATGTCGACTTGTAG. In some embodiments, a repair template is used with homology arms on either side of the GPDi promoter. In some embodiments, the homology arms are 111 base pairs to the left of the GPDi promoter. In some embodiments, the homology arm is 125 base pairs to the right of the GPDi promoter. In some embodiments, the homology arm is 111 base pairs to the left of the GPDi promoter, and the homology arm is 125 base pairs to the right of the GPDi promoter. In embodiments describing directionality, unless otherwise indicated, the interpretation should be 5' to 3' directionality. In some embodiments, the first (left) HDR guide is: CTCCCAACACTTGATCATGC. In some embodiments, the second (right) HDR guide is: TCACCTGCATGATCAAGTGT.In some embodiments, the repair template sequence for an HDR method performed on a genetically modified organism is:
[0251] The present disclosure provides a method for genetically modifying an organism to increase the production of one or more alkaloids. In some embodiments, genetic modification is achieved by introducing exogenous nucleic acids (such as donor sequences) into the cells of an organism. Exemplary cells of an organism include fungal cells. Exemplary fungal cells include protoplasts. Exogenous nucleic acids can encode one or more gene products, and when expressed by the organism of the genetic modification, compared with comparable wild-type organisms, the gene products cause the organism of the genetic modification to produce one or more alkaloids of the amount increased. In some cases, one or more genes can be one of the genes listed in Table 1 or Table 2. In some cases, one or more copies of the one or more genes included in Table 1 or Table 2 are provided by exogenous nucleic acids. For example, in some cases, at least 1, 2, 3, 4, 5, 6 or 7 copies of one or more genes are introduced into the genetically modified organism together with exogenous nucleic acids. In some cases, at least a portion of exogenous nucleic acids can be integrated into the genome of the organism. For example, exogenous nucleic acids can be inserted into the genome fracture. In some cases, at least a portion of the exogenous nucleic acid includes sequences homologous to sequences flanking the target sequence for targeted integration. Methods for introducing exogenous nucleic acids into organism cells are generally known to those skilled in the art, but can include the use of homology arms. In other cases, the exogenous nucleic acid can be randomly inserted into the genome of the target organism.
[0252] In some embodiments, exogenous nucleic acid can be integrated into the genome of the genetically modified organism by homologous recombination.Homologous recombination allows site-specific modification in endogenous genes, and therefore can correct hereditary or acquired mutations, and / or can engineer new changes into the genome of the genetically modified organism.
[0253] In some embodiments, exogenous nucleic acid includes a promoter sequence. Increasing the expression of the designed gene product can be achieved by regulating the promoter region to insert a stronger promoter upstream of the desired gene sequence to synthetically increase expression. In some embodiments, for example, a gene promoter is used, such as the 35S gene promoter.
[0254] In some embodiments, the exogenous nucleic acid may comprise a barcode or watermark sequence, which may be referred to as a "barcode". The barcode may comprise a non-natural sequence. In some embodiments, the barcode may be used to identify transgenic organisms via genotyping. In some embodiments, the exogenous nucleic acid may comprise a selective marker, such as an antibiotic resistance gene. The selective marker gene may comprise, for example, a hygromycin resistance gene.
[0255] In some embodiments, for identification purposes, a unique sequence is embedded in the genome of a genetically modified organism described herein using gene editing methods such as CRISPR. In some embodiments, this is referred to as a marker or marker sequence. In some embodiments, this is referred to as a watermark sequence. In some embodiments, this is referred to as an intergenic sequence or a portion thereof. In some embodiments, this is referred to as an intergenic watermark sequence. In some embodiments, this is referred to as a barcode as described above. In some embodiments, the sequence encoding the marker can be incorporated into a genetically modified cell or organism, such as a fungal cell, yeast cell, or plant cell as described herein. In some cases, the marker used as a selection or screening device can function in a reproducible genetically modified organism to produce a compound that will confer resistance to other toxic compounds on the tissues in the organism. In some embodiments, the incorporated sequence encoding the marker can be subsequently removed from the transformed genome. The removal of the sequence encoding the marker can be promoted by the presence of a direct repeat sequence before and after the region encoding the marker. In some embodiments, the marker sequence is followed by a protospacer adjacent motif (PAM) to provide appropriate cutting by a Cas nuclease.
[0256] In some embodiments, exogenous nucleic acid can be introduced into a genetically modified organism by transformation or transfection.
[0257] Transformation Suitable transformation techniques may include, but are not limited to: electroporation of fungal protoplasts; liposome-mediated transformation; polyethylene glycol (PEG)-mediated transformation; transformation using viruses; microinjection of cells; microprojectile bombardment of cells; vacuum infiltration; and Agrobacterium tumefaciens-mediated transformation. Transformation may mean the introduction of a nucleotide sequence into a cell in a manner that results in stable or transient expression of the sequence.
[0258] After transformation, fungi or other organisms can be selected using dominant selective markers incorporated into, for example, transformation vectors. In certain embodiments, such markers confer antibiotic or herbicide resistance to the transformed fungi or other organisms, and the selection of transformants can be completed by exposing fungi and other organisms to antibiotics or herbicides of appropriate concentrations. In some embodiments, ccdb negative selection markers are used. In some embodiments, ccdb negative selection markers are prepared by transforming ccdb sensitive Escherichia coli strains (such as DH5α). After selecting the transformed fungi or other organisms and growing them to maturity, fungi and other organisms showing the changed proterties are identified. The changed proterties can be any one of those described above. Additionally, the expression level or activity of the polypeptide or polynucleotide described herein can be determined by using northern blotting, RT-PCR, RNA seq or microarray analysis of mRNA expression, or by using immunoblotting or protein blotting or gel shift assay analysis of protein expression.
[0259] Suitable methods for transforming fungi or other cells used together with the present disclosure can include almost any method by which nucleic acid can be introduced into the cell, such as by directly delivering DNA, such as by protoplast transformation mediated by PEG, by drying / inhibiting mediated DNA uptake, by electroporation, by stirring with silicon carbide fibers, by Agrobacterium-mediated conversion and by accelerating DNA-coated particles. By using technologies such as these, cells of almost any fungal species can be stably transformed, and these cells develop into transgenic fungi. The method by which exogenous nucleic acids are introduced into the cell of an organism can include using homology arms. In other cases, exogenous nucleic acids can be randomly inserted into the genome of the target organism.
[0260] Agrobacterium-mediated transformation
[0261] Agrobacterium-mediated transfer can be used to introduce exogenous nucleic acids into organisms selected for genetic modification, such as fungal cells. In some cases, exogenous nucleic acids can be introduced into entire fungal tissues, thereby overcoming the need for regenerating complete fungi from protoplasts. Agrobacterium-mediated transformation can be used to integrate one or more vectors into genetically modified organisms, including vectors or sequences encoding gene editing systems such as CRISPR systems or donor sequences.
[0262] The present disclosure includes advances in vectors for Agrobacterium-mediated gene transfer that facilitate the construction of vectors capable of expressing a variety of polypeptide-encoding genes by providing improved gene arrangements and restriction of sites within the vector. In some embodiments, the vector may have a convenient polylinker region flanked by a promoter and polyadenylation sites for direct expression of inserted polypeptide-encoding genes and suitable for the purposes described herein. In addition, Agrobacterium containing both armed and disarmed Ti genes can be used for transformation.
[0263] In some embodiments, fungal cell, yeast cell, plant cell can use electroporation to modify.In order to realize conversion by electroporation, can use fragile tissue, such as suspension culture or embryonic callus of cell, perhaps can directly transform immature embryo or other organized tissue alternatively.In some cases, electroporation can comprise 2 pulses, 3 pulses, 4 pulses, 5 pulses, 6 pulses, 7 pulses, 8 pulses, 9 pulses or 10 times or more pulses.In some embodiments, the protoplast of fungi and / or plant can be used for electroporation conversion.
[0264] Another method for delivering or transforming DNA segments to fungal cells and cells derived from other organisms according to the present invention is microprojectile bombardment. In this method, particles can be coated with nucleic acids and delivered into cells by propulsion. Exemplary particles include particles composed of tungsten, platinum, and preferably gold. It is envisioned that in some cases, DNA precipitation on metal particles is unnecessary for delivering DNA to recipient cells using microprojectile bombardment. However, it is envisioned that particles can contain DNA instead of being coated with DNA. In some embodiments, DNA-coated particles can increase the level of DNA delivery via particle bombardment. For bombardment, cells in the suspension are concentrated on a filter or solid culture medium. Alternatively, immature embryos or other target cells can be arranged on a solid culture medium. The cells that can be bombarded are located at an appropriate distance below the large ejection barrier. In some cases, the starting cell density for genome editing can be changed to optimize editing efficiency and / or cell viability.
[0265] In some embodiments, the fungi, yeast or plant of the present disclosure can be used to produce new plant varieties. In some embodiments, plant development is used to develop new, unique and excellent varieties or hybrids with desired phenotypes. In some embodiments, selection methods (such as molecular marker assisted selection) can be combined with breeding methods to accelerate the process. In some embodiments, the method comprises that (i) any organism comprising an expression cassette provided herein is hybridized with a recipient organism system as a donor to produce an FI colony, and (ii) the offspring is selected to have the expression cassette. Optionally, offspring can be further selected by testing the expression of the gene of interest. In some embodiments, the complete chromosome of the donor organism is transferred. For example, a transgenic organism with an expression cassette can be used as a male or female parent in cross-pollination to produce offspring by receiving transgenic from a donor, thereby producing offspring with an expression cassette. In the method for producing an organism with an expression cassette, protoplast fusion can also be used to transfer transgenic from a donor to a recipient. Protoplast fusion is the induction or spontaneous combination between two or more protoplasts (cells whose cell walls are removed by enzymatic treatment), such as somatic hybridization, to produce single binucleate or multinucleate cells.In some embodiments, can utilize a large number of selections.In a large number of selections, select, gather in the crops the independent plant of expectation, and when there is no offspring test, mix seed to produce the next generation.Due to selection only based on maternal parent, and do not have the control to pollination, therefore a large number of selections are equivalent to the form of random mating and selection.As described herein, the purpose of a large number of selections is to increase the ratio of superior genotype in the colony.
[0266] In some embodiments, a gene editing system is used to genetically modify an organism. The gene editing system can be selected from the group consisting of: CRISPR system, TALEN, zinc finger, transposon-based, ZEN, mega nuclease, Mega-TAL, and any combination thereof. In some embodiments, the gene editing system is guided to the target of interest by guiding a polynucleotide. In some embodiments, the gene editing system relates to an endonuclease or nuclease or a polypeptide encoding a nuclease, which can be from a CRISPR system. The endonuclease or nuclease or a polypeptide encoding a nuclease can be Cas or a polypeptide encoding Cas. CRISPR can refer to a family of DNA repeats present in certain bacterial genomes. In some cases, the CRISPR protein can include a Cas9 endonuclease, which can form a complex with a crRNA / tracrRNA hybrid to identify, bind, and ultimately cleave the exogenous DNA at the target site. The crRNA / tracrRNA hybrid can be designed as a single guide RNA (gRNA). For example, any one or more guide RNAs shown in Table 7A, Table 8 to Table 16. In some embodiments, the gRNA sequence is followed by a protospacer adjacent motif (PAM) to provide for proper cleavage by the Cas nuclease.
[0267] The identification of target DNA target region can depend on the protospacer adjacent motif (PAM), which can be located at the 3' end of the 20bp target sequence. When CRISPR complex (for example, Cas9 and the guide RNA of association) identifies the target DNA sequence, CRISPR complex can produce double-strand breaks (DSB) at the DNA target locus. In some cases, one of these two cell DNA repair mechanisms, non-homologous end joining (NHEJ) and homologous recombination (HR), can play a role in precise genome editing and gene manipulation. For example, NHEJ can be used, which is sometimes considered to be an error-prone repair mechanism that produces short nucleotide insertions or deletions in close proximity to one or more DSB sites. If these short insertions or deletions are present in the gene coding region, or are present in a part for the promoter that participates in raising the protein involved in transcription, the function of the endogenous gene (for example, the gene encoding psilocybin phosphatase) may be destroyed. Therefore, this program can be used to produce genetic mutations. In other embodiments, a homology-independent targeted integration (HITI) strategy that allows fragments (for example, exogenous nucleic acids) to be integrated into the genome by NHEJ repair can be used.
[0268] The present disclosure provides a method for producing a genetically modified organism of one or more alkaloids. Genetic modification can be accomplished using a genome editing (also referred to as gene editing) system, which refers to a set of technologies that confer the ability to change the DNA of an organism. The compositions and methods described herein utilize a genome editing system to perform targeted editing in the genome of an organism, and thereby produce one or more alkaloids of interest. For this reason, a genome editing system as used herein can have a programmable nuclease. In some embodiments, the genome editing system includes zinc finger nucleases (ZFNs). Zinc finger nucleases are artificial endonucleases that can include zinc finger proteins (ZFPs) designed to be fused to a cleavage domain, such as FokI restriction enzymes. In some embodiments, the genome editing system includes transcription activator-like effector nucleases (TALENs). TALENs are restriction enzymes that can be engineered to cut specific DNA sequences. They are formed by fusing TAL effector DNA binding domains with DNA cleavage domains (nucleases that cut DNA chains). Transcription activator-like effectors (TALEs) can be engineered to bind to virtually any desired DNA sequence, so that when combined with nucleases, DNA can be cut at specific positions. In some embodiments, the genome editing system is a meganuclease. In some embodiments, the gene editing system is used to incorporate exogenous nucleic acids into fungi, wherein the incorporation of the exogenous nucleic acid results in a genetic modification that modulates alkaloid production. In some embodiments, the exogenous nucleic acid comprises a sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to one of the sequences listed in Table 2. In some embodiments, the gene editing system is a CRISPR system, such as a CRISPR-Cas9 endonuclease system.
[0269] Various forms of CRISPR systems can be used. In some cases, Agrobacterium tumefaciens-mediated transformation can be used to introduce the CRISPR system into the genome of the target organism. When the expression of the Cas protein and the guide RNA can be under the control of a constitutive or inducible promoter. For example, in some embodiments, the Cas protein is under the control of the GDP gene promoter, and the guide RNA is under the control of the U6 gene promoter. In some embodiments, the guide RNA is directly inserted downstream of the Psilocybe edulis U6 promoter and directly inserted upstream of the guide RNA scaffold sequence. In some cases, the Cas protein is optimized for use in fungal cells.
[0270] In some cases, the endonuclease or nuclease or polypeptide encoding the nuclease can be selected from the group consisting of: Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9, Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm In some cases, the Cas protein can be Cas9. In some cases, the Cas9 is a modified Cas9 that binds to a canonical PAM. In some cases, Cas9 recognizes an atypical PAM. In some cases, the guide polynucleotide binds to a target sequence 3-10 nucleotides from the PAM. In some cases, the CRISPR enzyme coupled to the guide polynucleotide can be delivered to a genetically modified organism as an RNP. In some cases, the CRISPR enzyme coupled to the guide polynucleotide can be delivered to the genetically modified organism via mRNA encoding the CRISPR enzyme and the guide polynucleotide. In some cases, the Cas protein is referred to as a Cas endonuclease or endonuclease. In some cases, the endonuclease or nuclease or polypeptide encoding the nuclease can be Cas9 or a polypeptide encoding Cas9. In some cases, the endonuclease or nuclease or polypeptide encoding the nuclease can be catalytically inactivated. In some cases, the endonuclease or nuclease or polypeptide encoding the nuclease can be a catalytically inactivated Cas9 or a polypeptide encoding a catalytically inactivated Cas9. The Cas endonuclease can be optimized for expression in fungal cells. In some embodiments, the Cas endonuclease is codon optimized. Codon optimization is a process for improving gene expression and increasing the translation efficiency of the gene of interest by adapting to the codon bias of the organism to be modified. In some embodiments, the Cas endonuclease comprises a sequence at least 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO: 203. In some embodiments, the Cas endonuclease comprises a nuclear localization signal. The nuclear localization signal can comprise a sequence at least 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to ccaaaaaaaaaaagaaaagtcggaatccatggagtcccagcagca (SEQ ID NO: 201).In some embodiments, the Cas endonuclease comprises a FLAG tag. The FLAG tag comprises an artificial antigen for which specific, high-affinity monoclonal antibodies have been developed, and thus can be used to purify the protein by affinity chromatography, and can also be used to localize the protein within living cells. The FLAG tag can be attached by a codon-optimized linker that is at least 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to the sequence gattataaagatcatgatggagattataaagatcatgatatcgattataaagatgatgatgataaagcagca (SEQ ID NO: 200).
[0271]
[0272] In some cases, the CRISPR enzyme coupled to the guidance polynucleotide can be delivered to a genetically modified organism by a vector comprising a nucleic acid encoding the CRISPR enzyme and the guidance polynucleotide. On the one hand, the vector can be a binary vector or a Ti plasmid. On the one hand, the vector further comprises a selection marker or a reporter gene. In some cases, RNP, complex or vector can be delivered via electroporation, microinjection, mechanical cell deformation, lipid nanoparticles, AAV, lentivirus, Agrobacterium-mediated transformation, biolistic particle bombardment or protoplast transformation. In some cases, RNP, mRNA or vector further comprises a donor polynucleotide or a nucleic acid encoding a donor polynucleotide. On the one hand, the donor polynucleotide comprises homology to the sequence flanking the target sequence. On the one hand, the donor polynucleotide further comprises a barcode, a reporter gene or a selection marker.
[0273] In some embodiments, Cas endonucleases are used as base editors. In some embodiments, Cas nucleases are part of the Cas system. In some embodiments, the Cas endonuclease is part of a fusion protein. In some embodiments, the fusion protein introduces a nuclear base editor into a sequence described herein. In some embodiments, base editing results in a specific change in the sequence encoding a protein of interest. In some embodiments, base editing results in one or more specific changes in the sequence encoding a protein of interest. In some embodiments, the Cas system comprises an adenine base editor. In some embodiments, the Cas system comprises a cytosine base editor. In some embodiments, the Cas system comprises a cytosine to guanine base editor. In some embodiments, base editing results in a point mutation of a sequence described herein. In some embodiments, base editing results in more than one point mutation of a sequence described herein, and the endonuclease is coupled to a reverse transcriptase. In some embodiments, the guide editing (prime editing) Cas system further comprises a guide editing guide RNA (pegRNA). PegRNA targets the editing mechanism at a specific site on the genome and additionally contains a template sequence and a primer binding sequence. The template sequence encodes the expected genomic sequence change.
[0274] In some embodiments, the method of introducing a genetic modification comprises a primed editing method.In primed editing, an endonuclease makes a single-stranded cut in the target sequence.
[0275] In some embodiments, base editing or guided editing results in an alteration of the genomic sequence. In some embodiments, base editing or guided editing results in an alteration of the genomic sequence that controls gene expression. In some embodiments, base editing or guided editing results in an increase in gene expression of a gene of interest. In some embodiments, base editing or guided editing results in a decrease in gene expression of a gene of interest.
[0276] In some embodiments, the gene editing system further comprises an exogenous nucleic acid. In some embodiments, the exogenous nucleic acid includes a psilocybin synthase gene. In some embodiments, the exogenous nucleic acid includes a tryptophan decarboxylase gene, a psilocybin hydroxylase gene, a psilocybin-related methyltransferase gene, a psilocybin-related kinase gene, a psilocybin-related phosphotransferase gene, or any one of genes encoding a helix-loop-helix transcription factor that binds to an E-box motif. In some embodiments, the exogenous nucleic acid comprises a sequence having at least 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to one of SEQ ID NOs: 1-19, 67-70, or 90-98. In some embodiments, the gene editing system is used to integrate the exogenous nucleic acid into the psilocybin synthase gene. In some embodiments, the gene editing system is used to add or delete one or more nucleic acids of a psilocybin synthase gene (e.g., one of the genes listed in Table 2), thereby producing a frameshift mutation that results in gene downregulation. In some embodiments, the expression of a gene is reduced by about 50%, 75%, 80%, 85%, 90%, 95%, 99% or 100%. Downregulation of a gene can be measured by methods known in the art, including quantitative PCR or RNA sequencing.
[0277] In some embodiments, the gene editing system is used in combination with an exogenous nucleic acid to increase the expression of a polynucleotide, for example, a polynucleotide comprising a sequence having at least 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to one of those listed in any one of Table 2. In some embodiments, the gene editing system is used in combination with an exogenous nucleic acid to increase the expression of a polynucleotide, for example, a polynucleotide comprising a sequence having at least 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to one of SEQ ID NOs: 1-16, 67-70, 90-96. In some embodiments, the endonuclease is a Cas endonuclease as described in Table 5A or Table 5B. In some embodiments, the Cas endonuclease is a Cas9 endonuclease. In some embodiments, the Cas9 endonuclease comprises a sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% identical to SEQ ID NO: 202. In some embodiments, the endonuclease comprises a nuclear localization signal. For example, in some embodiments, the endonuclease comprises a nuclear localization signal comprising a sequence that is at least 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to SEQ ID NO: 201.
[0278] In some embodiments, Cas endonucleases are used as base editors. In some embodiments, Cas nucleases are part of the Cas system. In some embodiments, the Cas endonuclease is part of a fusion protein. In some embodiments, the fusion protein introduces a nuclear base editor into a sequence described herein. In some embodiments, base editing results in a specific change in the sequence encoding a protein of interest. In some embodiments, base editing results in one or more specific changes in the sequence encoding a protein of interest. In some embodiments, the Cas system comprises an adenine base editor. In some embodiments, the Cas system comprises a cytosine base editor. In some embodiments, the Cas system comprises a cytosine to guanine base editor. In some embodiments, base editing results in a point mutation of a sequence described herein. In some embodiments, base editing results in more than one point mutation of a sequence described herein, and the endonuclease is coupled to a reverse transcriptase. In some embodiments, the guide editing Cas system further comprises a guide editing guide RNA (pegRNA). The pegRNA targets the editing mechanism at a specific site on the genome and additionally contains a template sequence and a primer binding sequence. The template sequence encodes the expected genomic sequence change.
[0279] In some embodiments, the method of introducing a genetic modification comprises a primed editing method.In primed editing, an endonuclease makes a single-stranded cut in the target sequence.
[0280] In some embodiments, base editing or guided editing results in an alteration of the genomic sequence. In some embodiments, base editing or guided editing results in an alteration of the genomic sequence that controls gene expression. In some embodiments, base editing or guided editing results in an increase in gene expression of a gene of interest. In some embodiments, base editing or guided editing results in a decrease in gene expression of a gene of interest.
[0281] In some embodiments, the Cas endonuclease is encoded by a polynucleotide optimized for expression in a fungal cell from the genus Psilocybe. Codon optimization is a process for improving gene expression and increasing the translation efficiency of a gene of interest by adapting to the codon bias of a fungal cell. In some embodiments, the polynucleotide comprises codons that frequently appear in the genus Psilocybe. In some embodiments, the endonuclease comprises a nuclear localization signal. In some embodiments, the Cas endonuclease is encoded by a polynucleotide that is at least 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO: 203.
[0282] In some embodiments, expression of the gene editing system in the fungal cell results in a genetic modification that results in increased expression of a psychotropic alkaloid compared to a comparable fungal cell without the gene editing system. In some embodiments, the psychotropic alkaloid is one of: N-acetyl-serotonin, 4-hydroxy-L-tryptophan, 5-hydroxy-L-tryptophan, 7-hydroxy-L-tryptophan, 4-phosphoryloxy-N,N-dimethyltryptamine, serotonin or a derivative thereof, aeruginascin, 2-(4-hydroxy-1H-indol-3-yl)-N,N,N-trimethylethan-1-amine, 4-phosphoryloxy-N,N-dimethyltryptamine, ketamine, melatonin or a derivative thereof, N-acetylserotonin, 3,4-methylenedioxymethamphetamine, isatin, harmine, β-carboline, N,N-dimethyltryptamine (DMT) or a derivative thereof.
[0283] In some embodiments, an endonuclease can be used to genetically modify an organism. Endonucleases can be used to introduce genetic modification into the genome of, for example, a fungal cell, thereby resulting in an increase in the amount of one or more desired alkaloids and / or their derivatives or analogs compared to the amount of the same compound in a comparable control without genetic modification. In some embodiments, the endonuclease can be a Cas endonuclease, such as a Cas 9 endonuclease. The endonuclease can be guided by a nucleic acid such as a guide RNA. The guide RNA can be any of the guide RNAs disclosed in Table 8, Table 9, Table 10, Table 11, Table 12, Table 13, Table 14, Table 15, or Table 16. The guide RNA can be a sequence complementary to any of the guide RNAs disclosed in Table 8, Table 9, Table 10, Table 11, Table 12, Table 13, Table 14, Table 15, or Table 16. The guide RNA may comprise a sequence that binds to a sequence disclosed in Table 8, Table 9, Table 10, Table 11, Table 12, Table 13, Table 14, Table 15, or Table 16. The guide RNA may comprise a sequence that binds to a sequence disclosed in Table 8, Table 9, Table 10, Table 11, Table 12, Table 13, Table 14, Table 15, or Table 16 under stringent conditions. The guide RNA may comprise a target sequence as disclosed in Table 8, Table 9, Table 10, Table 11, Table 12, Table 13, Table 14, Table 15, or Table 16. The target sequence may be at least 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to one of the sequences disclosed in Table 8, Table 9, Table 10, Table 11, Table 12, Table 13, Table 14, Table 15, or Table 16.
[0284] In some embodiments, the endonuclease is delivered together with the guide polynucleotide to target the endonuclease to the endogenous nucleic acid of the organism. In some embodiments, the guide polynucleotide binds to the endogenous nucleic acid and ultimately cleaves the endogenous nucleic acid at the target site. The cleavage of the endogenous nucleic acid at the target site can result in the deleterious loss of the protein encoded by the nucleic acid. In some embodiments, the guide polynucleotide is used to target a gene, such as a psilocybin synthase gene, for knocking down or knocking out. The gene can be a psilocybin synthase gene. The gene can be one of the genes listed in Tables 1 and 2. The gene can be targeted by designing a guide polynucleotide that is complementary to a portion of one of the genes listed in Tables 1 and 2. The gene can be targeted by designing a guide polynucleotide that is complementary to a portion of one of the genes listed in Tables 8-16. The guide polynucleotide can target a gene comprising, for example, a sequence of one of SEQ ID NOs: 29-87. In some embodiments, the guide polynucleotide binds to a gene comprising the target sequence SEQ ID NOs: 29-87. In some embodiments, the guide polynucleotide binds within about 100 bases, about 75 bases, about 50 bases, about 25 bases, about 5 bases, or 1 base of a sequence comprising one of SEQ ID NOs: 29-87. In some embodiments, the guide polynucleotide binds to a gene at a locus that at least partially overlaps with a sequence comprising one of SEQ ID NOs: 29-87. In some embodiments, the guide polynucleotide comprises a targeting sequence that is complementary to one of SEQ ID NOs: 29-87. In some embodiments, the guide polynucleotide comprises a targeting sequence that binds to one of SEQ ID NOs: 29-87.
[0285] Thus, in some embodiments, the guide polynucleotide is combined with an endonuclease to knock down or knock out a gene, such as PsiD, PsiK, PsiM, PsiP1, PsiP2, PsiH, PsiH2, PsiR, TrpD, TrpE, or any combination thereof. Unless otherwise indicated, as used herein, PsiP refers to a PsiP phosphatase family gene or its protein expression product. When a fungus contains multiple PsiP genes, the genes or their protein expression products referred to herein may be numbered to distinguish them, e.g., PsiP1 and PsiP2.
[0286] In some embodiments, the gRNA sequence is followed by a protospacer adjacent motif (PAM) to provide for proper cleavage by the Cas nuclease.
[0287] The identification of target DNA target region can depend on the protospacer adjacent motif (PAM), which can be located at the 3' end of the 20bp target sequence. When CRISPR complex (for example, Cas9 and the guide RNA of association) identifies the target DNA sequence, CRISPR complex can produce double-strand breaks (DSB) at the DNA target locus. In some cases, one of these two cell DNA repair mechanisms, non-homologous end joining (NHEJ) and homologous recombination (HR), can play a role in precise genome editing and gene manipulation. For example, NHEJ can be used, which is sometimes considered to be an error-prone repair mechanism that produces short nucleotide insertions or deletions in close proximity to one or more DSB sites. If these short insertions or deletions are present in the gene coding region, or are present in a part for the promoter that participates in raising the protein involved in transcription, the function of the endogenous gene (for example, the gene encoding psilocybin phosphatase) may be destroyed. Therefore, this program can be used to produce genetic mutations. In other embodiments, a homology-independent targeted integration (HITI) strategy that allows fragments (for example, exogenous nucleic acids) to be integrated into the genome by NHEJ repair can be used.
[0288] Various forms of CRISPR systems can be used. In some cases, Agrobacterium tumefaciens-mediated transformation can be used to introduce the CRISPR system into the genome of the target organism. When the expression of the Cas protein and the guide RNA can be under the control of a constitutive or inducible promoter. For example, in some embodiments, the Cas protein is under the control of the GDP gene promoter, and the guide RNA is under the control of the U6 gene promoter. In some embodiments, the guide RNA is directly inserted downstream of the Psilocybe edulis U6 promoter and directly inserted upstream of the guide RNA scaffold sequence. In some cases, the Cas protein is optimized for use in fungal cells.
[0289] In some embodiments, an endonuclease system for genetically modifying an organism described herein comprises a CRISPR enzyme and a guide nucleic acid that hybridizes to a target sequence in or near a gene, or a promoter or enhancer associated with a gene. In some cases, the target sequence can be at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, or at least 22 nucleotides in length.
[0290] In some embodiments, the target sequence can be up to 7 nucleotides in length. In some cases, the target sequence can hybridize to at least one of SEQ ID NOs: 1-19 or 90-91, a gene selected from Table 1, or a regulatory element of a gene. In some cases, the guide nucleic acid can be chemically modified. In one embodiment, the guide polynucleotide is a single guide RNA (sgRNA). In one embodiment, the guide nucleic acid can be a chimeric single guide comprising RNA and DNA. In some cases, the CRISPR enzyme can include or be a Cas protein or a variant or derivative thereof. In some cases, the Cas protein includes Cast, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5d, CasSt, Cas5h, Cas5a, Cas6, Cas7, Cas8, Cas9, Cas10, Csy1, Csy2, Csy3, Csy4, Csel, Cse2, Cse3, Cse4, CseSe, Csci, Csc2, Csa5, Csn1, Csn2, Csml, Csm2, Csm3, Csrn4, Csm5, Csm6, Cmr, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, CsxlS, Csf In some cases, the CRISPR enzyme coupled to the guide polynucleotide can be delivered to the genetically modified organism as an RNP. In some cases, the CRISPR enzyme coupled to the guide polynucleotide can be delivered to the genetically modified organism via mRNA encoding the CRISPR enzyme and the guide polynucleotide.
[0291] Table 8. Exemplary gRNA target + PAM sequences for PsiDs
[0292] SEQ ID NO. Instructions Sequence+PAM 29 638 / fw ATTGCGGCTGGTTGAACGAG CGG 30 515 / fw TCTCTGCATTCACGAGACAA AGG 31 711 / rev AGAGTTGAAGCCGTAGTATG GGG 32 275 / fw TTTCATTGAAAGCGACCCGG TGG 33 622 / fw CAGTTCGACGACAGACATTG CGG 34 793 / fw ATCGACCGACCTGTCGTCGG TGG
[0293] Table 9. Exemplary gRNA target + PAM sequences for PsiP
[0294]
[0295]
[0296] Table 10. Exemplary gRNA target + PAM sequences for PsiP2
[0297] SEQ ID NO. Instructions Sequence+PAM 41 486 / rev TTGGATATCTGGCTCCATGA CGG 42 454 / fw CATCTCCGGTTATACCGCAA GGG 43 124 / rev GCTGTTATAGTAGCGTTGGG AGG 44 914 / fw CGTGGTAACTGTAGCTCGAA TGG 45 335 / fw CTTCCCTCTAATCAATCCTG GGG 46 454 / fw CATCTCCGGTTATACCGCAA GGG
[0298] Table 11 shows the gRNA target sequences for TrpE
[0299] SEQ ID NO. Instructions Sequence+PAM 47 1077 / fw TTGCTGGTACCATCAAACGA GGG 48 487 / rev GTCGTACGACACATATCCGA TGG 49 571 / fw AGATGTTCTTGGGATTCCAG AGG 50 821 / fw GTCGGAAAAGATGGCTACGA AGG 51 925 / rev GATTTGACGAAGATGACGGT AGG 52 803 / fw AATGAGGGGGTGTCCAACGT CGG
[0300] Table 12. Exemplary gRNA target + PAM sequences for TrpM
[0301] SEQ ID NO. Instructions Sequence+PAM 53 1432 / rev CAAGGAATATGCGTCCACAT CGG 54 852 / rev AAAAATACAACATGAAGGGG CGG 55 910 / rev CAGCGATAAAAGAAAAGACA CGG 56 707 / rev ATTGGTAATCCACCGATGGG AGG 57 790 / rev CTCTGACATGGAGGTCAAGG AGG 58 580 / rev GGATCTTGAAATGTCTCCAA GGG
[0302] Table 13. Exemplary gRNA target + PAM sequences for PsiH
[0303] SEQ ID NO. Instructions Sequence+PAM 70 / Fw TCGTTTCTCGTAGAGTGAGG CGG 91 / Rev AAGGGAATAGGAATGCCAGG CGG 255 / Fw AGACACCGATATTCTCTACG TGG 195 / Rev TCATATATTAGAAGTCAACG CGG
[0304] Table 14. gRNA+PAM target sequences for PsiRs.
[0305]
[0306]
[0307] In some embodiments, it is a watermark sequence. In some embodiments, the watermark sequence is referred to as an intergenic sequence. In some embodiments, the watermark sequence is a guide RNA sequence. In some embodiments, the plasmids described herein comprise a watermark sequence. In some embodiments, the watermark sequence is introduced using a guide RNA target. In some embodiments, the watermark sequence is introduced using a guide RNA target and a PAM. In some embodiments, the guide RNA target is a sequence in Table 15. In some embodiments, the guide RNA target is 80%, 85%, 90%, 95%, or 100% identical to a sequence in Table 15.
[0308] Table 15. Exemplary gRNA target + PAM sequences for introducing intergenic watermarks
[0309] SEQ ID NO. Instructions Sequence+PAM 59 662 / fw GTGAACATTTCACCAATCTG CGG 60 853 / fw TCGAAGGAGGAGACTATAGG CGG 61 526 / rev GAACCATCCAAATGATACAA CGG 62 301 / rev GAACCGACGAACTTCAAGAT GGG 63 456 / fw CAGTACGTCGCGTCGAACGA AGG 64 769 / rev GTCTAAAGGTTGGTTAGTGA GGG
[0310] Table 16. gRNA target sequences for gene editing of Psi genes
[0311]
[0312]
[0313] In some embodiments, the endonuclease comprises at least one nuclear localization signal. In some embodiments, the endonuclease is delivered to the cell as a functional protein (e.g., ribonucleoprotein), wherein the protein comprises a nuclear localization size and associates with a guide RNA. In other cases, an exogenous nucleic acid encoding an endonuclease guided by at least one RNA comprising at least one nuclear localization signal is introduced into the cell of an organism for genetic modification.
[0314] In some embodiments, the CRISPR enzyme coupled to the guide polynucleotide can be delivered to a genetically modified organism by a vector comprising a nucleic acid encoding the CRISPR enzyme and the guide polynucleotide. In one embodiment, the vector further comprises a selection marker or a reporter gene. In other cases, the RNP, complex or vector can be delivered via Agrobacterium-mediated transformation, gene gun particle bombardment or protoplast transformation. In some cases, the RNP, mRNA or vector further comprises a donor polynucleotide or a nucleic acid encoding a donor polynucleotide. In one embodiment, the donor polynucleotide (e.g., an exogenous nucleic acid) comprises homology to a sequence flanking the target sequence. In one embodiment, the donor polynucleotide further comprises a barcode, a reporter gene or a selection marker.
[0315] In some embodiments, the exogenous nucleic acid is incorporated into a plasmid. In some cases, the plasmid is pGWB5 or pGHGWY. In some cases, the plasmid is delivered to the genetically modified organism via electroporation, microinjection, mechanical cell deformation, lipid nanoparticles, AAV, lentivirus, Agrobacterium-mediated transformation, biolistic particle bombardment, or protoplast transformation. In some cases, the plasmid further comprises a barcode, a reporter gene, or a selectable marker. In some cases, the plasmid further comprises a promoter. In some cases, the promoter is 35S, GPD, EF1a, actin, or CcDED1. In some cases, the promoter may be 75%, 80%, 85%, 90%, or 95% identical to SEQ ID NO.: 165. In some cases, the promoter may be 100% identical to SEQ ID NO.: 165. In some cases, the promoter may be 75%, 80%, 85%, 90%, or 95% identical to SEQ ID NO.: 250. In some cases, the promoter may be 100% identical to SEQ ID NO.:250. In some cases, the promoter may be 75%, 80%, 85%, 90%, or 95% identical to SEQ ID NO.:251. In some cases, the promoter may be 100% identical to SEQ ID NO.:251. In some cases, the promoter may be 75%, 80%, 85%, 90%, or 95% identical to SEQ ID NO.:252. In some cases, the promoter may be 100% identical to SEQ ID NO.:252. In some cases, the promoter may be 75%, 80%, 85%, 90%, or 95% identical to SEQ ID NO.:253. In some cases, the promoter may be 100% identical to SEQ ID NO.:253. In some cases, the promoter may be 75%, 80%, 85%, 90%, or 95% identical to SEQ ID NO.:30. In some cases, the promoter may be 100% identical to SEQ ID NO.: 30. In some cases, the promoter may be 75%, 80%, 85%, 90%, or 95% identical to SEQ ID NO.: 32. In some cases, the promoter may be 100% identical to SEQ ID NO.: 32.
[0316] In some embodiments, genetic modification can be performed by contacting cells of an organism with a gene editing system. In some embodiments, the gene editing system comprises a Cas endonuclease, a TALE-nuclease, a transposon-based nuclease, a zinc finger nuclease, a mega-nuclease, argonaut, a Mega-TAL, or a DNA-guided nuclease. In some embodiments, the gene editing system comprises a DNA-guided nuclease with argonaut.
[0317] Analysis of alkaloids produced in genetically modified organisms
[0318] In some embodiments, the alkaloids are quantified by liquid chromatography-mass spectrometry (LC-MS). In some embodiments, the sample for quantification is first freeze-dried and then quantified by dry weight analysis. In some embodiments, the alkaloids of the free dry sample are quantified by LC-MS. In some embodiments, the alkaloids are quantified by HRMS. In some embodiments, the alkaloids are detected by high resolution mass spectrometry (HRMS). In some embodiments, the alkaloids are also extracted from fungal tissue samples and then analyzed. In some embodiments, the alkaloids are detected by 1 H NMR (nuclear magnetic resonance), 13 C or 31 P NMR analysis. In some embodiments, the alkaloids are 1 H NMR, 13 C and 31 P NMR analysis. In some embodiments, the alkaloids are purified before analysis. In some embodiments, the alkaloids are separated and purified. In some embodiments, the alkaloids are separated and purified by chromatography. In some embodiments, the alkaloids are separated and purified using high performance liquid chromatography (HPLC). In some embodiments, the alkaloids are separated and purified using UPLC or UHPLC. In some embodiments, the alkaloids are not separated or purified, but directly analyzed in the fungal sample. In some embodiments, an extract of an alkaloid or multiple alkaloids isolated from a genetically modified fungus is prepared. In some embodiments, the alkaloids can be purified and separated separately. In some embodiments, the alkaloid content is measured as the total alkaloid content, which means that the amount includes the net alkaloid content of the multiple alkaloid compounds produced by the genetically modified fungal cells.
[0319] In some embodiments, the alkaloid produced results from genetic modification of genes within the psilocybin biosynthetic pathway. In some embodiments, the alkaloid produced results from genetic modification of genes near the psilocybin biosynthetic pathway gene cluster.
[0320] Alkaloid production in genetically modified organisms
[0321] In some embodiments, the genetic modifications described herein allow for the production of alkaloids in increased amounts measured by dry weight % compared to the amounts of comparable unmodified organisms (i.e., wild-type organisms). In some cases, the alkaloids are secondary metabolites. In some embodiments, the genetically modified fungi also contain non-naturally occurring alkaloids. In some embodiments, the genetically modified fungi contain non-naturally occurring harmala alkaloids. In some embodiments, the genetically modified fungi contain N,N-dimethyltryptamine and harmala alkaloids. In some cases, the alkaloids are neuroactive alkaloids. In some cases, the alkaloids are psychotropic alkaloids. In some cases, the alkaloids are neuroactive alkaloids. In some cases, the alkaloids are psychotropic alkaloids. In some cases, the alkaloids are tryptophan-derived alkaloids. For example, the alkaloids can be psilocybin or its derivatives or analogs. In some cases, the alkaloids are dephosphorylated psilocybin. In some cases, the alkaloids can be norpsilocybin. In some cases, the alkaloids can be tryptamine. In some cases, the alkaloids can be 4-hydroxytryptamine. In some cases, the alkaloid may be N,N-dimethyltryptamine. In some cases, the alkaloid may be serotonin. In some cases, the alkaloid may be melatonin. In some cases, the alkaloid may be melanin. In some cases, the alkaloid may be N-acetyl-serotonin. In some cases, the alkaloid may be 4-hydroxy-L-tryptophan. In some cases, the alkaloid may be 5-hydroxy-L-tryptophan. In some cases, the alkaloid may be 7-hydroxy-L-tryptophan. In some cases, the alkaloid may be 4-phosphoryloxy-N,N-dimethyltryptamine. In some cases, the alkaloid may be aeruginascin. In some cases, the alkaloid may be 2-(4-hydroxy-1H-indol-3-yl)-N,N,N-trimethyleth-1-ammonium, 4-phosphoryloxy-N,N-dimethyltryptamine. In some cases, the alkaloid may be ketamine. In some cases, the alkaloid may be N-acetylserotonin. In some cases, the alkaloid may be 3,4-methylenedioxymethamphetamine. In some cases, the alkaloid can be a beta-carboline.
[0322] In some embodiments, the combination of alkaloids can be produced at a higher concentration measured in % by dry weight. In some cases, the alkaloids include any one or more of psilocybin, demethyldephosphorus psilocybin, dephosphorus psilocybin, tryptamine, 4-hydroxytryptamine, N,N-dimethyltryptamine, norpsilocybin, nordimethylpsilocybin, serotonin, melatonin, melanin, N-acetyl-serotonin, 4-hydroxy-L-tryptophan, 5-hydroxy-L-tryptophan, 7-hydroxy-L-tryptophan, 4-phosphoryloxy-N,N-dimethyltryptamine, serotonin, aeruginascin, 2-(4-hydroxy-1H-indol-3-yl)-N,N,N-trimethylethan-1-amine, 4-phosphoryloxy-N,N-dimethyltryptamine, ketamine, N-acetylserotonin, 3,4-methylenedioxymethamphetamine, β-carboline, or any derivative or any analog thereof.
[0323] For example, in some embodiments, the genetically modified organisms can independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200% and more up to 400% percent of a tryptamine-derivative alkaloid or a tryptophan-derivative alkaloid compound as measured by dry weight and compared to a comparable control without the genetic modification.
[0324] In some embodiments, the genetically modified organisms may independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200% and more up to 400% percent of a psilocybin compound or derivative thereof as measured by dry weight and compared to a comparable control without the genetic modification.
[0325] In some embodiments, the genetically modified organisms may independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200% and more up to 400% percent dephosphorylated psilocybin compound as measured by dry weight and compared to a comparable control without the genetic modification.
[0326] In some cases, the genetically modified organisms may independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200% and more up to 400% of a compound, such as demethyldephosphinopine, psilocybin, dephosphinopine, or DMT, as measured by dry weight and compared to a comparable control without the genetic modification.
[0327] In some embodiments, the genetically modified organisms may independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200% and more up to 400% percent of nordimethylpsilocybin or a norpsilocybin compound or derivative thereof as measured by dry weight and compared to a comparable control without the genetic modification.
[0328] In some embodiments, the genetically modified organisms may independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 240%, 241%, 242%, 243%, 244%, 245%, 246%, 247%, 248%, 249%, 250%, 0%, 125%, 150%, 175%, 200% and more up to 400% percentages of serotonin, melatonin, melanin, N-acetyl-hydroxytryptamine, serotonin, aeruginascin, 2-(4-hydroxy-1H-indol-3-yl)-N,N,N-trimethylethane-1-amine, ketamine, N-acetylserotonin, 3,4-methylenedioxymethamphetamine, a beta-carboline compound or any derivative thereof.
[0329] In some embodiments, the detection of tryptamine derivatives or secondary metabolites produced by genetically modified organisms can be characterized by LCMS. In some cases, the detection of tryptamine derivatives or secondary metabolites produced by genetically modified organisms can be characterized by MALDI-TOF. In some cases, the detection of tryptamine derivatives or secondary metabolites produced by genetically modified organisms can be characterized by any analytical technique comparable to LCMS or GCMS.
[0330] In some embodiments, the genetically modified organism is analyzed using conventional methods to identify and / or quantify the amount of a secondary metabolite described herein present in the genetically modified organism.
[0331] Production of Peganum harmala alkaloids
[0332] Another class of alkaloids also derived from L-tryptophan (4) are the harmal alkaloids (e.g., harmane and harmine), which contain a β-carboline core scaffold. Harmine alkaloids have been detected in Psilocybin fungi at very low concentrations of about 0.2 μg / g. Harmine alkaloids are neuroactive compounds that inhibit the enzyme monoamine oxidase (MAO), which degrades psilocybin in the body. In some cases, the monoamine oxidase can be: MAO A, MAO B, or a combination of MAO A and MAO B. In some cases, an inhibitor of MAO A, MAO B, or MAO can be: i) contained in any composition or pharmaceutical composition herein; or ii) administered simultaneously or sequentially with a composition or pharmaceutical composition herein via the same or different routes of administration. Thus, the presence of a monoamine oxidase inhibitor (which can be a β-carboline-containing alkaloid) can help prevent the degradation of psilocybin or DMT in humans (i.e., increase the half-life of psilocybin or DMT). Therefore, the presence of β-carboline-containing alkaloids can help prevent DMT from degrading in the human body. In some embodiments, inhibition of the PsiH gene can lead to increased production of the Peganum harmalidoids described herein. Exemplary β-carboline-containing alkaloids include harmine, harmaline, harmalol, tetrahydroharmine, harmaline, isoharmine, methyl harmalate, harmic acid, harmanamide, and acetylnorharmine and their derivatives and analogs. In some embodiments, the Peganum harmalidoids are produced by genetically modified organisms described herein. In some embodiments, the Peganum harmalidoids can be one of the following:
[0333]
[0334] In some embodiments, the genetically modified organisms can independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200% and more up to 400% percent of a harmine compound or derivative thereof as measured by dry weight and compared to a comparable control without the genetic modification.
[0335] In some embodiments, the genetically modified organisms can independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200% and more up to 400% percent of a harmine compound or derivative thereof as measured by dry weight and compared to a comparable control without the genetic modification.
[0336] In some embodiments, the genetically modified organisms can independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200% and more up to 400% percent of a harmalol compound or derivative thereof as measured by dry weight and compared to a comparable control without the genetic modification.
[0337] In some embodiments, the genetically modified organisms can independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200% and more up to 400% percent of a 1,2,3,4-tetrahydroharmaline compound or derivative thereof as measured by dry weight and compared to a comparable control without the genetic modification.
[0338] In some embodiments, the genetically modified organisms can independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200% and more up to 400% percent of a harmalane compound or derivative thereof as measured by dry weight and compared to a comparable control without the genetic modification.
[0339] In some embodiments, the genetically modified organisms may independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200% and more up to 400% percent of a compound of isoharmine or a derivative thereof as measured by dry weight and compared to a comparable control without the genetic modification.
[0340] In some embodiments, the genetically modified organisms can independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200%, and more up to 400% percent of the methyl-7-methoxy-β-carboline-1-carboxylate compound or derivative thereof as measured by dry weight and compared to a comparable control without the genetic modification.
[0341] In some embodiments, the genetically modified organisms can independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200% and more up to 400% percentage of methyl-7-methoxy-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4β]-indole-1-carboxylate compound or a derivative thereof as measured by dry weight and compared to a comparable control without the genetic modification.
[0342] In some embodiments, the genetically modified organisms can independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200%, and more up to 400% percent of the harmanilic acid compound or derivative thereof as measured by dry weight and compared to a comparable control without the genetic modification.
[0343] In some embodiments, the genetically modified organisms can independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200% and more up to 400% percent of a compound of the invention or a derivative thereof as measured by dry weight and compared to a comparable control without the genetic modification.
[0344] In some embodiments, the genetically modified organisms can independently comprise about: 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200% and more up to 400% percent of an acetylnorharmaline compound or derivative thereof as measured by dry weight and compared to a comparable control without the genetic modification.
[0345] In some embodiments, the detection of tryptamine derivatives or secondary metabolites produced by genetically modified organisms can be characterized by LCMS. In some cases, the detection of tryptamine derivatives or secondary metabolites produced by genetically modified organisms can be characterized by MALDI-TOF. In some cases, the detection of tryptamine derivatives or secondary metabolites produced by genetically modified organisms can be characterized by any analytical technique comparable to LCMS or GCMS.
[0346] In some embodiments, conventional methods are used to analyze the genetically modified organisms to identify and / or quantify the amount of secondary metabolites described herein present in the genetically modified organisms. In some embodiments, the genetically engineered fungi comprise Pegan harmala alkaloids (e.g., harmanine and harmaline). In some embodiments, the amount of Pegan harmala in the genetically engineered fungi described herein has an increased amount of Pegan harmala alkaloids compared to comparable wild-type fungi.
[0347] Regulation of DMT in genetically modified fungi
[0348] As described herein, N,N-dimethyltryptamine (DMT) can participate in the psilocybin biosynthesis pathway. Additional methods for producing DMT through genetically modified fungi can be obtained by utilizing well-described metabolic and proteomic gene pathways. As described herein, many downstream alkaloids are produced through the genomic pathway responsible for tryptophan biosynthesis. DMT is one such downstream alkaloid of tryptophan. One genomic pathway of particular interest involves targeting indoleethylamine-N-methyltransferase (INMT) and TrpM gene sequences. In some embodiments, the engineered fungi described herein comprise overexpression of DMT. In some embodiments, the engineered fungi described herein comprise increased production of DMT and overexpression of a PsiD gene. In some embodiments, the engineered fungi described herein comprise overexpression of an INMT gene and overexpression of a PsiD gene. In some embodiments, the engineered fungi described herein comprise overexpression of an INMT gene and reduced expression of a PsiH gene. In some embodiments, the engineered fungi described herein comprise overexpression of an INMT gene and reduced expression of a PsiH2 gene. In some embodiments, the engineered fungi described herein comprise overexpression of the INMT gene and reduced expression of the PsiH and PsiH2 genes. In some embodiments, the engineered fungi described herein produce increased amounts of the rare alkaloids described herein.
[0349] In some embodiments, the engineered fungi described herein comprise overexpression of the HsINMT gene and overexpression of the PsiD gene. In some embodiments, the engineered fungi described herein comprise overexpression of the HsINMT gene and reduced expression of the PsiH gene. In some embodiments, the engineered fungi described herein comprise overexpression of the HsINMT gene and reduced expression of the PsiH2 gene. In some embodiments, the engineered fungi described herein comprise overexpression of the HsINMT gene and reduced expression of the PsiH and PsiH2 genes. In some embodiments, the engineered fungi described herein produce an increased amount of rare alkaloids described herein. In some embodiments, the HsINMT gene is optimized for Psilocybe fungi. In some embodiments, the HsINMT gene is included in the Ustilago mays optimized sequence.
[0350] In some embodiments, the engineered fungi described herein comprise overexpression of the PcINMT gene and overexpression of the PsiD gene. In some embodiments, the engineered fungi described herein comprise overexpression of the PcINMT gene and reduced expression of the PsiH gene. In some embodiments, the engineered fungi described herein comprise overexpression of the PcINMT gene and reduced expression of the PsiH2 gene. In some embodiments, the engineered fungi described herein comprise overexpression of the PcINMT gene and reduced expression of the PsiH and PsiH2 genes. In some embodiments, the engineered fungi described herein produce increased amounts of the rare alkaloids described herein. In some embodiments, the PcINMT gene is optimized for Psilocybe fungi. In some embodiments, the PcINMT gene is included in the optimized sequence for Ustilago maydis.
[0351] In some embodiments, the engineered fungi described herein comprise overexpression of the ZfINMT gene and overexpression of the PsiD gene. In some embodiments, the engineered fungi described herein comprise overexpression of the ZfINMT gene and reduced expression of the PsiH gene. In some embodiments, the engineered fungi described herein comprise overexpression of the ZfINMT gene and reduced expression of the PsiH2 gene. In some embodiments, the engineered fungi described herein comprise overexpression of the ZfINMT gene and reduced expression of the PsiH and PsiH2 genes. In some embodiments, the engineered fungi described herein produce increased amounts of the rare alkaloids described herein. In some embodiments, the ZfINMT gene is optimized for Psilocybe fungi. In some embodiments, the ZfINMT gene is included in the optimized sequence for Ustilago maydis.
[0352] In some embodiments, the engineered fungi described herein comprise overexpression of a plant INMT gene and overexpression of a PsiD gene. In some embodiments, the engineered fungi described herein comprise overexpression of a plant INMT gene and reduced expression of a PsiH gene. In some embodiments, the engineered fungi described herein comprise overexpression of a plant INMT gene and reduced expression of a PsiH2 gene. In some embodiments, the engineered fungi described herein comprise overexpression of a plant INMT gene and reduced expression of a PsiH and PsiH2 gene. In some embodiments, the engineered fungi described herein produce increased amounts of the rare alkaloids described herein. In some embodiments, the plant INMT gene is optimized for Psilocybe fungi. In some embodiments, the plant INMT gene is included in the Ustilago maydis optimized sequence.
[0353] In some embodiments, the engineered fungi described herein produce increased amounts of the novel alkaloids described herein. In some embodiments, the engineered fungi described herein produce increased amounts of DMT. In some embodiments, the engineered fungi described herein produce increased amounts of Pegan harmala alkaloids. In some embodiments, the engineered fungi described herein produce increased amounts of Pegan harmala alkaloids and increased production of DMT. In some embodiments, the plasmids used herein comprise the human INMT gene.In some embodiments, the human INMT gene is optimized for Psilocybe cubensis, and the optimized HsINMT gene comprises the following sequence: ATGAAAGGAGGATTCACAGGAGGAGATGAATATCAAAAACATTTCCTCCCAAGAGATTATCTCGCAACATATTATTCTTTCGATGGATCTCCATCTCCAGAAGCAGAAATGCTCAAATTCAACCTCGAATGCCTCCATAAAACATTCGGACCAGGAGGACTCCAAGGAGATACACTCATCGATATCGGATCTGGACCAACAATCTATCAAGTCCTCGCAGCATTCGATTCTTTCCAAGATATCACACTCTCTGATTTCACAGATAGAAACAGAGAAGAACTCGAAAAATGGCTCAAAAAAGAACCAGGAGCATATGATTGGACACCAGCAGTCAAATTCGCATGCGAACTCGAAGGAAACTCTGGAAGATGGGAAGAAAAAGAAGAAAAACTCAGAGCAGCAGTCAAAAGAGTCCTCAAATGCGATGTCCATCTCGGAAACCCACTCGCACCAGCAGTCCTCCCACTCGCAGATTGCGTCCTCACACTCCTCGCAATGGAATGCGCATGCTGCTCTCTCGATGCATATAGAGCAGCACTCTGCAACCTCGCATCTCTCCTCAAACCAGGAGGACATCTCGTCACAACAGTCACACTCAGACTCCCATCTTATATGGTCGGAAAAAGAGAATTCTCTTGCGTCGCACTCGAAAAAGAAGAAGTCGAACAAGCAGTCCTCGATGCAGGATTCGATATCGAACAACTCCTCCATTCTCCACAATCTTATTCTGTCACAAACGCAGCAAACAACGGAGTCTGCTTCATCGTCGCAAGAAAAAAACCAGGACCA(SEQ ID NO:190).In some embodiments, the INMT gene is optimized for Psilocybe cubensis, and the sequence comprises: atgaagggcggcttcaccggcggcgacgagtaccagaagcacttcctcccccgcgactacctcgccacctactactcgttcgacggctcgccctcgcccgaggccgagatgctcaagttcaacctcgagtgcctccacaagaccttcggccccggcggcctccagggcgacaccctcatcgacatcggctcgggccccaccatctaccaggtcctcgccgccttcgactcgttccaggacatcaccctctcggacttcaccgaccgcaaccgcgaggagctcgagaagtggctcaagaaggagcccggcgcctacgactggacccccgccgtcaagttcgcctgcgagctcgagggcaactcgggccgctgggaggagaaggaggagaagctccgcgccgccgtcaagcgcgtcctcaagtgcgacgtccacctcggcaaccccctcgcccccgccgtcctccccctcgccgactgcgtcctcaccctcctcgccatggagtgcgcctgctgctcgctcgacgcctaccgcgccgccctctgcaacctcgcctcgctcctcaagcccggcggccacctcgtcaccaccgtcaccctccgcctcccctcgtacatggtcggcaagcgcgagttctcgtgcgtcgccctcgagaaggaggaggtcgagcaggccgtcctcgacgccggcttcgacatcgagcagctcctccactcgccccagtcgtactcggtcaccaacgccgccaacaacggcgtctgcttcatcgtcgcccgcaagaagcccggcccctag (SEQ ID NO:191).
[0354] In some embodiments, the plasmid used herein comprises a zebrafish INMT gene. In some embodiments, the zebrafish INMT gene optimized for Psilocybe edulis comprises: (SEQ ID NO: 192). In some embodiments, the INMT gene described herein is incorporated into a plasmid and operably linked to a promoter. In some embodiments, the INMT gene described herein is incorporated into a plasmid and operably linked to a terminator.In some embodiments, the terminator sequence comprises: AGTAGATGCCGACCGGATCTGTCGATCGACAAGCTCGAGTTTCTCCATAATAATGTGTGAGTAGTTCCCAGATAAGGGAATTAGGGTTCCTATAGGGTTTCGCTCATGTGTTGAGCATATAAGAAACCCTTAGTATGTATTTGTATTTGTAAAATACTTCTATCAATAAAATTTCTAATTCCTAAAACCAAAATCCAGTACTAAAATCCAGATC (SEQ ID NO: 193).
[0355] PsTrpM of Psilocybe serbica can monomethylate and dimethylate L-tryptophan. In some embodiments, L-tryptophan can be metabolically decarboxylated by the L-amino acid decarboxylase (AAAD) gene product. In some embodiments, N,N-dimethyltryptophan (DMTP) is produced by genetically engineered fungi. In some embodiments, DMTP is metabolically converted to DMT, 5-hydroxy-DMT, or bufotoxin. In some embodiments, the genetically modified fungi described herein comprise multiple copies of the transgenes described herein. In some embodiments, the genetically engineered fungi described herein comprise multiple copies of the transgenes described herein. In some embodiments, the transgene is TrpM. In some embodiments, TrpM expression in the genetically engineered fungi is compared with TrpM expression in comparable wild-type fungi. In some embodiments, TrpM expression is assessed using a molecular ladder comparing wild-type Psilocybe fungi to DMTP-expressing fungi ( Figure 31A ). In some embodiments, as shown in Figure 331B, TrpM expression is assessed in arbitrary units.
[0356] In some embodiments, sequence constructs for gene synthesis and subsequence plasmid preparation can be prepared using gene synthesis methods. In some embodiments, hygromycin resistance vectors can be used as selection markers in plasmids. Exemplary vector constructs for alkaloid regulation are shown in Tables 17A-17D. Exemplary vectors for producing DMT in genetically modified organisms are shown in Table 18. In some embodiments, human INMT is optimized for expression in fungi (e.g., Psilocybe and Ustilago codon optimized forms). In some embodiments, PcINMT is optimized for expression in fungi. In some embodiments, RT-PCR amplification includes the complete coding sequence of PcINMT of approximately 789 base pairs. In some embodiments, as Figure 31A-Figure 31B PcINMT expression was assessed in arbitrary units as shown.
[0357] In some embodiments, plant constructs are used. In some embodiments, fungal constructs are used. In some embodiments, zebrafish constructs are used. In some embodiments, African clawed frog (Xenopus laevis, Xl) constructs are used. In some embodiments, primate constructs are used. In some embodiments, human constructs are used. In some embodiments, test constructs are used at approximately -20 degrees Celsius, -10 degrees Celsius, 0 degrees Celsius, 10 degrees Celsius, 25 degrees Celsius, 30 degrees Celsius, 40 degrees Celsius, 50 degrees Celsius, 60 degrees Celsius, 70 degrees Celsius, or up to about 80 degrees Celsius. In some embodiments, amino acids from the PsiD gene can affect INMT protein production. In some embodiments, the Psilocybe Kozak sequence results in overexpression of the transgene in Psilocybe. In some embodiments, the Psilocybe Kozak sequence results in underexpression of the transgene in Psilocybe. In some embodiments, the Kozak sequence is a consensus sequence. In some embodiments, plant constructs are used. In some embodiments, fungal constructs are used. In some embodiments, zebrafish constructs are used. In some embodiments, Xenopus laevis (X1) constructs are used. In some embodiments, primate constructs are used. In some embodiments, human constructs are used. In some embodiments, test constructs are used at about -20 degrees Celsius, -10 degrees Celsius, 0 degrees Celsius, 10 degrees Celsius, 25 degrees Celsius, 30 degrees Celsius, 40 degrees Celsius, 50 degrees Celsius, 60 degrees Celsius, 70 degrees Celsius, or up to about 80 degrees Celsius. In some embodiments, amino acids from the PsiD gene can affect INMT protein production. In some embodiments, the Psilocybe Kozak sequence results in overexpression of the transgene in Psilocybe. In some embodiments, the Psilocybe Kozak sequence results in underexpression of the transgene in Psilocybe. In some embodiments, the Kozak sequence is a consensus sequence.
[0358] Table 17A. Exemplary test constructs for DMT production in fungi
[0359] Construct Test constructs for production of DMT in fungi. Construct 1 AbGPD-i:HsINMT Psilocybe edulis codon optimized Construct 2 AbGPD-i:HsINMT codon-optimized Construct 3 AbGPD-i: zebrafish INMT Construct 4 AbGPD-i: Xenopus INMT
[0360] In some embodiments, selected contiguous amino acids from the PsiD gene product are used to modulate INMT production levels in a genetically modified organism. In some embodiments, the contiguous amino acids are a chain of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 consecutive amino acids from a PsiD gene. In some embodiments, gene product levels are measured in mycelial samples of a genetically modified organism. In some embodiments, INMT inhibition can be caused by DMT production. In some embodiments, the allosteric inhibitory binding site for DMT is removed. In some embodiments, Asp28 (D) and / or Glu34 (E) are mutated to alanine residues. In some embodiments, this results in an INMT protein sequence having a D28A and / or E34A mutation.
[0361] Table 17B. Exemplary test constructs for DMT production in fungi
[0362] Construct Test constructs for production of DMT in fungi. Construct 5 AbGPD-i:PsiDN13-HsINMT Construct 6 AbGPD-i-Kozak:HsINMT codon optimized for Ustilago maydis Construct 7 AbGPD-i:HsINMT without feedback loop Construct 8 AbGPD-i: Xenopus INMT
[0363] In some embodiments, Psilocybe serbica possesses gene products that can monomethylate and dimethylate L-tryptophan. Other Psilocybe species also exist that do not possess gene products that monomethylate and dimethylate L-tryptophan. This stems from an ancient duplication event that retained a portion of the egtDB gene, which is required for ergothioneine biosynthesis. Phylogenetically, this is unrelated to the production of PcPsiM. In some embodiments, DMTP (N,N, dimethyl-L-tryptophan) can be metabolically decarboxylated to DMT after ingestion in humans through the action of aromatic L-amino acid decarboxylase (AAAD). Many fungal species also possess AAAD proteins. In some embodiments, DMTP can be metabolized to DMT in P. cochinchinensis fruiting bodies. In some embodiments, the above metabolic processes can provide indirect DMT production in fungi.
[0364] Table 17C. Exemplary test constructs for DMT production in fungi
[0365] Construct Test constructs for DMT production in fungi Construct 9 AbGPD-i:PsTrpM Psilocybe edulis codon optimized Construct 10 AbGPD-i:PsTrpM Psilocybe serbica Construct 11 AbGPD-i:PsTrpM optimized for 1 Psilocybe fungus
[0366] Pegan harmal alkaloids inhibit monoamine oxidase (MAO), which can degrade psilocybin and DMT in the human body. In some embodiments, psilocybin and DMT are present in the genetically modified fungi described herein. In some embodiments, DMT is present together with a monoamine oxidase inhibitor. In some embodiments, the fungus is a species that produces Pegan harmal alkaloids (i.e., Pegan harmal alkaloids such as harmanine and harmine), but in very low amounts (approximately 0.2 μg / g). In some embodiments, the genetically modified fungus can produce Pegan harmal alkaloids. In some embodiments, the genetically modified fungus can produce Pegan harmal alkaloids at a higher concentration than produced by naturally occurring fungi of the same species. In some embodiments, the genetically modified fungus is a Psilocybin fungus. In some embodiments, the genetically modified fungus is a Psilocybin fungus and can produce Pegan harmal alkaloids at a higher concentration than produced by naturally occurring fungi of the same Psilocybin species. In nature, Pegan harmal alkaloids are a component of the alkaloid entourage in Psilocybin fungi. In some embodiments, a native or non-native gene of a fungus can produce the β-carboline scaffold. In bacteria, the β-carboline scaffold is produced from L-tryptophan. In plants, the condensation of tryptamine and strychnine (a monoterpene) produces the tetrahydro-β-carboline scaffold.
[0367] Table 17D. Exemplary test constructs for DMT production in fungi
[0368] Construct Test constructs for production of DMT in fungi. Construct 12 AbGPD-i: bacterial McbB codon-optimized Psilocybin mushroom Construct 13 AbGPD-i: plant STST codon-optimized Psilocybin mushroom Construct 14 AbGPD-i: Bacterial McbB optimized 1 (sequence not available yet) Construct 15 AbGPD-i: Plant STST codon optimized 1 (sequence not available yet)
[0369] Table 18. Exemplary vectors for DMT and INMT regulation in fungi
[0370]
[0371]
[0372]
[0373]
[0374]
[0375]
[0376]
[0377] Unlike many other Psilocybe fungi, Psilocybe serbica monomethylates and dimethylates L-tryptophan. PsTrpM originated from an ancient duplication event that retained part of the gene for egtDB, which is required for ergothioneine biosynthesis, and is phylogenetically unrelated to PcPsiM.
[0378] In some embodiments, DMTP (N,N'-dimethyl-L-tryptophan) can be metabolized and decarboxylated to DMT by aromatic L-amino acid decarboxylase (AAAD) after ingestion in humans. However, since fungi also possess AAAD proteins, DMTP can be metabolized to DMT in Psilocybin fruiting bodies. In some embodiments, DMT production occurs via an indirect biosynthetic pathway that is an alternative to the psilocybin biosynthetic pathway.
[0379] In some embodiments, the genetically modified organism produces an elevated amount of N,N,-dimethyltryptamine compared to the amount of N,N-dimethyltryptamine produced in a naturally occurring, otherwise identical genetically modified organism. In some embodiments, the genetically modified organism expresses a gene product as shown in Table 19.
[0380] Table 19. Exemplary gene products regulated by DMT in fungi for genetic modification
[0381]
[0382]
[0383]
[0384] Pharmaceutical compositions, nutritional compositions, supplement compositions, formulations and methods
[0385] The present disclosure also provides pharmaceutical compositions and / or nutritional compositions comprising genetically modified organisms, genetically modified cells, or extracts, derivatives, or products thereof. The present disclosure also provides pharmaceutical or nutritional agents, methods of using the same, and methods of preparing pharmaceutical or nutritional compositions comprising genetically modified organisms, genetically modified cells, or extracts, derivatives, or products thereof.
[0386] In some embodiments, compositions comprising pharmaceutical compositions or nutritional compositions as disclosed herein can be used to treat or stabilize conditions or symptoms associated with conditions such as depression, anxiety, post-traumatic stress, addiction or withdrawal-related side effects (such as smoking cessation) and psychological distress (including cancer-related psychological distress). In some embodiments, the neurological health condition, disease or disorder is depression, anxiety, post-traumatic stress disorder (PTSD), mental disorder, trauma, mood disorder, speech disorder, neurodegenerative disease, psychological distress, compulsion, compulsive disorder, obsessive disorder, expression of symptoms in neurodivergent individuals, cancer-related psychological distress, addiction, headache, multiple sclerosis, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, dementia, fear, eating disorders, ischemic events or any combination thereof. Specifically, the genetically modified organisms described herein or extracts, derivatives or products thereof can be used to alleviate various symptoms associated with mental disorders and conditions.
[0387] In some embodiments, the compositions comprising the genetically modified organisms described herein can be used to treat specific symptoms. Exemplary symptoms for the treatment include pain, nausea, weight loss, emaciation, multiple sclerosis, allergies, infections, vasoconstriction, depression, migraine, hypertension, neuroprotection after stroke, and inhibition of tumor growth, inhibition of angiogenesis and inhibition of metastasis, antioxidants and neuroprotectants. In some embodiments, the genetically modified organisms can be used to treat persistent muscle spasms, including those with the following characteristics: multiple sclerosis, severe arthritis, peripheral neuropathy, intractable pain, migraine, terminal illness requiring hospice care, hydrocephalus with intractable headache, intractable headache syndrome, neuropathic facial pain, herpes zoster, chronic non-malignant pain, causalgia, chronic inflammatory demyelinating polyneuropathy, bladder pain, myoclonus, post-concussion syndrome, residual limb pain, obstructive sleep apnea, traumatic brain injury, elevated intraocular pressure, opioid or opiate withdrawal and / or loss of appetite.
[0388] In some embodiments, compositions comprising the genetically modified organisms described herein can include pharmaceutically or nutritionally relevant compounds and / or extracts, including flavonoids, monoamine oxidase inhibitors, and phytosterols (e.g., apigenin, quercetin, cannabinoid A, β-sitosterol, etc.). The compositions of the present disclosure described herein can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations, and the like, including those suitable for: (1) parenteral administration, such as by subcutaneous, intramuscular, intravenous, or epidural injection, as, for example, a sterile solution or suspension or sustained-release formulation; (2) topical application, such as as a cream, ointment, or controlled-release patch or spray applied to the skin; (3) intravaginally or intrarectally, such as as a pessary, cream, or foam; (4) ophthalmic; (5) transdermal; (6) transmucosal; or (7) nasal.
[0389] In some embodiments, the compositions described herein further comprise an additional agent selected from at least one of the following: amyrin, betulinic acid, celastrol, Cesamet (nabilone), marinol (dronabinol; Δ9-THC), Sativex (cannabidiol; Δ9-THC), biochanin A, curcumin, cyanidin, desmodianones, delphinidin, (+)-catechin, falcarinol, 18β-glycyrrhetinic acid, honokiol, isoperrottetin A, kratom, paeoniflorin, pelargonidin, prestimerin, magnolol, malvidin, rutin, 6-methyltetrapterol A, magnolol, miconioside, resveratrol, salvinorin A, yangonin, and 2-arachidonoylglycerol, lysergic acid diethylamide, and its derivatives and analogs.
[0390] In some embodiments, the composition can be co-administered with an additional agent selected from at least one of the following: amyrin, betulinic acid, celastrol, Cesamet (nabilone), marinol (dronabinol; Δ9-THC), Sativex (cannabidiol; Δ9-THC), biochanin A, curcumin, cyanidin, desmodianones, delphinidin, (+)-catechin, falcarinol, 18β-glycyrrhetinic acid, honokiol, isoperrottetin A, kratom, paeoniflorin, pelargonidin, prestimerin, magnolol, malvidin, rutin, 6-methyltetrapterol A, magnolol, miconioside, resveratrol, salvinorin A, methoxycapsaicin, and 2-arachidonoylglycerol, lysergic acid diethylamide, and its derivatives and analogs.
[0391] The pharmaceutical compositions described herein can be formulated in neutral form or in salt form. Pharmaceutically acceptable salts include those formed with free amino groups, such as those derived from hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, tartaric acid, and the like; and those formed with free carboxyl groups, such as those derived from sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, ferric hydroxide, isopropylamine, triethylamine, 2-ethylaminoethanol, histidine, procaine, and the like.
[0392] The compositions disclosed herein may include a preservative, such as a compound that can be added to a diluent to substantially reduce bacterial action in the reconstituted formulation to facilitate, for example, the production of a multi-purpose reconstituted formulation. Examples of potential preservatives include octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride (a mixture of alkylbenzyldimethylammonium chlorides in which the alkyl group is a long-chain compound), and benzethonium chloride.
[0393] The pharmaceutical composition of the present disclosure is formulated as and is compatible with its expected route of administration.The example of route of administration includes but is not limited to parenteral, for example, intravenous, intradermal, subcutaneous, oral, intranasal (for example inhalation), transdermal (for example surface), through mucosal and rectal administration.In a specific embodiment, according to conventional procedure, composition is formulated as and is suitable for intravenous, subcutaneous, intramuscular, oral, intranasal or surface administration to the mankind's pharmaceutical composition.Usually, the composition for intravenous administration is a solution in a sterile isotonic aqueous buffer.
[0394] If necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to relieve pain at the injection site. In some embodiments, the method of the present disclosure may include administering a composition formulated for parenteral administration by injection (e.g., by bolus injection or continuous infusion). The preparation for injection may be in the form of a unit dosage form (e.g., ampoule or multidose container) containing an added preservative. The composition may take the form of a suspension, solution, or emulsion in an oily or aqueous vehicle, and may contain agents such as suspending agents, stabilizers, and / or dispersants. Alternatively, the active ingredient may be in powder form for construction with a suitable vehicle (e.g., sterile pyrogen-free water) prior to use.
[0395] Thus, in some embodiments, the present disclosure can provide pharmaceutical compositions comprising an effective amount of a genetically modified organism, derivative, or extract thereof, in combination with a pharmaceutically acceptable excipient, carrier, or diluent.
[0396] In some embodiments, organisms, derivatives or extracts of genetic modifications disclosed herein can be used for evaporation, production of electronic juice (e-juice) or tinctures for electronic cigarettes, or for producing other consumable products such as edibles, balsams or surface spreads. In some embodiments, the compositions of modifications provided herein can be used as supplements, such as food supplements. In some embodiments, organisms or extracts or products of genetic modifications can be used to prepare edibles. Edible formulations can start by extracting one or more alkaloids from organisms, which can then be used as ingredients in various edible formulations. The extraction method of edibles includes extraction into edible oils, milk, cream, balsams, flour and butter. Extraction media / edibles rich in lipids are thought to contribute to absorption into the bloodstream. Lipids can be used as excipients in combination with various compositions provided herein. In other embodiments, the compositions provided herein can include oral forms, transdermal forms, oil formulations, edible foods or food matrices, aqueous dispersions, emulsions, solutions, suspensions, elixirs, gels, syrups, aerosols, mists, powders, tablets, lozenges, gels, lotions, pastes, formulation sticks, balms, creams, or ointments.
[0397] In some embodiments, the genetically modified organisms, derivatives, or extracts disclosed herein are functional mushrooms. In some embodiments, the genetically modified organisms, derivatives, or extracts disclosed herein are formulated with other functional mushrooms or extracts thereof. In some embodiments, the genetically modified organisms, derivatives, or extracts disclosed herein are formulated with nootropic herbs. In some embodiments, the genetically modified organisms, derivatives, or extracts disclosed herein are formulated with phytochemicals.
[0398] Also provided herein are kits for compositions comprising genetically modified cells disclosed herein. The kits can include packaging, instructions, and various compositions provided herein. In some embodiments, the kits can contain additional compositions for producing various plants and plant parts provided herein, such as pots, soil, fertilizers, water, and cultivation tools.
[0399] In some embodiments, a second therapeutic agent can be administered simultaneously or sequentially with any of the compositions or pharmaceutical compositions described herein.
[0400] Manufacturing applications
[0401] In some embodiments, genetically modified organisms, derivatives, or extracts thereof as disclosed herein can be used to construct biodegradable plastics.
[0402] In some embodiments, the biodegradable material is a composite material. In some embodiments, the composite material is used to construct an automobile. In some embodiments, the composite material is used to construct an aerospace tool or container. In some embodiments, the composite material is used to construct a tool or container in the aerospace industry. In some embodiments, the composite material is used to construct clothing or textiles.
[0403] In some embodiments, the genetically engineered organisms, products, derivatives, or extracts thereof are used as biodegradable fuels.
[0404] Exemplary characterization and analysis of genetically engineered fungi
[0405] Figure 1 Alkaloid biosynthetic pathways for genetically modified organisms are shown. Exemplary pathways represent enzymatic pathways for producing one or more alkaloids using organisms genetically modified to carry the pathway. The one or more alkaloids produced by the exemplary pathways can include, for example, psilocybin 101, norpsilocybin 103, nordimethylpsilocybin 104, aeruginascin 105, dephosphorylated psilocybin 102, tryptamine 107, 4-hydroxytryptamine 109, or N,N-dimethyltryptamine 110.
[0406] In particular, an organism carrying a genetic modification of the pathway described can be described as having a genetic modification that results in increased expression of L-tryptophan decarboxylase 123 compared to a comparable wild-type organism. The genetic drug can comprise an exogenous nucleic acid encoding one or more copies of a PsiD gene (e.g., SEQ ID NO: 90). In some embodiments, the PsiD gene is driven by a GDP promoter. When the exogenous nucleic acid is expressed in the genetically modified organism, L-tryptophan decarboxylase 123 can convert L-tryptophan 106 and / or 4-hydroxy-L-tryptophan 108 into tryptamine 107 or 4-hydroxytryptamine 109, respectively. Advantageously, upregulated expression of L-tryptophan decarboxylase 123 can result in increased production of 4-hydroxytryptamine 109 and / or tryptamine 107. As shown, because 4-hydroxytryptamine 109 and tryptamine 107 can be precursors of compounds including psilocybin 101, norpsilocybin 103, nordimethylpsilocybin 104, aeruginascin 105, dephosphorylated psilocybin 102, and N,N-dimethyltryptamine 110, increased expression of L-tryptophan decarboxylase 123 can lead to increased production of any one or more of psilocybin 101, norpsilocybin 103, nordimethylpsilocybin 104, aeruginascin 105, dephosphorylated psilocybin 102, tryptamine 107, 4-hydroxytryptamine 109, or N,N-dimethyltryptamine 110.
[0407] As described herein, the genetically modified organisms can be further modified to express elevated levels of the gene products encoded by any of PsiH, PsiK, or PsiM. The activity of the gene products encoded by PsiH, PsiK, and PsiM can be monitored, for example, by following the black arrows below the circles labeled with the PsiH, PsiK, and PsiM involved in the illustrated transformation. Figure 1 In some embodiments, the genetically modified organism can be a fungal cell from the class Basidiomycetes, such as a fungal cell from the genus Psilocybe.
[0408] Figure 2 A biosynthetic pathway hosted by a genetically modified organism engineered for psilocybin production is shown. The exemplary pathway can be hosted by a genetically modified organism, such as a fungal cell from the genus Psilocybin. The genetically modified organism can be genetically modified to reduce or eliminate expression of psilocybin phosphatase 225, which, when expressed in a wild-type fungal cell from the genus Psilocybin, converts psilocybin 201 to dephosphorylated psilocybin 202.
[0409] By reducing or eliminating the expression of psilocybin phosphatase 225, the genetically modified organism can contain increased amounts of psilocybin 201 compared to a comparable wild-type organism. Without being bound by any one embodiment, in some cases, the genetic modification comprises deleting or inserting one or more nucleotides in an endogenous nucleic acid involved in the expression of psilocybin phosphatase 225. For example, the modification can include an insertion / deletion that results in a deleterious disruption of the coding sequence of a gene encoding a psilocybin phosphatase (e.g., PsiP). In certain embodiments, the genetically modified organism can be further modified to produce increased amounts of additional alkaloids, such as norpsilocybin 203, nordimethylpsilocybin 204, aeruginascin 205, tryptamine 207, 4-hydroxytryptamine 209, L-tryptophan 206, 4-hydroxy-L-tryptophan 208, or N,N-dimethyltryptamine 210. For example, the genetically modified organism can be further modified to express elevated levels of a gene product encoded by any of PsiH, PsiK, or PsiM. The activity of the gene products encoded by PsiH, PsiK, and PsiM can be monitored by following the direction of the black arrow below the circle marked by any of PsiH, PsiK, and PsiM. Figure 2 It can be inferred from the diagram in .
[0410] Figure 3 Additional alkaloid biosynthetic pathways for genetically modified organisms are shown. The genetically modified organism can be a fungal cell from the genus Psilocybe. Exemplary pathways represent pathways for producing one or more desired alkaloids using the genetically modified organism. The one or more desired alkaloids can include, for example, psilocybin 301. The one or more desired alkaloids can also include norpsilocybin 303, nordimethylpsilocybin 304, aeruginascin 305, tryptamine 307, 4-hydroxytryptamine 309, or N,N-dimethyltryptamine 310. The genetically modified organism carrying the pathway shown can include a genetic modification that results in increased expression of L-tryptophan decarboxylase 323 compared to a comparable wild-type organism. When expressed in a genetically modified organism, L-tryptophan decarboxylase 323 can result in increased production of any one or more of psilocybin 301, norpsilocybin 303, nordimethylpsilocybin 304, aeruginascin 305, and N,N-dimethyltryptamine 310. The genetically modified organism can also comprise a second genetic modification that results in reduced expression of psilocybin phosphatase 325, which, when expressed in a wild-type fungal cell from the genus Psilocybin, converts psilocybin 301 to dephosphorylated psilocybin 302. Thus, by reducing or eliminating expression of psilocybin phosphatase 325, fewer psilocybin molecules will be converted to dephosphorylated psilocybin.
[0411] Described herein are genetically modified organisms, methods for preparing the genetically modified organisms, and methods for optimizing secondary metabolite production for isolating psilocybin and its derivatives and analogs. In particular, the present disclosure relates to targeting specific genes and combinations thereof, and subsequently introducing genetic modifications into fungal cells in order to regulate and optimize gene expression important to the psilocybin biosynthetic pathway. In some cases, the introduction of genetic modifications results in increased production of small molecule alkaloids such as psilocybin. Also provided herein are methods for assessing psilocybin production based on cell phenotype. In some embodiments, phenotypic discrimination of genetically modified organisms based on alkaloid production can be detected by color development of exposed or oxidized cell tissues. In some embodiments, phenotypic discrimination and phenotypic distinction can be used interchangeably. Also provided herein are methods for preparing genetically modified organisms using gene editing systems, such as clustered regularly interspaced short palindromic repeats (CRISPR), Argonaut, zinc fingers, TALENs, Agrobacterium-mediated transformation, or other nuclease-based techniques and reagents for producing genetically modified organisms. The compositions and methods provided herein can be used to produce fungi or plants with increased tryptamine-derived substances. The compositions provided herein can be used for a variety of purposes, including but not limited to therapeutic uses, preventive uses, palliative uses, and recreational uses. The methods and genetically modified organisms disclosed herein include methods for modifying fungal cells to allow up-regulation and down-regulation of gene expression (which may cause the fungal cells to contain elevated levels of secondary metabolites native to the fungal cells).
[0412] For example, according to one aspect, the present disclosure provides a composition comprising an engineered fungal cell having a modification (e.g., a genetic modification) that results in reduced expression of psilocybin phosphatase in the engineered fungal cell compared to a comparable fungal cell without the modification. The fungal cell can be from the genus Psilocybe. For example, the fungal cell can be from Psilocybe edulis or Psilocybe leucogenes. In some embodiments, the composition is in the form of an aerosol, powder, gel, semi-gel, liquid, or solid.
[0413] The modification may comprise a deletion or insertion of one or more nucleotides in the nucleic acid sequence encoding the psilocybin phosphatase. For example, the modification may be a deletion or insertion of one or more nucleotides at a regulatory element involved in the expression of the psilocybin phosphatase. The deletion or insertion may result in a frameshift mutation, for example, resulting in a deleterious disruption of the coding sequence of the gene encoding the psilocybin phosphatase. Unless otherwise indicated, as used herein, PsiP may refer to a PsiP phosphatase family gene or its protein expression product. When a fungus comprises multiple PsiP genes, the genes or their protein expression products referred to herein may be numbered to distinguish them, for example, PsiP1 and PsiP2. In some cases, the nucleic acid sequence comprises at least a portion of a nucleotide sequence associated with a PsiP (e.g., PsiP or PsiP2) and may comprise a sequence that is at least 95% or 100% identical to one of SEQ ID NOs: 15-19.
[0414] In some embodiments, the modification can include incorporating an exogenous nucleic acid into the engineered fungal cell, wherein the exogenous nucleic acid encodes a gene product that, when expressed, inhibits or eliminates expression of psilocybin phosphatase in the engineered fungal cell. The gene product can include an siRNA or shRNA, wherein the siRNA or shRNA comprises a nucleic acid sequence complementary to an mRNA encoding psilocybin phosphatase and thereby silences expression of the psilocybin phosphatase by RNA interference. The siRNA or shRNA can comprise a sequence complementary to at least a portion of an mRNA encoded by PsiP or PsiP2.
[0415] In some embodiments, the modification can include incorporating an exogenous nucleic acid into the engineered fungal cell, wherein the exogenous nucleic acid encodes a gene product that, when expressed, inhibits or eliminates expression of L-tryptophan decarboxylase in the engineered fungal cell. The gene product can include an siRNA or shRNA, wherein the siRNA or shRNA comprises a nucleic acid sequence complementary to an mRNA encoding L-tryptophan decarboxylase and thereby silences expression of the L-tryptophan decarboxylase by RNA interference. The siRNA or shRNA can comprise a sequence complementary to at least a portion of an mRNA encoded by a PsiD gene.
[0416] In some embodiments, the modification can reduce the expression of psilocybin phosphatase by at least 50% compared to a comparable fungal cell without the modification. For example, the modification can reduce the expression of psilocybin phosphatase by 50%, 60%, 70%, 80%, 90%, 95%, or 100% compared to a comparable fungal cell without the modification. By reducing the expression of psilocybin phosphatase, the modification can result in decreased expression of psilocybin in the engineered fungal cell compared to a comparable fungal cell without the modification (e.g., a fungal cell from P. cochinchinensis with wild-type normal expression levels of psilocybin phosphatase). Thus, the modification can result in increased expression of psilocybin in the engineered fungal cell compared to a comparable fungal cell without the modification.
[0417] In some embodiments, the engineered fungal cell further comprises a second modification that results in at least one of: increased tryptophan decarboxylation, increased tryptamine 4-hydroxylation, increased serotonin O-phosphorylation, or increased psilocybin production via sequential N-methylation, compared to a comparable fungal cell without the second modification. For example, the engineered fungal cell may further comprise a second modification that results in increased expression of a gene product, compared to a comparable fungal cell without the second modification, wherein the gene product is encoded by a gene selected from the group consisting of: PsiD, PsiM, PsiH, PsiH2, PsiK, PsiM, TrpE, TrpM, PsiL, PsiP, PsiP2, PsiH2, and PsiR. In some embodiments, the engineered fungal cell may further comprise a second modification that results in increased expression of a gene product, compared to a comparable fungal cell without the second modification, wherein the gene product is encoded by a gene selected from the group consisting of: PsiD, PsiM, PsiH, PsiH2, PsiK, PsiM, TrpE, TrpM, PsiL, PsiP, PsiP2, PsiH2, and PsiR. In some embodiments, the engineered fungal cell can further comprise a second modification that results in increased expression of a gene product compared to a comparable fungal cell without the second modification, wherein the gene product is encoded by a gene selected from the group consisting of: PsiD, PsiM, PsiH, PsiH2, PsiK, PsiM, TrpE, TrpM, PsiL, PsiP, PsiP2, PsiH2, PsiR, and any combination thereof. The gene product can include, for example, at least a portion of any of the amino acids listed in Table 3.
[0418] In some embodiments, the second modification can be an exogenous nucleic acid incorporated into the engineered fungal cell, wherein the exogenous nucleic acid comprises a sequence at least 80%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 1-19 or 90-98. In other cases, the exogenous nucleic acid comprises a sequence at least 75%, 80%, 85%, 90%, 99%, or 100% identical to any one of SEQ ID NOs: 1-19 or 90-98. In some cases, the exogenous nucleic acid comprises a sequence at least 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to one of the sequences in Table 2 or Table 3. In some cases, the exogenous nucleic acid comprises a sequence at least 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to one of the sequences in Table 2.
[0419] In some embodiments, any one of SEQ ID NOs: 1-28 comprises a base editor. In some embodiments, any one of SEQ ID NOs: 1-28 is incorporated using a Cas protein or a Cas fusion protein.
[0420] As a result of the genetic modification, the engineered fungal cell can express at least 6 times more of a gene product than that expressed in a comparable fungal cell without the second modification. For example, the engineered fungal cell can express at least 10 times more of a gene product (e.g., mRNA encoding tryptophan decarboxylase) than that expressed in a comparable wild-type fungal cell. To assess the expression of the gene product, qPCR or Western blot analysis can be performed.
[0421] The exogenous nucleic acid may comprise a gene promoter located upstream of the gene whose expression is desired to be upregulated. The gene may be any one of PsiD, PsiM, PsiH, PsiK, or PsiR. The gene promoter may be any one of the 35S promoter, GDP promoter, or CcDED1 promoter. The gene may be any one of PsiD, PsiM, PsiH, PsiH2, PsiK, PsiM, TrpE, TrpM, PsiL, PsiP, PsiP2, PsiH2, and PsiR. The gene promoter may be any one of the 35S promoter, GDP promoter, or CcDED1 promoter.
[0422] In some embodiments, the present disclosure provides pharmaceutical compositions comprising engineered fungal cells or extracts thereof. The pharmaceutical compositions may comprise an effective amount of engineered fungal cells or extracts thereof for treating a health condition. The compositions may be formulated so that an effective amount of the composition for treating a health condition can be delivered in a single dose. In other cases, the present disclosure provides supplements comprising extracts of engineered fungal cells. In other cases, the present disclosure provides food supplements comprising extracts of engineered fungal cells.
[0423] Modification can be accomplished by contacting fungal cells (e.g., fungal protoplasts) with a gene editing system. The gene editing system can be any of Cas endonucleases, Agrobacterium-mediated exogenous nucleic acid insertions, TALE-nucleases, transposon-based nucleases, zinc finger nucleases, mega-nucleases, mega-TALs, or DNA-guided nucleases. For example, in some cases, the gene editing system is a nucleic acid-guided endonuclease (e.g., Cas9) that is delivered to the fungal cell in the form of an active ribonucleoprotein. The gene editing system can be delivered to the fungal cell in an active form with, for example, a surfactant such as Triton X-100. In some embodiments, the gene editing system includes a nuclear localization signal to facilitate entry of the gene editing system into the nucleus of the fungal cell.
[0424] On the one hand, provided herein are compositions comprising engineered fungal cells comprising a genetic modification that increases the expression of an mRNA encoding L-tryptophan decarboxylase by at least 6 times compared to comparable fungal cells not containing the genetic modification, wherein the fungal cells are from Basidiomycota. For example, the fungal cells can be mycelia. The compositions can be formulated in an effective amount for oral, topical, or enteric delivery.
[0425] Without limiting the scope of the present disclosure, genetic modification can include the exogenous nucleic acid incorporated into the engineered fungal cell, wherein the exogenous nucleic acid comprises one or more genes, and at least one of the one or more genes encodes an L-tryptophan decarboxylase. For example, the exogenous nucleic acid can comprise 1, 2, 3, 4, 5 or more copies of a gene encoding an L-tryptophan decarboxylase. At least one of the one or more genes can have a sequence at least 95% identical to SEQ ID NO: 1. In other cases, at least one of the one or more genes can have a sequence at least 75%, 80%, 85%, 90%, 99% or 100% identical to SEQ ID NO: 1. In some embodiments, the exogenous nucleic acid can comprise 1, 2, 3, 4, 5 or more copies of a gene encoding an L-tryptophan decarboxylase. At least one of the one or more genes can have a sequence at least 95% identical to SEQ ID NO: 90. In other cases, at least one of the one or more genes can have a sequence that is at least: 75%, 80%, 85%, 90%, 99%, or 100% identical to SEQ ID NO:90.
[0426] In some embodiments, the exogenous nucleic acid includes a promoter located upstream of one or more genes, wherein the promoter includes one of a 35S promoter, a GPD promoter, or a CcDED1 promoter. The exogenous nucleic acid may include a promoter sequence upstream of a sequence at least 95% identical to SEQ ID NO: 1. The exogenous nucleic acid may include a promoter sequence upstream of a sequence at least 95% identical to SEQ ID NO: 90. The exogenous nucleic acid sequence may be integrated into the chromosome of the engineered fungal cell. For example, the exogenous nucleic acid may be integrated into the chromosome at a region involved in regulating psilocybin synthesis.
[0427] As a result of the genetic modification, the engineered fungal cell can have a phenotype that is visually different from the phenotype of a comparable fungal cell that does not contain the genetic modification, wherein the phenotype includes a blue color. For example, the engineered fungal cell can reflect light with a wavelength between about 450 nanometers and 500 nanometers.
[0428] In some embodiments, the genetic modification results in increased expression of psilocybin in the fungal cell, compared to a comparable fungal cell without the genetic modification. The engineered fungal cell may further include a second modification that results in one of: increased tryptamine 4-hydroxylation, increased serotonin O-phosphorylation, increased psilocybin production via sequential N-methylation, or decreased psilocybin dephosphorylation, compared to a comparable fungal cell without the second modification. For example, the engineered fungal cell may further include the second modification that results in increased expression of a gene product, compared to a comparable fungal cell without the second modification, wherein the gene product is involved in psilocybin synthesis and is encoded by any of PsiM, PsiH, PsiH2, PsiK, or PsiR. For example, the engineered fungal cell can further comprise a second modification that results in increased expression of a gene product involved in psilocybin synthesis and encoded by any of PsiM, PsiH, PsiH2, PsiK, PsiL, PsiP, PsiP2, TrpE, or PsiR compared to a comparable fungal cell without the second modification. The gene product can be upregulated by at least 6-fold compared to a comparable fungal cell without the second modification.
[0429] The present disclosure also provides pharmaceutical compositions comprising engineered fungal cells or extracts thereof. The pharmaceutical compositions may comprise a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may be formulated into a dosage form for topical, oral, inhalation, or enteric delivery. The pharmaceutical compositions may be formulated so that an effective amount of the composition for treating a health condition may be delivered to a subject in need thereof in a single dose. For example, the health condition may be any one of depression, anxiety, post-traumatic stress, addiction, or psychological distress (including cancer-related psychological distress).
[0430] In one aspect, the present disclosure provides a composition comprising an engineered fungal cell comprising a first genetic modification that results in increased expression of L-tryptophan decarboxylase in the engineered fungal cell compared to a comparable fungal cell without the first genetic modification, and a second genetic modification that results in decreased expression of psilocybin phosphatase in the engineered fungal cell compared to a comparable fungal cell without the second genetic modification. The fungal cell can be from Psilocybe cubansis or Stropharia cubensis.
[0431] In some embodiments, the first genetic modification comprises an exogenous nucleic acid incorporated into the engineered fungal cell, wherein the exogenous nucleic acid encodes an L-tryptophan decarboxylase. For example, the exogenous nucleic acid can comprise a sequence at least 95% identical to SEQ ID NO: 1. For example, the exogenous nucleic acid can comprise a sequence at least 95% identical to SEQ ID NO: 90. The exogenous nucleic acid further comprises a sequence that serves as a gene promoter, wherein the gene promoter comprises any one of a 35S promoter, a GPD promoter, or a CcDED1 promoter.
[0432] In some embodiments, the second genetic modification may involve deletion of at least a portion of an endogenous nucleic acid sequence encoding psilocybin phosphatase. The endogenous nucleic acid sequence may have a sequence that is at least, for example, 95% identical to SEQ ID NO: 1. The endogenous nucleic acid sequence may have a sequence that is at least, for example, 95% identical to SEQ ID NO: 90. In other cases, the second genetic modification may involve insertion / deletion within the promoter or enhancer of the gene encoding psilocybin phosphatase. The second genetic modification may include inserting an exogenous nucleic acid sequence into the engineered fungal cell, wherein the exogenous nucleic acid sequence encodes a gene product that, when expressed, inhibits or eliminates expression of mRNA encoding psilocybin phosphatase.
[0433] In some embodiments, the first genetic modification results in at least a 6-fold increase in expression of L-tryptophan decarboxylase in the engineered fungal cell compared to a comparable fungal cell without the first genetic modification. The second genetic modification inhibits expression of psilocybin phosphatase by at least 50% compared to a comparable fungal cell without the second genetic modification.
[0434] In one aspect, the present disclosure provides a composition comprising an engineered fungus comprising a genetic modification that results in increased expression of L-tryptophan decarboxylase, such that the engineered fungus, or a portion thereof, changes from a first color to a second color upon exposure to air, wherein the second color is visually different from the color of a corresponding portion of a comparable fungus without the genetic modification upon equivalent exposure to air. For example, the second color can be the result of the fungus reflecting light having a wavelength between about 450 nanometers and 500 nanometers.
[0435] In some embodiments, the genetic modification includes an exogenous nucleic acid encoding one or more genes. The one or more genes preferably encode L-tryptophan decarboxylase. In some cases, the exogenous nucleic acid can be incorporated into the engineered fungus using a vector. For example, one of the vectors or plasmids listed in Table 20A. The vector can be selected from the group consisting of pGWB5, pGHGWY, and pGHGWY. Exemplary promoter sequences are further shown in Table 20B, Table 21A, and Table 21B.
[0436] Table 20A. Exemplary gene expression vectors.
[0437] carrier Gene promoter Gene insertion Promoter characteristics pGWB5 35S PsiH / PsiD / PsiK / PsiH Cauliflower mosaic virus 35S promoter pG GPD PsiH / PsiD / PsiK / PsiH Fungal-specific promoter pG CcDED1 PsiH / PsiD / PsiK / PsiH Fungal-specific promoter
[0438] Table 20B. Exemplary GPD and pU6 promoter sequences.
[0439]
[0440]
[0441] Table 21A. Pleurotus gloeosporioides (Pcy) vector design for overexpression of PsiH2 in Psilocybe edulis.
[0442]
[0443]
[0444] Table 21B. P. tampanensis (Pt) vector design for PsiH2 overexpression in P. tampanensis
[0445]
[0446]
[0447] In some embodiments, PsiD gene overexpression includes a vector expressing the PsiD gene under the control of a 35S promoter (Table 22: SEQ ID NO: 104, 17,647 bp; Figure 3A). In some embodiments, the PsiH gene overexpression comprises a vector expressing the PsiH gene under the control of a 35S promoter (Table 22: SEQ ID NO: 103, 18,494 bp; Figure 3 B). In some embodiments, the PsiK gene overexpression comprises a vector expressing the PsiK gene under the control of a 35S promoter (Table 22: SEQ ID NO: 102, 17,420 bp; Figure 3 C). In some embodiments, the PsiM gene overexpression comprises a vector expressing the PsiM gene under the control of a 35S promoter (Table 22: SEQ ID NO: 101, 17,267 bp; Figure 3 D) In some embodiments, PsiR gene overexpression comprises a vector expressing the PsiR gene under the control of a GPD promoter (Table 22: SEQ ID NO: 108). In some embodiments, PsiH2 gene overexpression comprises a vector expressing the PsiH2 gene under the control of a GPD promoter (Table 22: SEQ ID NO: 109 and SEQ ID NO: 110).
[0448] In some embodiments, Psi gene overexpression includes a vector expressing the Psi gene under the control of the GcDED1 promoter (Table 22: SEQ ID NO: 105, 9,462 bp; Figure 4 A). In some embodiments, Psi gene overexpression comprises a vector expressing the Psi gene under the control of a GPD promoter (Table 22: SEQ ID NO: 106, 8,067 bp; Figure 4 B).
[0449] In some embodiments, PsiD overexpression comprises a vector that expresses the Psi gene under the control of the GPD promoter resulting in a fungus comprising a blue phenotype (Table 22: SEQ ID NO: 107).
[0450] Table 22. Psilocybin expression vector sequences.
[0451]
[0452]
[0453]
[0454]
[0455]
[0456]
[0457]
[0458]
[0459]
[0460]
[0461]
[0462]
[0463]
[0464]
[0465]
[0466]
[0467]
[0468]
[0469]
[0470]
[0471]
[0472]
[0473]
[0474]
[0475]
[0476]
[0477]
[0478]
[0479]
[0480]
[0481]
[0482]
[0483]
[0484]
[0485] In some embodiments, the engineered fungus comprises a psilocybin concentration that is at least 10% greater than the psilocybin concentration in a comparable fungus without the genetic modification. The engineered fungus can be selected from the group consisting of Psilocybin, Triocene, Gymnocybe, Pseudomonas, Glechoma, or Stropharia. In some cases, the engineered fungus comprises one or more transgenes selected from the group consisting of (i) PsiD, (ii) PsiD and PsiK, (iii) PsiD, PsiK, PsiM, and (iv) PsiD, PsiK, PsiM, PsiH.
[0486] In one aspect, the present disclosure provides a method comprising introducing an exogenous nucleic acid encoding an L-tryptophan decarboxylase into a fungal cell; growing the fungal cell into a mycelial mass; and expressing the L-tryptophan decarboxylase in the mycelial mass, wherein the presence of the exogenous nucleic acid results in an increased level of expression of the L-tryptophan decarboxylase in the mycelial mass compared to a comparable wild-type mycelial mass. For example, the fungal cell can be a fungal protoplast, such as a fungal protoplast from the phylum Basidiomycota.
[0487] In some embodiments, expression of the L-tryptophan decarboxylase results in a mycelial mass comprising a phenotype that is visually different from the phenotype of a comparable mycelial mass lacking the genetic modification, wherein the phenotype comprises a blue color. Due to the overexpression of the L-tryptophan decarboxylase, the mycelial mass can reflect light at wavelengths between 450 nanometers and 500 nanometers. In some cases, the mycelial mass has a psilocybin concentration greater than 1.7%, as measured by dry mycelial mass.
[0488] In one aspect, a method is provided herein, comprising: obtaining a genetically modified organism comprising a genetic modification, wherein the genetic modification results in increased expression of an L-tryptophan decarboxylase compared to a comparable organism without the genetic modification; detecting a change from a first color to a second color in tissue of the genetically modified organism when the tissue is exposed to air, wherein the second color is visually different from tissue of the comparable organism when equally exposed to air. For example, the change to the second color occurs within 5 minutes. The second color can include reflected light having a wavelength between 450 nanometers and 500 nanometers.
[0489] In some embodiments, an exogenous nucleic acid is delivered to an organism, wherein the exogenous nucleic acid encodes one or more genes to be expressed inside the organism. In some embodiments, one or more genes are driven by a promoter having high promoter activity for fungal cells. In some embodiments, the promoter comprises one of a U6 promoter or a GDP promoter. For example, in some embodiments, the promoter is selected from the promoter sequences described in Table 20B. For example, in some embodiments, the promoter is selected from:
[0490] pU6-1 promoter: CGATTTCTTTAGGGCCGTAGGCTAGTAATCATCGACCGTTTTAATCATTAATGTACTTAGACAATAAATATAAGATGCAATACAAGTCAATGGGAGAAACTAGACTTTACAAAACCTTTAAAAGCCCTGGTGAGATATGAGAAGG TTTATGACAGAATATATCGCCATTAATGTGAGGTTGTGGACACTGCTGGTAGTCAAGGCTGCCCGTGAACCATATTTAGTCACATGTAATCACCCCGCGTGCTAAACAAAAAGCAAAATATCAGTAAGATAGTCACAGTCATAACACTGTTGAAT
[0491] >pU6-2 promoter:
[0492] TGCCAAAAAGCCTTCTTGTGGCCTGCTTACTATTAAGGCAACTAATTCAAGAACAAGTGATTCTGGGTAGGTAGATGCCACAGTTCATGATAATAAAGGCGAAGTCAGAAGGAGTAGTCCGTTGATGAAGAAAGCAGAAGGCAAGGAATG TTGGTGGCTTTTGGTTGCGGTAGCACTGAAACCGTGTCCGGACTTCGCCGGGAGCAGACAATGGCTTGGTTGGATTACATAATAATACCCCGCGGGCCAGACAATATTCAAAATCCTAACAAAGATGTCTCAGGTAATACATTCGCTAAT
[0493] pU6-11 promoter:
[0494] GGTACCAGCAGTACCAGCACCAGCCACTGCATTATTGAATCTGACATCTGCAACAGCAAGGTACAATTTTTGTTTTACATTTTACTCATTAATATTAGCACCTATAGCTGTGGCCAATCTTTTGACGACGACTCTCTCACGCTGGAGGAAAGCATGGTACGGGCATTAATTGCCAGCGTAGAACAAGCGTAGGATATGGGCAACCTCGCTGATTTCTATATTTGGTAAGAAGTCTCACCCCGTGAGCTAAGCAAAAAGCAAAACCCTTGCTATGTCAACATCCCACTGCCATACACTATT
[0495] In some embodiments, the GDP promoter is used. The GDP promoter can have the sequence: GAGCTCTGAAAGACGCAGCCGACGGTAAACACCCGGGCATCGAGAAAGGCATTGTCGACTATACGGAAGAAGACGTTGTTTCCACCGATTTCGTTGGGAGCAACTATTCGATGATCTTTGACGCAAAAGCGGGCATCGCGTTGAACTCGCGTTTTATGAAATTAGTTGCATGGTATGATAATGAGTGGGGATATGCGCGTAGAGTCTGCGATGAGGTTGTGTATGTAGCGAAGAAGAATTAAGAGGTCCGCAAGTAGATTGAAAGTTCAGTACGTTTTTAACAATAGAGCATTTTCGAGGCTTGCGTCATTCTGTGTCAGGCTAGCAGTTTATAAGCGTTGAGGATCTAGAGCTGCTGTTCCCGCGTCTCGAATGTTCTCGGTGTTTAGGGGTTAGCAATCTGATATGATAATAATTTGTGATGACATCGATAGTACAAAAACCCCAATTCCGGTCACATCCACCATCTCCGTTTTCTCCCATCTACACACAACAAGCTCATCGCCggtaccATGGTTTGTCTCTCGCTTGCATACCACCCAGCAGCTCACTGATGTCGACTTGTAGGTTAAA
[0496] In some embodiments, the exogenous nucleic acid comprises a start intron between the promoter and the gene to be expressed. In some embodiments, the start intron comprises ATGGTTTGTCTCTCGCTTGCATACCACCCAGCAGCTCACTGATGTCGACTTGTAGGTTAAA.
[0497] In some embodiments, genetically modifying an organism involves introducing an exogenous nucleic acid into the organism. In some embodiments, the exogenous nucleic acid encodes a PsiM. In some embodiments, the PsiM gene is codon-optimized. In some embodiments, the codon-optimized PsiM is driven by a GPD promoter. In some embodiments, the exogenous nucleic acid comprises a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% identical to SEQ ID NO: 500.
[0498] In some embodiments, the exogenous nucleic acid encodes an aromatic L-amino acid decarboxylase (AAAD) gene from P. cochinchinensis. In some embodiments, the AAAD gene is codon-optimized for expression in P. cochinchinensis. In some embodiments, the AAAD gene is driven by a GPD promoter. In some embodiments, the exogenous nucleic acid comprises a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% identical to SEQ ID NO: 501.
[0499] In one aspect, the method may include culturing a mycelial mass under conditions sufficient to grow a population of genetically modified fungal cells, and extracting alkaloids from the population of fungal cells before primordia form on the mycelial mass. All fungal cells in the population of fungal cells may be genetically modified fungal cells. The mycelial mass may not contain original fungal cells. The mycelial mass may be cultured for less than 10 days. The population of fungal cells may be from the phylum Basidiomycota. Alkaloids may be extracted from the population of fungal cells within 7 days of culturing the mycelial mass. Cultivating the mycelial mass may include placing the mycelial mass in a closed container and providing the closed container with a climate comprising a temperature of approximately 19 degrees Celsius to 25 degrees Celsius and a humidity of approximately 90% to 100%. The amount of alkaloids extracted from the population of fungal cells may be greater than 1.8% of the dry mycelial mass. The alkaloid may include any of psilocybin, demethyldesphosphorus psilocybin, dephosphorus psilocybin, tryptamine, 4-hydroxytryptamine, N,N-dimethyltryptamine, demethylpsilocybin, dedimethylpsilocybin, serotonin, melatonin, melanin, N-acetyl-serotonin, 4-hydroxy-L-tryptophan, 5-hydroxy-L-tryptophan, 7-hydroxy-L-tryptophan, 4-phosphoryloxy-N,N-dimethyltryptamine, serotonin, aeruginascin, 2-(4-hydroxy-1H-indol-3-yl)-N,N,N-trimethylethan-1-amine, 4-phosphoryloxy-N,N-dimethyltryptamine, ketamine, N-acetylserotonin, 3,4-methylenedioxymethamphetamine, harmine, β-carboline, or any derivative or analog thereof. The genetic modification may result in increased expression of monoamine oxidase. The alkaloid may include N,N-dimethyltryptamine. The genetic modification may result in increased expression of a gene product involved in alkaloid biosynthesis in the population of fungal cells compared to a comparable population of wild-type fungal cells. The gene product may be encoded by a gene selected from the group consisting of PsiD, PsiH, PsiH2, PsiK, PsiM, PsiP, and PsiR, and wherein the gene comprises a sequence at least 95% identical to any one of SEQ ID NOs: 1-16. The population of fungal cells may comprise at least two genetic modifications. In some embodiments, at least one of the at least two genetic modifications may result in increased expression of a gene product encoded by at least one gene selected from the group consisting of PsiD, PsiH, PsiH2, PsiK, PsiM, PsiP, and PsiR, and wherein the gene comprises a sequence at least 95% identical to any one of SEQ ID NOs: 1-16. In some embodiments, at least one of the at least two genetic modifications can result in increased expression of a gene product encoded by at least one gene selected from PsiD and PsiK, and wherein the gene comprises a sequence at least 95% identical to SEQ ID NO: 1 and SEQ ID NO: 3.In some embodiments, at least one of the at least two genetic modifications can result in increased expression of a gene product encoded by at least one gene selected from PsiD and PsiK, wherein the gene comprises a sequence at least 95% identical to SEQ ID NO:90 and SEQ ID NO:3. The genetic modification can include deletions of nucleotides in a nucleic acid involved in expressing a gene product that regulates alkaloid production in a population of fungal cells. The genetic modification can include insertions / deletions within the promoter or enhancer of a gene encoding psilocybin phosphatase. The genetic modification can result in increased expression of L-tryptophan decarboxylase and 4-hydroxytryptamine kinase compared to a population of comparable wild-type fungal cells. The genetic modification can result in increased expression of tryptamine monooxygenase compared to a population of comparable wild-type fungal cells. The mycelial mass can exhibit a phenotype that is visually distinct from a comparable wild-type mycelial mass. The phenotype can include blue coloration. The genetic modification can result in at least one of: increased tryptophan decarboxylation, increased tryptamine 4-hydroxylation, increased 4-hydroxytryptamine O-phosphorylation, or increased psilocybin production via sequential N-methylation, compared to a population of comparable wild-type fungal cells. The genetic modification can result in a 6-fold increase in gene product expression in the population of fungal cells, compared to a population of comparable wild-type fungal cells. The population of fungal cells can further comprise a second genetic modification, the second genetic modification resulting in at least one of: increased tryptamine 4-hydroxylation, increased 4-hydroxytryptamine O-phosphorylation, or increased psilocybin production via sequential N-methylation, compared to a population of comparable wild-type fungal cells. Extraction can be performed when the mycelial mass comprises a blue coloration. Obtaining the mycelial mass can comprise genetically modifying fungal protoplasts and culturing the genetically modified fungal protoplasts to produce a population of fungal cells. Genetically modifying the fungal protoplasts can comprise integrating an exogenous nucleic acid into the genome of the fungal protoplasts. The exogenous nucleic acid may comprise a gene encoding a gene product involved in alkaloid biosynthesis, wherein the gene is selected from PsiM, PsiH, PsiH2, PsiK, PsiM, PsiR, or a variant thereof. The exogenous nucleic acid may comprise a sequence at least 95% identical to any one of SEQ ID NOs 1-16. Genetically modifying fungal protoplasts may comprise delivering the exogenous nucleic acid to the fungal protoplasts by electroporation, microinjection, mechanical cell deformation, lipid nanoparticles, lentivirus, or Agrobacterium-mediated transformation. The genetic modification may be accomplished by an endonuclease system. The endonuclease system may comprise an endonuclease complexed with a guide nucleic acid. The endonuclease may comprise a Cas endonuclease, and the nucleic acid comprises a guide RNA. The guide RNA may comprise a targeting sequence that is 95% identical to any one of SEQ ID NOs: 29-64. The population of fungal cells may comprise increased expression of L-tryptophan decarboxylase compared to a population of comparable wild-type fungal cells.The mycelial mass may reflect light having a wavelength between approximately 425 nanometers and 525 nanometers.
[0500] Disclosed herein is a method for enhancing alkaloid production, the method comprising: obtaining a genetically modified fungal cell, wherein the genetically modified fungal cell can produce an increased amount of one or more alkaloids compared to a comparable wild-type fungal cell, producing a mycelial mass under conditions sufficient to grow a population of the genetically modified fungal cell, wherein the mycelial mass comprises a phenotype that is visually different from the phenotype of a comparable wild-type mycelial mass; and isolating the one or more alkaloids from the mycelial mass. The phenotype can include a blue coloration. The visually different phenotype can be observed by a greater amount of reflected light at a wavelength ranging from 400 nm to 510 nm. The visually different phenotype can be observed by a greater amount of reflected light at a wavelength ranging from 445 nm to 510 nm. The visually different phenotype can be observed by a greater amount of reflected light at a wavelength ranging from 400 nm to 475 nm. The one or more alkaloids can be isolated from the mycelial mass before primordia are formed. The fungal cell can be a fungal protoplast. The genetic modification can result in at least a 2-fold increase in expression of mRNA encoding L-tryptophan decarboxylase in the mycelial mass compared to a comparable wild-type mycelial mass. The genetic modification can result in increased production of L-tryptophan decarboxylase and 4-hydroxytryptamine kinase compared to a comparable wild-type mycelial mass. The genetic modification can provide increased mRNA expression of the following genes: PsiD and PsiK. The genetic modification can provide increased production of proteins encoded by the following genes: PsiD and PsiK. Genetically modifying the fungal cell can include introducing an exogenous nucleic acid into the fungal cell. The exogenous nucleic acid can encode an endonuclease system. The endonuclease system can comprise a Cas endonuclease and a guide nucleic acid. The exogenous nucleic acid can encode a gene product involved in the biosynthesis of at least one of the one or more alkaloids. The exogenous nucleic acid can comprise a sequence that is 95% identical to any one of SEQ ID NOs: 1-16. The mycelial mass may comprise a modification that results in one of increased tryptamine 4-hydroxylation, increased 4-hydroxytryptamine O-phosphorylation, or increased psilocybin production via sequential N-methylation compared to a comparable wild-type mycelial mass. The mycelial mass may comprise altered expression of a gene product encoded by any one of PsiD, PsiM, PsiH, PsiH2, PsiK, PsiM, or PsiR compared to a comparable wild-type mycelial mass. The fungal mycelium may reflect light having a wavelength between about 450 nanometers and 500 nanometers. Genetically modifying the fungal cell may comprise introducing an endonuclease system into the fungal cell. The endonuclease system may comprise a Cas endonuclease complexed with a guide nucleic acid. The guide nucleic acid may comprise a targeting sequence that binds to a regulatory element of a gene encoding a gene product involved in psilocybin synthesis. The gene may comprise one of PsiD, PsiH, PsiH2, PsiK, PsiM, PsiP, or PsiR.The targeting sequence may comprise a sequence having 95% identity to any one of SEQ ID NOs: 1-16. The endonuclease system may be introduced into the fungal cell in the form of a ribonucleoprotein. The endonuclease system may be introduced into the fungal cell using a chemical reagent. The chemical reagent may include a surfactant. The one or more alkaloids may include at least one of psilocybin, demethyldesphosphorus psilocybin, dephosphorus psilocybin, tryptamine, 4-hydroxytryptamine, N,N-dimethyltryptamine, norpsilocybin, nordimethylpsilocybin, serotonin, melatonin, melanin, N-acetyl-serotonin, 4-hydroxy-L-tryptophan, 5-hydroxy-L-tryptophan, 7-hydroxy-L-tryptophan, 4-phosphoryloxy-N,N-dimethyltryptamine, serotonin, aeruginascin, 2-(4-hydroxy-1H-indol-3-yl)-N,N,N-trimethylethan-1-amine, 4-phosphoryloxy-N,N-dimethyltryptamine, ketamine, N-acetylserotonin, 3,4-methylenedioxymethamphetamine, harmine, β-carboline, or any derivative or any analog thereof.
[0501] Disclosed herein are compositions comprising a mycelial mass, an isolate, or an extract thereof, further comprising a population of fungal cells, wherein the population of fungal cells comprises at least one genetic modification that results in the population of genetically modified fungal cells producing an increased amount of an alkaloid compared to a population of comparable wild-type fungal cells, wherein the mycelial mass lacks detectable expression of a gene product encoded by a PsiR, and wherein the mycelial mass has not yet formed a fungal primordium. All fungal cells in the population of fungal cells may be genetically modified fungal cells. The mycelial mass may not comprise primordial fungal cells. The mycelial mass may be cultured for less than 10 days. The population of fungal cells may be from the phylum Basidiomycota. Alkaloids may be extracted from the population of fungal cells within 7 days of culturing the mycelial mass. Culturing the mycelial mass may comprise placing the mycelial mass in a closed container and providing the closed container with a climate comprising a temperature of about 19 degrees Celsius to 25 degrees Celsius and a humidity of about 90% to 100%. The amount of alkaloid extracted from the population of fungal cells may be greater than 1.8% of the dry mycelial mass. The alkaloid may include any of psilocybin, demethyldesphosphorus psilocybin, dephosphorus psilocybin, tryptamine, 4-hydroxytryptamine, N,N-dimethyltryptamine, demethylpsilocybin, dedimethylpsilocybin, serotonin, melatonin, melanin, N-acetyl-serotonin, 4-hydroxy-L-tryptophan, 5-hydroxy-L-tryptophan, 7-hydroxy-L-tryptophan, 4-phosphoryloxy-N,N-dimethyltryptamine, serotonin, aeruginascin, 2-(4-hydroxy-1H-indol-3-yl)-N,N,N-trimethylethan-1-amine, 4-phosphoryloxy-N,N-dimethyltryptamine, ketamine, N-acetylserotonin, 3,4-methylenedioxymethamphetamine, harmine, β-carboline, or any derivative or analog thereof. The genetic modification may result in increased expression of monoamine oxidase. The alkaloid may include N,N-dimethyltryptamine. The genetic modification may result in increased expression of a gene product involved in alkaloid biosynthesis in the population of fungal cells compared to a comparable population of wild-type fungal cells. The gene product may be encoded by a gene selected from the group consisting of PsiD, PsiH, PsiH2, PsiK, PsiM, PsiP, and PsiR, and wherein the gene comprises a sequence at least 95% identical to any one of SEQ ID NOs: 1-16. The population of fungal cells may comprise at least two genetic modifications. In some embodiments, at least one of the at least two genetic modifications may result in increased expression of a gene product encoded by at least one gene selected from the group consisting of PsiD, PsiH, PsiH2, PsiK, PsiM, PsiP, and PsiR, and wherein the gene comprises a sequence at least 95% identical to any one of SEQ ID NOs: 1-16.In some embodiments, at least one of the at least two genetic modifications can result in increased expression of a gene product encoded by at least one gene selected from PsiD and PsiK, wherein the gene comprises a sequence at least 95% identical to SEQ ID NO: 1 and SEQ ID NO: 3. The genetic modification can include deletions of nucleotides in a nucleic acid involved in expressing a gene product that regulates alkaloid production in a population of fungal cells. The genetic modification can include insertions / deletions within the promoter or enhancer of a gene encoding psilocybin phosphatase. The genetic modification can result in increased expression of L-tryptophan decarboxylase and 4-hydroxytryptamine kinase compared to a population of comparable wild-type fungal cells. The genetic modification can result in increased expression of tryptamine monooxygenase compared to a population of comparable wild-type fungal cells. The genetic modification can result in at least a 2-fold increase in expression of mRNA encoding L-tryptophan decarboxylase in a mycelial mass compared to a comparable wild-type mycelial mass. The genetic modification can result in increased expression of L-tryptophan decarboxylase and 4-hydroxytryptamine kinase compared to a comparable wild-type mycelial mass. The genetic modification may include multiple gene products encoded by PsiD and PsiK. The genetic modification may result in increased expression of tryptamine monooxygenase compared to a population of comparable wild-type fungal cells. The mycelial mass may exhibit a phenotype that is visually different from a comparable wild-type mycelial mass. The phenotype may include a blue coloration. The mycelial mass may reflect light having a wavelength between approximately 425 nanometers and 525 nanometers. The visually different phenotype may be observed by a greater amount of reflected light at a wavelength in the range of 400 nm to 510 nm. The visually different phenotype may be observed by a greater amount of reflected light at a wavelength in the range of 445 nm to 510 nm. The visually different phenotype may be observed by a greater amount of reflected light at a wavelength in the range of 400 nm to 475 nm. One or more alkaloids may be separated from the mycelial mass prior to primordium formation. The genetic modification can result in at least one of: increased tryptophan decarboxylation, increased tryptamine 4-hydroxylation, increased 4-hydroxytryptamine O-phosphorylation, or increased psilocybin production via sequential N-methylation, compared to a population of comparable wild-type fungal cells. The genetic modification can result in a 6-fold increase in gene product expression in the population of fungal cells, compared to a population of comparable wild-type fungal cells. The population of fungal cells can further comprise a second genetic modification, the second genetic modification resulting in at least one of: increased tryptamine 4-hydroxylation, increased 4-hydroxytryptamine O-phosphorylation, or increased psilocybin production via sequential N-methylation, compared to a population of comparable wild-type fungal cells. Extraction can be performed when the mycelial mass comprises a blue coloration. Obtaining the mycelial mass can comprise genetically modifying fungal protoplasts and culturing the genetically modified fungal protoplasts to produce a population of fungal cells. Genetically modifying the fungal protoplasts can comprise integrating an exogenous nucleic acid into the genome of the fungal protoplasts.The exogenous nucleic acid may comprise a gene encoding a gene product involved in alkaloid biosynthesis, wherein the gene is selected from PsiM, PsiH, PsiH2, PsiK, PsiM, PsiR, or a variant thereof. The exogenous nucleic acid may comprise a sequence at least 95% identical to any one of SEQ ID NOs 1-16. Genetically modifying fungal protoplasts may comprise delivering the exogenous nucleic acid to the fungal protoplasts by electroporation, microinjection, mechanical cell deformation, lipid nanoparticles, lentivirus, or Agrobacterium-mediated transformation. The genetic modification may be accomplished by an endonuclease system. The endonuclease system may comprise an endonuclease complexed with a guide nucleic acid. The endonuclease may comprise a Cas endonuclease, and the nucleic acid comprises a guide RNA. The guide RNA may comprise a targeting sequence that is 95% identical to any one of SEQ ID NOs: 29-64. The population of fungal cells may comprise increased expression of L-tryptophan decarboxylase compared to a population of comparable wild-type fungal cells.
[0502] Disclosed herein is a composition comprising: a mycelial mass, wherein the mycelial mass comprises a population of fungal cells, wherein the fungal cells comprise a genetic modification to a gene encoding a gene product involved in psilocybin biosynthesis, and wherein the genetic modification causes the mycelial mass to visually appear blue. All fungal cells in the population of fungal cells may be genetically modified fungal cells. The mycelial mass may not comprise original fungal cells. The mycelial mass may be cultured for less than 10 days. The population of fungal cells may be from the phylum Basidiomycota. Alkaloids may be extracted from the population of fungal cells within 7 days of culturing the mycelial mass. Culturing the mycelial mass may comprise placing the mycelial mass in a closed container and providing the closed container with a climate comprising a temperature of approximately 19°C to 25°C and a humidity of approximately 90% to 100%. The amount of alkaloids extracted from the population of fungal cells may be greater than 1.8% of the dry mycelial mass. The alkaloid may include any of psilocybin, demethyldesphosphorus psilocybin, dephosphorus psilocybin, tryptamine, 4-hydroxytryptamine, N,N-dimethyltryptamine, demethylpsilocybin, dedimethylpsilocybin, serotonin, melatonin, melanin, N-acetyl-serotonin, 4-hydroxy-L-tryptophan, 5-hydroxy-L-tryptophan, 7-hydroxy-L-tryptophan, 4-phosphoryloxy-N,N-dimethyltryptamine, serotonin, aeruginascin, 2-(4-hydroxy-1H-indol-3-yl)-N,N,N-trimethylethan-1-amine, 4-phosphoryloxy-N,N-dimethyltryptamine, ketamine, N-acetylserotonin, 3,4-methylenedioxymethamphetamine, harmine, β-carboline, or any derivative or analog thereof. The genetic modification may result in increased expression of monoamine oxidase. The alkaloid may include N,N-dimethyltryptamine. The genetic modification may result in increased expression of a gene product involved in alkaloid biosynthesis in the population of fungal cells compared to a comparable population of wild-type fungal cells. The gene product may be encoded by a gene selected from the group consisting of PsiD, PsiH, PsiH2, PsiK, PsiM, PsiP, and PsiR, and wherein the gene comprises a sequence at least 95% identical to any one of SEQ ID NOs: 1-16. The population of fungal cells may comprise at least two genetic modifications. In some embodiments, at least one of the at least two genetic modifications may result in increased expression of a gene product encoded by at least one gene selected from the group consisting of PsiD, PsiH, PsiH2, PsiK, PsiM, PsiP, and PsiR, and wherein the gene comprises a sequence at least 95% identical to any one of SEQ ID NOs: 1-16. In some embodiments, at least one of the at least two genetic modifications can result in increased expression of a gene product encoded by at least one gene selected from PsiD and PsiK, and wherein the gene comprises a sequence at least 95% identical to SEQ ID NO: 1 and SEQ ID NO: 3.The genetic modification may include deletions of nucleotides in a nucleic acid involved in the expression of a gene product that regulates alkaloid production in a population of fungal cells. The genetic modification may include insertions / deletions within the promoter or enhancer of a gene encoding psilocybin phosphatase. The genetic modification may result in increased expression of L-tryptophan decarboxylase and 4-hydroxytryptamine kinase compared to a population of comparable wild-type fungal cells. The genetic modification may result in increased expression of tryptamine monooxygenase compared to a population of comparable wild-type fungal cells. The genetic modification may result in at least a 2-fold increase in expression of mRNA encoding L-tryptophan decarboxylase in a mycelial mass compared to a comparable wild-type mycelial mass. The genetic modification may result in increased expression of L-tryptophan decarboxylase and 4-hydroxytryptamine kinase compared to a comparable wild-type mycelial mass. The genetic modification may include multiple gene products encoded by PsiD and PsiK. The genetic modification may result in increased expression of tryptamine monooxygenase compared to a population of comparable wild-type fungal cells. The mycelial mass may exhibit a phenotype that is visually different from a comparable wild-type mycelial mass. The phenotype may include a blue coloration. The mycelial mass may reflect light having a wavelength between approximately 425 and 525 nanometers. The visually different phenotype may be observed by a greater amount of reflected light at a wavelength range of 400 to 510 nm. The visually different phenotype may be observed by a greater amount of reflected light at a wavelength range of 445 to 510 nm. The visually different phenotype may be observed by a greater amount of reflected light at a wavelength range of 400 to 475 nm. One or more alkaloids may be isolated from the mycelial mass before primordium formation. One or more alkaloids may be isolated from the mycelial mass before primordium formation. Compared to a population of comparable wild-type fungal cells, the genetic modification may result in at least one of: increased tryptophan decarboxylation, increased tryptamine 4-hydroxylation, increased 4-hydroxytryptamine O-phosphorylation, or increased psilocybin production via continuous N-methylation. The genetic modification can result in a 6-fold increase in gene product expression in the population of fungal cells compared to a comparable population of wild-type fungal cells. The population of fungal cells can further comprise a second genetic modification that results in at least one of increased tryptamine 4-hydroxylation, increased 4-hydroxytryptamine O-phosphorylation, or increased psilocybin production via continuous N-methylation compared to a comparable population of wild-type fungal cells. Extraction can be performed when the mycelial mass comprises a blue coloration. Obtaining the mycelial mass can comprise genetically modifying fungal protoplasts and culturing the genetically modified fungal protoplasts to produce a population of fungal cells. Genetically modifying the fungal protoplasts can comprise integrating an exogenous nucleic acid into the genome of the fungal protoplasts. The exogenous nucleic acid can comprise a gene encoding a gene product involved in alkaloid biosynthesis, wherein the gene is selected from the group consisting of PsiM, PsiH, PsiH2, PsiK, PsiM, PsiR, or variants thereof.The exogenous nucleic acid may comprise a sequence at least 95% identical to any one of SEQ ID NOs 1-16. Genetic modification of fungal protoplasts may include delivery of exogenous nucleic acids to fungal protoplasts by electroporation, microinjection, mechanical cell deformation, lipid nanoparticles, lentivirus, or Agrobacterium-mediated transformation. Genetic modification may be accomplished by an endonuclease system. The endonuclease system may comprise an endonuclease complexed with a guide nucleic acid. The endonuclease may comprise a Cas endonuclease, and the nucleic acid comprises a guide RNA. The guide RNA may comprise a targeting sequence with 95% identity to any one of SEQ ID NOs: 29-64. The colony of fungal cells may comprise increased expression of L-tryptophan decarboxylase compared to a colony of comparable wild-type fungal cells.
[0503] A composition comprising: a mycelial mass, wherein the mycelial mass comprises a population of genetically modified fungal cells, and wherein the mycelial mass comprises an enhanced level of dephosphorylated psilocybin in an amount sufficient to render the mycelial mass visually blue. The genetically modified fungal cells may comprise a genetic modification that provides for an increased amount of alkaloid production compared to a population of comparable wild-type fungal cells, and wherein the mycelial mass is visually blue. All fungal cells in the population of fungal cells may be genetically modified fungal cells. The mycelial mass may not comprise original fungal cells. The mycelial mass may be cultured for less than 10 days. The population of fungal cells may be from the phylum Basidiomycota. Alkaloids may be extracted from the population of fungal cells within 7 days of culturing the mycelial mass. Culturing the mycelial mass may comprise placing the mycelial mass in a closed container and providing the closed container with a climate comprising a temperature of approximately 19°C to 25°C and a humidity of approximately 90% to 100%. The amount of alkaloids extracted from the population of fungal cells may be greater than 1.8% of the dry mycelial mass. The alkaloid may include any of psilocybin, demethyldesphosphorus psilocybin, dephosphorus psilocybin, tryptamine, 4-hydroxytryptamine, N,N-dimethyltryptamine, demethylpsilocybin, dedimethylpsilocybin, serotonin, melatonin, melanin, N-acetyl-serotonin, 4-hydroxy-L-tryptophan, 5-hydroxy-L-tryptophan, 7-hydroxy-L-tryptophan, 4-phosphoryloxy-N,N-dimethyltryptamine, serotonin, aeruginascin, 2-(4-hydroxy-1H-indol-3-yl)-N,N,N-trimethylethan-1-amine, 4-phosphoryloxy-N,N-dimethyltryptamine, ketamine, N-acetylserotonin, 3,4-methylenedioxymethamphetamine, harmine, β-carboline, or any derivative or analog thereof. The genetic modification may result in increased expression of monoamine oxidase. The alkaloid may include N,N-dimethyltryptamine. The genetic modification may result in increased expression of a gene product involved in alkaloid biosynthesis in the population of fungal cells compared to a comparable population of wild-type fungal cells. The gene product may be encoded by a gene selected from the group consisting of PsiD, PsiH, PsiH2, PsiK, PsiM, PsiP, and PsiR, and wherein the gene comprises a sequence at least 95% identical to any one of SEQ ID NOs: 1-16. The population of fungal cells may comprise at least two genetic modifications. In some embodiments, at least one of the at least two genetic modifications may result in increased expression of a gene product encoded by at least one gene selected from the group consisting of PsiD, PsiH, PsiH2, PsiK, PsiM, PsiP, and PsiR, and wherein the gene comprises a sequence at least 95% identical to any one of SEQ ID NOs: 1-16.In some embodiments, at least one of the at least two genetic modifications can result in increased expression of a gene product encoded by at least one gene selected from PsiD and PsiK, wherein the gene comprises a sequence at least 95% identical to SEQ ID NO: 1 and SEQ ID NO: 3. The genetic modification can include deletions of nucleotides in a nucleic acid involved in expressing a gene product that regulates alkaloid production in a population of fungal cells. The genetic modification can include insertions / deletions within the promoter or enhancer of a gene encoding psilocybin phosphatase. The genetic modification can result in increased expression of L-tryptophan decarboxylase and 4-hydroxytryptamine kinase compared to a population of comparable wild-type fungal cells. The genetic modification can result in increased expression of tryptamine monooxygenase compared to a population of comparable wild-type fungal cells. The genetic modification can result in at least a 2-fold increase in expression of mRNA encoding L-tryptophan decarboxylase in a mycelial mass compared to a comparable wild-type mycelial mass. The genetic modification can result in increased expression of L-tryptophan decarboxylase and 4-hydroxytryptamine kinase compared to a comparable wild-type mycelial mass. The genetic modification can include multiple gene products encoded by PsiD and PsiK. The genetic modification can result in increased expression of tryptamine monooxygenase compared to a population of comparable wild-type fungal cells. The mycelial mass can exhibit a phenotype that is visually different from a comparable wild-type mycelial mass. The phenotype can include a blue coloration. The mycelial mass can reflect light having a wavelength between approximately 425 nanometers and 525 nanometers. The visually different phenotype can be observed by a greater amount of reflected light at a wavelength in the range of 400 nm to 510 nm. The visually different phenotype can be observed by a greater amount of reflected light at a wavelength in the range of 445 nm to 510 nm. The visually different phenotype can be observed by a greater amount of reflected light at a wavelength in the range of 400 nm to 475 nm. One or more alkaloids can be separated from the mycelial mass before primordia form. The genetic modification can result in at least one of: increased tryptophan decarboxylation, increased tryptamine 4-hydroxylation, increased 4-hydroxytryptamine O-phosphorylation, or increased psilocybin production via sequential N-methylation, compared to a population of comparable wild-type fungal cells. The genetic modification can result in a 6-fold increase in gene product expression in the population of fungal cells, compared to a population of comparable wild-type fungal cells. The population of fungal cells can further comprise a second genetic modification, the second genetic modification resulting in at least one of: increased tryptamine 4-hydroxylation, increased 4-hydroxytryptamine O-phosphorylation, or increased psilocybin production via sequential N-methylation, compared to a population of comparable wild-type fungal cells. Extraction can be performed when the mycelial mass comprises a blue coloration. Obtaining the mycelial mass can comprise genetically modifying fungal protoplasts and culturing the genetically modified fungal protoplasts to produce a population of fungal cells. Genetically modifying the fungal protoplasts can comprise integrating an exogenous nucleic acid into the genome of the fungal protoplasts.The exogenous nucleic acid may comprise a gene encoding a gene product involved in alkaloid biosynthesis, wherein the gene is selected from PsiM, PsiH, PsiH2, PsiK, PsiM, PsiR, or a variant thereof. The exogenous nucleic acid may comprise a sequence at least 95% identical to any one of SEQ ID NOs 1-16. Genetically modifying fungal protoplasts may comprise delivering the exogenous nucleic acid to the fungal protoplasts by electroporation, microinjection, mechanical cell deformation, lipid nanoparticles, lentivirus, or Agrobacterium-mediated transformation. The genetic modification may be accomplished by an endonuclease system. The endonuclease system may comprise an endonuclease complexed with a guide nucleic acid. The endonuclease may comprise a Cas endonuclease, and the nucleic acid comprises a guide RNA. The guide RNA may comprise a targeting sequence that is 95% identical to any one of SEQ ID NOs: 29-64. The population of fungal cells may comprise increased expression of L-tryptophan decarboxylase compared to a population of comparable wild-type fungal cells.
[0504] In some embodiments, the exogenous nucleic acid encodes a heterologous protein. In some embodiments, the nucleic acid encodes a PsiM gene from P. cyanea. In some embodiments, the PsiM gene is codon-optimized for expression in P. coli. In some embodiments, the codon-optimized PsiM is driven by a GPD promoter. In some embodiments, the exogenous nucleic acid comprises a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% identical to SEQ ID NO:502.
[0505] In some embodiments, the exogenous nucleic acid encodes a heterologous protein. In some embodiments, the heterologous protein comprises TrpM from P. serbica. In some embodiments, the TrpM gene is codon-optimized for expression in P. cochinchinensis. In some embodiments, the TrpM gene is driven by a GPD promoter. In some embodiments, the exogenous nucleic acid comprises a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% identical to SEQ ID NO:503.
[0506] In some embodiments, the exogenous nucleic acid encodes the isostrusidine synthase gene (STST) from Catharanthus roseus. In some embodiments, the STST gene is codon-optimized for expression in Psilocybe edulis. In some embodiments, the STST gene is driven by a GPD promoter. In some embodiments, the exogenous nucleic acid comprises a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% identical to SEQ ID NO: 504.
[0507] In some embodiments, the exogenous nucleic acid encodes the indoleethylamine N-methyltransferase (INMT) gene from Homo sapiens. In some embodiments, the INMT gene is codon-optimized for expression in Psilocybin mushrooms. In some embodiments, the INMT gene is driven by a GPD promoter. In some embodiments, the exogenous nucleic acid comprises a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% identical to SEQ ID NO: 505.
[0508] In some embodiments, the exogenous nucleic acid encodes McbB from the marine actinomycete M. thermotolerans. In some embodiments, the MccB gene is codon-optimized for expression in Psilocybe edulis. In some embodiments, the MccB gene is driven by a GPD promoter. In some embodiments, the exogenous nucleic acid comprises a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% identical to SEQ ID NO:506.
[0509] In some embodiments, the present disclosure provides tools and reagents for performing genetic modifications. In some embodiments, the present disclosure provides vectors for introducing guide nucleic acids into organisms. In some embodiments, the vector comprises a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% identical to SEQ ID NO: 507.
[0510] In some embodiments, the vector comprises a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% identical to SEQ ID NO:508.
[0511] In some embodiments, the vector comprises a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% identical to SEQ ID NO:509.
[0512] In some embodiments, the vector comprises a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% identical to SEQ ID NO:510.
[0513] In some embodiments, the vector comprises a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% identical to SEQ ID NO:511.
[0514] Table 23. Exemplary plasmid sequences
[0515]
[0516]
[0517]
[0518]
[0519]
[0520]
[0521]
[0522]
[0523]
[0524]
[0525]
[0526] In some embodiments, the present disclosure provides reagents, such as plasmids, that can be used to introduce genetic modifications into organisms. In some embodiments, the plasmid is optimized for introducing genetic modifications into the genome of a fungal cell. In some embodiments, the plasmid encodes a gene editing system. In some embodiments, the plasmid encodes one or more guide polynucleotides alone or in combination with a gene editing system. In some embodiments, the guide polynucleotide comprises a targeting sequence for binding to a psilocybin synthase gene to introduce the genetic modification into the psilocybin synthase gene. In some embodiments, the psilocybin synthase gene comprises PsiP1. In some embodiments, the psilocybin synthase gene comprises TrpE. In some embodiments, the guide polynucleotide comprises a sequence for binding to a non-coding region in a psi locus.
[0527] For example, provided herein are plasmids comprising a guide polynucleotide in combination with a codon-optimized Cas9 and a hygromycin resistance gene, the guide polynucleotide having a targeting sequence for binding to PsiP1 and PsiP2. See SEQ ID NOs: 601-602. Also provided herein are plasmids comprising a guide polynucleotide for binding to TrpE and a watermark (i.e., a non-coding region in the Psi locus) sequence in combination with codon-optimized Cas9 and hygromycin resistance (see SEQ ID NO: 603). Provided herein are plasmids encoding a guide polynucleotide for a targeting sequence comprising a watermark (i.e., a non-coding region in the Psi locus) sequence in combination with codon-optimized Cas9 and hygromycin resistance (see SEQ ID NO: 604). Also provided herein are plasmids comprising a guide polynucleotide with a target sequence for TrpE in combination with codon-optimized Cas9 and hygromycin resistance (see SEQ ID NO: 605). Also provided herein are plasmids encoding a guide polynucleotide comprising a sequence for binding to PsiR in combination with codon-optimized Cas9 and hygromycin resistance (see SEQ ID NO: 606). In some embodiments, the plasmid is at least 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to one of the plasmids listed in Table 24. In some embodiments, the plasmid comprises a sequence selected from the group consisting of any one of SEQ ID NOs: 300-301, 303-313, 402, and 601-606.
[0528] Table 24. Additional exemplary gene editing plasmids
[0529]
[0530]
[0531]
[0532]
[0533]
[0534]
[0535]
[0536]
[0537]
[0538]
[0539]
[0540]
[0541]
[0542]
[0543]
[0544]
[0545]
[0546]
[0547]
[0548]
[0549]
[0550]
[0551]
[0552]
[0553]
[0554]
[0555]
[0556]
[0557]
[0558]
[0559]
[0560]
[0561]
[0562]
[0563]
[0564]
[0565]
[0566]
[0567]
[0568]
[0569]
[0570]
[0571]
[0572]
[0573]
[0574]
[0575] Genetic modification may involve upregulating expression of PsiR. Analysis of PsiD, PsiM, PsiT2, PsiH, PsiK, PsiT1, PsiP, and PsiL revealed that the PsiD, PsiH, PsiM, and PsiT2 genes contain one E-box motif in their promoters (PsiT1 has two), while PsiP contains four E-box motifs (500 bp upstream of the ATG). PsiL and PsiK do not have one or more E-box motifs in their upstream regions. Therefore, upregulating PsiR is expected to modulate the expression of the Psi genes, thereby enhancing the production of one or more alkaloids.
[0576] The regulatory sequences for PsiD, PsiM, PsiT2, PsiH, PsiK, PsiT1, PsiP, and PsiL are listed below.
[0577] The regulatory sequences for PsiD, PsiM, PsiT2, PsiH, PsiK, PsiT1, PsiP, and PsiL are listed in Table 25 below.
[0578] Table 25. Regulatory gene sequences of Psilocybin mushrooms
[0579]
[0580]
[0581]
[0582] In silico analysis of PsiR expression levels and splice forms was performed using publicly available databases.
[0583] Primers used to validate PsiR splice variants are as follows:
[0584] PsiR_F1 AACTCACGATCCTGCCTTG PsiR_R1 ACTGGGTACAATGCGGC
[0585] In particular, a CRISPR vector kit for performing one or more genetic modifications on an organism is disclosed. In some embodiments, the organism is a fungal organism. The fungal organism can be a fungal protoplast. The CRISPR vector kit includes 6 entry vectors (pMGA, pMGB, pMGC, pMGD, pMGE, pMGF). The backbone of the vector can be the commercially available vector pUC57. Exemplary vector sequences are shown in Table 24 below, with the vector name shown in brackets.
[0586] refer to Figure 4 , vectors pMGA, pMGB, pMGC and pMGD can be used to clone gRNA directly downstream of the Psilocybe occidentalis U6 promoter. Exemplary U6 promoters are described below. Vector pMGE can be composed of a strong promoter driving the Psilocybe occidentalis codon-optimized Cas9 gene or nickase variant (D10A, nCas9). Table 28 shows the optimal codons for designing Cas endonucleases and the NLS sequences for use in Psilocybe occidentalis. Such codon optimization can be used to improve gene expression and increase the translation efficiency of Cas9 by regulating the codon bias of fungal cells. The Psilocybe occidentalis codon-optimized Cas9 gene can comprise a sequence that is at least: 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO.: 203, which can achieve high expression and translation efficiency in fungal cells.
[0587] In some embodiments, the present invention provides the method for the generation of the pMGF carrier.Carrier pMGF can be made up of the strong promoter that drives the hygromycin resistance gene.The hygromycin resistance gene is useful during selection.Carrier PMGA, PMGB, PMGC, PMGD, PMGE and PMGF can be assembled into binary purpose vector (pMGZ) together, and its flank is the left border and the right border that are suitable for the Pseudomonas aeruginosa transformation of Agrobacterium-mediated.Agrobacterium can be used for plasmid system to be integrated into fungal cell.In other cases, carrier PMGA, PMGB, PMGC, PMGD, PMGE and PMGF can be integrated into commercial plasmid (for example, pUC57 or viral plasmid) and in the absence of Agrobacterium, be delivered into fungal cell.
[0588] Vector pMGA, PMGB, PMGC and PMGD can be used to clone the guide RNA of interest.Guide RNA can be inserted into the direct downstream of Psilocybe edulis U6 promoter and the direct upstream of inserting guide RNA scaffold sequence, see below.Guide RNA of interest can include the sequence combined with alkaloid synthase gene.The following elements can be a part of pMGA, PMGB, PMGC and PMGD vectors: BsaI site (forward orientation), overhang 1 for assembling in the destination vector, U6 promoter, overhang A for gRNA insertion, BbsI site (reverse orientation), ccdb negative selection marker, BbsI site (forward orientation), overhang B for gRNA insertion, guide RNA scaffold sequence, U6 terminator, overhang 2 and BsaI site (reverse orientation) for assembling in the destination vector.BsaI site can include sequence GGTCTC (forward, 5'-> 3' orientation) and sequence GAGACC (reverse, 5'-> 3' orientation). Exemplary pMGA, PMGB, PMGC, and PMGD plasmid sequences are provided in Tables 24 and 25.
[0589] The pMGA, PMGB, PMGC, and PMGD vectors can be identical except for the overhangs used for assembly in the destination vector. The overhang sequences used to generate the vectors are described in Table 26. The different overhang sequences can be used to ensure that all guides are included in the final vector.
[0590] Table 26. Vector overhang sequences.
[0591]
[0592]
[0593] The U6 promoter may include any of pU6-1, pU6-2, and pU6-11 described below. Entry vectors for all three promoters were designed and designated pMGA-1, pMGB-1, pMGC-1, pMGD-1, pMGA-2, pMGB-2, pMGC-2, pMGD-2, pMGA-11, pMGB-11, pMGC-11, and pMGD-11.
[0594] pU6-1 promoter: CGATTTCTTTAGGGCCGTAGGCTAGTAATCATCGACCGTTTTAATCATTAATGTACTTAGACAATAAATATAAGATGCAATACAAGTCAATGGGAGAAACTAGACTTTACAAAACCTTTAAAAGCCCTGGTGAGATATGAGAAGGTT TATGACAGAATATATCGCCATTAATGTGAGGTTGTGGACACTGCTGGTAGTCAAGGCTGCCCGTGAACCATATTTAGTCACATGTAATCACCCCGCGTGCTAAACAAAAAGCAAAATATCAGTAAGATAGTCACAGTCATAACACTGTTGAAT(SEQ ID NO:400).
[0595] >pU6-2 promoter:
[0596] TGCCAAAAAGCCTTCTTGTGGCCTGCTTACTATTAAGGCAACTAATTCAAGAACAAGTGATTCTGGGTAGGTAGATGCCACAGTTCATGATAATAAAGGCGAAGTCAGAAGGAGTAGTCCGTTGATGAAGAAAGCAGAAGGCAAGGAATGTT GGTGGCTTTTGGTTGCGGTAGCACTGAAACCGTGTCCGGACTTCGCCGGGAGCAGACAATGGCTTGGTTGGATTACATAATAATACCCCGCGGGCCAGACAATATTCAAAATCCTAACAAAGATGTCTCAGGTAATACATTCGCTAAT(SEQ ID NO:401).
[0597] pU6-11 promoter:
[0598] GGTACCAGCAGTACCAGCACCAGCCACTGCATTATTGAATCTGACATCTGCAACAGCAAGGTACAATTTTTGTTTTACATTTTACTCATTAATATTAGCACCTATAGCTGTGGCCAATCTTTTGACGACGACTCTCTCACGCTGGAGGAAAG CATGGTACGGGCATTAATTGCCAGCGTAGAACAAGCGTAGGATATGGGCAACCTCGCTGATTTCTATATTTGGTAAGAAGTCTCACCCCGTGAGCTAAGCAAAAAGCAAAACCCTTGCTATGTCAACATCCCACTGCCATACACTATT(SEQ ID NO:403).
[0599] Figure 5 An alignment of three U6 promoters used for gene editing is shown. U6 is highlighted between residues 282 and 420. A conserved region of ca 40 nt upstream of the three U6 promoters is highlighted between residues 222 and 281.
[0600] The overhangs used for guide insertion are as follows (Table 27). Note that the last four nucleotides in the original sequence of the U6-1 promoter overhang are GTTT. Because it can be the same as the scaffold overhang, the sequence can be changed to GAAT to prevent the plasmid from recircularizing in the absence of the guide, thereby enhancing cloning efficiency.
[0601] Table 27. Overhang sequences for guide insertion
[0602] carrier Overhang A Overhang B pMGA-1, pMGB-1, pMGC-1, pMGD-1 GAAT GTTT pMGA-2, pMGB-2, pMGC-2, pMGD-2 TAAT GTTT pMGA-11, pMGB-11, pMGC-11, pMGD-11 TATT GTTT
[0603] The BbsI site can be GAAGAC (forward, 5'->3' orientation) and GTCTTC (reverse, 5'->3' orientation). The Ccdb negative selection marker allows selection of vectors with inserted guide RNA instead of ccdb by transformation of ccdb-sensitive E. coli strains (e.g., DH5α). The sequence of Ccdb (in bold), including the promoter and terminator sequences, is as follows:
[0604] gccggatccagtgctaacatggtctagaaggaggtcagctatgcagtttaaggtttacacctataaaagagagagccgttatcgtctgtttgtggatgtacagagtgatattattgacacgcccgggcgacggatggtgatccccctggccagtgcacgtctgctgtcagataaagtctcccgt gaactttacccagtggtgcatatcggggatgaaagctggcgcatgatgaccacccgatatggccagtgtgccagtctccgttatcggggaagaagtggctgatctcagccaccgcgaaaatgacatcaaaaacgccattaacctgatgttctggggaatataactgcagaggaggtaatcaa(SEQ IDNO:404).
[0605] The sequence of the guide RNA scaffold including the U6 terminator (TTTTTT) is as follows: GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAG TGGCACCGAGTCGGTGCTTTTTT (SEQ ID NO: 405).
[0606] The guides can be ordered as a pair of oligonucleotides with additional nucleotides at the 5' end to create an overhang, allowing their directional insertion into the entry vector immediately downstream of the U6 promoter and immediately upstream of the scaffold sequence (see Overhang A and B sequences in Table 27). Note that...
Claims
1. A composition comprising an engineered fungal cell, wherein the engineered fungal cell comprises a genetic modification containing an exogenous polynucleotide, wherein expression of the exogenous polynucleotide produces a polypeptide having indoleethylamine N-methyltransferase (INMT) activity; and wherein the engineered fungal cell comprises N,N-dimethyltryptamine (DMT).
2. The composition of claim 1, wherein the engineered fungal cell comprises a polypeptide having INMT activity.
3. The composition of claim 2, wherein the engineered fungal cell has increased expression of a PsiD gene compared to expression of the PsiD gene in a comparable wild-type fungal cell.
4. The composition of claim 1, wherein the engineered fungal cell comprises an increased amount of DMT compared to the amount of DMT in a comparable wild-type fungal cell.
5. The composition of claim 2, wherein the engineered fungal cell has an increased amount of DMT compared to the amount of DMT in a comparable wild-type fungal cell.
6. The composition of claim 4, wherein the increased amount of DMT is shown by: i) a different phenotype, ii) spectrophotometric analysis; iii) the amount of DMT per dry weight of fungi comprising the engineered fungal cells, or iv) a combination of any of these.
7. The composition of claim 4, wherein the engineered fungal cell has an increased amount of DMT and an increased amount of psilocybin, dephosphorylated psilocybin, or both compared to the amount of DMT and the amount of psilocybin, dephosphorylated psilocybin, or both in a comparable wild-type fungal cell.
8. The composition of claim 1, wherein the engineered fungal cell is from the phylum Basidiomycota.
9. The composition of claim 8, wherein the engineered fungal cell is from the genus Psilocybe.
10. The composition of claim 1, wherein the exogenous polynucleotide comprises a human INMT (HsINMT) gene.
11. The composition of claim 1, wherein the exogenous polynucleotide comprises a zebrafish INMT (ZfINMT) gene.
12. The composition of claim 1, wherein the engineered fungal cell has reduced expression of a PsiH gene, a PsiH2 gene, or both, compared to expression of the PsiH gene, the PsiH2 gene, or both in a comparable wild-type fungal cell.
13. The composition of claim 3, wherein the engineered fungal cell is from the phylum Basidiomycota.
14. The composition of claim 13, wherein the engineered fungal cell is from the genus Psilocybin.
15. The composition of claim 3, wherein the exogenous polynucleotide comprises a human INMT (HsINMT) gene.
16. The composition of claim 3, wherein the exogenous polynucleotide comprises a zebrafish INMT (ZfINMT) gene.
17. The composition of claim 3, wherein the engineered fungal cell has reduced expression of a PsiH gene, a PsiH2 gene, or both, compared to expression of the PsiH gene, the PsiH2 gene, or both in a comparable wild-type fungal cell.
18. The composition of claim 1, wherein the engineered fungal cell further comprises increased expression of a polynucleotide encoding a polypeptide having aromatic amino acid decarboxylase (AAAD) activity.
19. The composition of claim 18, wherein the engineered fungal cell comprises an increased amount of DMT compared to the amount of DMT in a comparable wild-type fungal cell.
20. The composition of claim 19, wherein the increased amount of DMT is shown by: i) a different phenotype, ii) spectrophotometric analysis; iii) the amount of DMT per dry weight of fungi comprising the engineered fungal cells, or iv) a combination of any of these.
21. The composition of claim 19, wherein the engineered fungal cell has an increased amount of DMT and an increased amount of psilocybin, dephosphorylated psilocybin, or both compared to the amount of DMT and the amount of psilocybin, dephosphorylated psilocybin, or both in a comparable wild-type fungal cell.
22. The composition of claim 18, wherein the engineered fungal cell is from the phylum Basidiomycota.
23. The composition of claim 22, wherein the engineered fungal cell is from the genus Psilocybin.
24. The composition of claim 17, wherein the exogenous polynucleotide comprises a human INMT (HsINMT) gene.
25. The composition of claim 17, wherein the exogenous polynucleotide comprises a zebrafish INMT (ZfINMT) gene.
26. The composition of claim 18, wherein the engineered fungal cell has reduced expression of a PsiH gene, a PsiH2 gene, or both.
27. The composition of claim 2, wherein the engineered fungal cell has increased expression of an AAAD gene.
28. The composition of claim 1 or claim 18, wherein the increased expression is measured by a method comprising reverse transcriptase-polymerase chain reaction (RT-PCR).
29. The composition of claim 1, wherein the exogenous polynucleotide comprises an INMT gene, and the INMT gene is an optimized INMT gene of Psilocybe cubensis.
30. The composition of claim 18, wherein the exogenous polynucleotide comprises a polynucleotide sequence at least 95% identical to SEQ ID NO:
92.
31. The composition of any one of claims 1-30, wherein the engineered fungal cell further comprises an increased amount of N,N-dimethyltryptophan (DMTP) compared to a comparable wild-type fungal cell.
32. The composition of any one of claims 1-31, wherein the engineered fungal cell comprises a reduced amount of the second alkaloid as compared to the amount of the second alkaloid in a comparable wild-type fungal cell.
33. The composition of any one of claims 1-31, wherein the engineered fungal cell comprises an amount of the second alkaloid comparable to the amount of the second alkaloid in a comparable wild-type fungal cell.
34. The composition of any one of claims 32-33, wherein the second alkaloid is psilocybin.
35. A composition comprising an engineered fungal cell comprising a first genetic modification, wherein the first genetic modification results in increased expression of INMT or AAAD, or a combination of both, and wherein the engineered fungal cell comprises modulated expression of a PsiD compared to a comparable wild-type fungal cell.
36. The composition of claim 35, wherein the engineered fungal cell has an increased number of PsiD gene copies compared to a comparable wild-type fungal cell.
37. The composition of claim 35, wherein the first genetic modification comprises modification of a promoter operably linked to the PsiD gene.
38. The composition of claim 35, wherein the first genetic modification comprises a genetic modification that induces a frameshift in the PsiD gene such that a protein expressed by the PsiD gene comprising the genetic modification has reduced function when the PsiD gene is transcribed and translated.
39. The composition of claim 38, wherein the first genetic modification comprises excision of the PsiD gene.
40. The composition of claim 39, wherein the excision is CRISPR-mediated excision.
41. The composition of claim 35, wherein the engineered fungal cell further comprises a second genetic modification comprising a first exogenous polynucleotide comprising a hygromycin resistance gene.
42. The composition of claim 41, wherein the first exogenous polynucleotide is stably incorporated into the genome of the engineered fungal cell.
43. The composition of claim 41, wherein the first exogenous polynucleotide is not stably incorporated into the genome of the engineered fungal cell.
44. The composition of claim 42, wherein the first exogenous polynucleotide is contained in a plasmid present in the engineered fungal cell.
45. The composition of claim 43, wherein the first exogenous polynucleotide is operably linked to a promoter.
46. The composition of claim 45, wherein the promoter is a 35S promoter.
47. The composition of claim 45, wherein the first exogenous polynucleotide is operably linked to the promoter.
48. The composition of claim 47, wherein the promoter is a 35S promoter.
49. The composition of claim 35, wherein the second genetic modification comprises a second exogenous polynucleotide, wherein the second exogenous polynucleotide comprises an INMT gene.
50. The composition of claim 35, wherein the engineered fungal cell comprises an increased amount of alkaloids compared to a comparable wild-type fungal cell.
51. The composition of claim 50, wherein the alkaloid is N,N-dimethyltryptamine (DMT).
52. The composition of claim 50, wherein the increased amount of alkaloid is determined spectrophotometrically.
53. The composition of claim 35, wherein the engineered fungal cell comprises an increased amount of alkaloids compared to a comparable wild-type fungal cell.
54. The composition of claim 53, wherein the alkaloid is N,N-dimethyltryptamine (DMT).
55. The composition of claim 53, wherein the increased amount of alkaloid is determined spectrophotometrically.
56. The composition of claim 49, wherein the second exogenous polynucleotide is the INMT gene.
57. The composition of claim 56, wherein the INMT gene is a human INMT (HsINMT) gene.
58. The composition of claim 57, wherein the engineered fungal cell comprises an increased amount of alkaloids compared to a comparable wild-type fungal cell.
59. The composition of claim 58, wherein the alkaloid is N,N-dimethyltryptamine (DMT).
60. The composition of claim 57, wherein the increased amount of alkaloid is determined spectrophotometrically.
61. A composition according to any preceding claim, wherein the engineered fungus belongs to the phylum Basidiomycota.
62. The composition of any preceding claim, wherein the composition, the engineered fungal cell, or both further comprises a monoamine oxidase inhibitor.
63. The composition of any one of claims 35-62, wherein the engineered fungal cell is contained in a fungus or a portion thereof.
64. A composition comprising an engineered fungal cell comprising a first genetic modification and a second genetic modification, wherein the first genetic modification results in reduced expression of a PsiD gene product; and the second genetic modification results in increased expression of a protein encoded by a hygromycin resistance gene.
65. The composition of claim 64, wherein the first genetic modification comprises modification of a promoter operably linked to the PsiD gene.
66. The composition of claim 64, wherein the first genetic modification comprises a genetic modification that induces a frameshift in the PsiD gene such that when the PsiD gene is transcribed and translated, the protein expressed by the PsiD gene comprising the genetic modification has reduced or no function compared to a protein expressed by a comparable PsiD gene not comprising the genetic modification.
67. The composition of claim 64, wherein the first genetic modification comprises excision of the PsiD gene.
68. The composition of claim 67, wherein the excision is CRISPR-mediated excision.
69. The composition of claim 64, wherein the second genetic modification comprises a first exogenous polynucleotide comprising a hygromycin resistance gene.
70. The composition of claim 69, wherein the first exogenous polynucleotide is stably incorporated into the genome of the engineered fungal cell.
71. The composition of claim 69, wherein the first exogenous polynucleotide is not stably incorporated into the genome of the engineered fungal cell.
72. The composition of claim 70, wherein the first exogenous polynucleotide is contained in a plasmid present in the engineered fungal cell.
73. The composition of claim 70, wherein the first exogenous polynucleotide is operably linked to a promoter.
74. The composition of claim 73, wherein the promoter is a 35S promoter.
75. The composition of claim 71, wherein the first exogenous polynucleotide is operably linked to a promoter.
76. The composition of claim 75, wherein the promoter is a 35S promoter.
77. The composition of claim 70, wherein the engineered fungal cell further comprises a second exogenous polynucleotide comprising an INMT gene.
78. The composition of claim 77, wherein the engineered fungal cell comprises an increased amount of alkaloids compared to a comparable wild-type fungal cell.
79. The composition of claim 78, wherein the alkaloid is N,N-dimethyltryptamine (DMT).
80. The composition of claim 78, wherein the increased amount of alkaloid is determined spectrophotometrically.
81. The composition of claim 71, wherein the engineered fungal cell further comprises a second exogenous polynucleotide comprising an INMT gene.
82. The composition of claim 81, wherein the engineered fungal cell comprises an increased amount of alkaloids compared to a comparable wild-type fungal cell.
83. The composition of claim 82, wherein the alkaloid is N,N-dimethyltryptamine (DMT).
84. The composition of claim 82, wherein the increased amount of alkaloid is determined spectrophotometrically.
85. The composition of claim 72, wherein the engineered fungal cell further comprises a second exogenous polynucleotide comprising an INMT gene.
86. The composition of claim 85, wherein the engineered fungal cell comprises an increased amount of alkaloids compared to a comparable wild-type fungal cell.
87. The composition of claim 86, wherein the alkaloid is N,N-dimethyltryptamine (DMT).
88. The composition of claim 86, wherein the increased amount of alkaloid is determined spectrophotometrically.
89. The composition of claim 85, wherein the INMT gene is a human INMT (HsINMT) gene.
90. The composition of claim 89, wherein the engineered fungal cell comprises an increased amount of alkaloids compared to a comparable wild-type fungal cell.
91. The composition of claim 90, wherein the alkaloid is N,N-dimethyltryptamine (DMT).
92. The composition of claim 90, wherein the increased amount of alkaloid is determined spectrophotometrically.
93. A composition according to any preceding claim, wherein the engineered fungus belongs to the phylum Basidiomycota.
94. The composition of any preceding claim, wherein the composition, the engineered fungal cell, or both further comprises a monoamine oxidase inhibitor.
95. The composition of any one of claims 64-94, wherein the engineered fungal cell is contained in a fungus or a portion thereof.
96. A composition, wherein the composition comprises: An engineered fungal cell, wherein the engineered fungal cell comprises a modification, wherein the modification provides for a reduction in expression of psilocybin phosphatase in the engineered fungal cell compared to a comparable fungal cell without the modification.
97. The composition of claim 96, wherein the engineered fungal cell is from the genus Psilocybin.
98. The composition of claim 96, wherein the modification comprises a deletion or insertion of nucleotides in a nucleic acid sequence encoding psilocybin phosphatase.
99. The composition of claim 98, wherein the nucleic acid sequence comprises at least a portion of one of SEQ ID NOs: 15-16.
100. The composition of claim 96, wherein the modification comprises a deletion or insertion of nucleotides in a promoter or enhancer of a gene encoding psilocybin phosphatase.
101. The composition of claim 96, wherein the modification comprises an exogenous nucleic acid incorporated into the engineered fungal cell, and wherein the exogenous nucleic acid encodes a gene product that, when expressed, inhibits or eliminates expression of psilocybin phosphatase in the engineered fungal cell.
102. The composition of claim 101, wherein the gene product comprises a siRNA or shRNA, wherein the siRNA or shRNA comprises a nucleic acid sequence complementary to an mRNA encoding a psilocybin phosphatase.
103. The composition of claim 102, wherein the siRNA or shRNA comprises a sequence complementary to at least a portion of any one of SEQ ID NOs: 15-16.
104. The composition of claim 96, wherein the modification reduces expression of psilocybin phosphatase by at least 50% compared to a comparable fungal cell without the modification.
105. The composition of claim 96, wherein the modification results in reduced expression of dephosphorylated psilocybin in the engineered fungal cell compared to a comparable fungal cell without the modification.
106. The composition of claim 96, wherein the modification results in increased expression of psilocybin in the engineered fungal cell compared to a comparable fungal cell without the modification.
107. The composition of claim 96, wherein the engineered fungal cell further comprises a second modification that results in at least one of: increased tryptophan decarboxylation, increased tryptamine 4-hydroxylation, increased serotonin O-phosphorylation, or increased psilocybin production via sequential N-methylation, compared to a comparable fungal cell without the second modification.
108. The composition of claim 96, wherein the engineered fungal cell further comprises a second modification that results in increased expression of a gene product compared to a comparable fungal cell without the second modification, wherein the gene product is encoded by a gene selected from the group consisting of: PsiD, PsiM, PsiH, PsiH2, PsiK, and PsiR.
109. The composition of claim 108, wherein the second modification comprises an exogenous nucleic acid incorporated into the engineered fungal cell, wherein the exogenous nucleic acid comprises a sequence at least 95% identical to any one of SEQ ID NOs: 1-19 or 90.
110. The composition of claim 108, wherein expression of the gene product in the engineered fungal cell is at least 6-fold higher than expression in a comparable fungal cell without the second modification.
111. The composition of claim 109, wherein the exogenous nucleic acid comprises a gene promoter located upstream of one of PsiD, PsiM, PsiH, PsiK, or PsiR, wherein the gene promoter is any one of a 35S promoter, a GDP promoter, or a CcDED1 promoter.
112. The composition of any one of claims 96-111, wherein the modification is accomplished by contacting the fungal cell with a gene editing system.
113. The composition of claim 112, wherein the gene editing system comprises a guide polynucleotide.
114. The composition of claim 18, wherein the guide polynucleotide is bound to a gene comprising any one of SEQ ID NOs: 29-87.
115. The composition of claim 96, wherein the fungal cell is a fungal protoplast.
116. The composition of claim 112, wherein the gene editing system comprises one of: a Cas endonuclease, Agrobacterium-mediated insertion of exogenous nucleic acids, a TALE-nuclease, a transposon-based nuclease, a zinc finger nuclease, a mega-nuclease, a mega-TAL, or a DNA-guided nuclease.
117. The composition of claim 96, wherein the composition is in the form of an aerosol, powder, gel, semi-gel, liquid or solid.
118. The composition of claim 96, wherein the modification provides for elimination of expression.
119. A pharmaceutical composition comprising the engineered fungal cell or extract thereof from any one of claims 96-118.
120. The pharmaceutical composition of claim 119, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier.
121. The pharmaceutical composition of claim 119 or 120, wherein the pharmaceutical composition is formulated for topical, oral, inhalation or enteric delivery.
122. The pharmaceutical composition of any one of claims 119-121, wherein the pharmaceutical composition comprises an effective amount of the engineered fungal cell or an extract thereof for treating a health condition.
123. The pharmaceutical composition of any one of claims 119-122, wherein the composition is formulated such that an effective amount of the composition for treating the health condition can be delivered in a single dose.
124. A nutritional composition comprising an extract of the engineered fungal cell of any one of claims 96-111.
125. A supplement comprising an extract of the engineered fungal cell of any one of claims 96-118.
126. A food supplement comprising an extract of the engineered fungal cell of any one of claims 96-118.
127. A method of treatment, wherein the method comprises administering a composition or extract thereof from any one of claims 96-118 to a subject diagnosed with a health condition.
128. The method of claim 127, wherein the health condition comprises one of depression, anxiety, post-traumatic stress, addiction, or psychological distress including cancer-related psychological distress.
129. A composition comprising: An engineered fungal cell comprising: A genetic modification, wherein the genetic modification results in at least a 6-fold increase in expression of mRNA encoding L-tryptophan decarboxylase in the engineered fungal cell compared to a comparable fungal cell without the genetic modification, Wherein the fungal cell is from the phylum Basidiomycota.
130. The composition of claim 129, wherein the fungal cells comprise mycelium.
131. according to the composition described in claim 129, wherein said genetic modification comprises the exogenous nucleic acid that is integrated into said engineered fungal cell, wherein said exogenous nucleic acid comprises one or more genes, and at least one of said one or more genes encodes L-tryptophan decarboxylase.
132. The composition of claim 131, wherein at least one of the one or more genes comprises a sequence at least 95% identical to SEQ ID NO:
90.
133. The composition of claim 131, wherein the exogenous nucleic acid comprises a promoter located upstream of the one or more genes, wherein the promoter comprises one of a 35S promoter, a GPD promoter, or a CcDED1 promoter.
134. The composition of claim 131, wherein the exogenous nucleic acid comprises a gene selected from Table 2.
135. The composition of claim 131, wherein the exogenous nucleic acid comprises a sequence at least 95% identical to SEQ ID NO:
90.
136. The composition of claim 131, wherein the exogenous nucleic acid sequence is integrated into the chromosome of the engineered fungal cell using a gene editing system.
137. A composition according to claim 136, wherein the gene editing system comprises a guide polynucleotide capable of binding to a sequence comprising any one of SEQ ID NOs: 29-87.
138. The composition of claim 136, wherein the exogenous nucleic acid is integrated into the chromosome at a region involved in regulating psilocybin synthesis.
139. The composition of claim 129, wherein the engineered fungal cell comprises a phenotype that is visually different from a comparable fungal cell that does not contain the genetic modification, wherein the phenotype comprises a blue color.
140. The composition of claim 129, wherein the engineered fungal cells reflect light having a wavelength between about 450 nanometers and 500 nanometers.
141. The composition of claim 129, wherein the genetic modification results in increased expression of psilocybin in the fungal cell compared to a comparable fungal cell without the genetic modification.
142. The composition of claim 129, wherein the engineered fungal cell further comprises a second modification that results in one of: increased tryptamine 4-hydroxylation, increased serotonin O-phosphorylation, increased psilocybin production via sequential N-methylation, or decreased psilocybin dephosphorylation, compared to a comparable fungal cell without the second modification.
143. The composition of claim 129, wherein the engineered fungal cell further comprises a second modification that results in increased expression of a gene product compared to a comparable fungal cell without the second modification, wherein the gene product is involved in psilocybin synthesis and is encoded by any one of PsiM, PsiH, PsiH2, PsiK, or PsiR.
144. The composition of claim 143, wherein the gene product is upregulated at least 6-fold compared to a comparable fungal cell without the second modification.
145. The composition of claim 129, wherein the genetic modification is accomplished by contacting the fungal cell with a gene editing system.
146. The composition of claim 145, wherein the gene editing system comprises a guide polynucleotide.
147. The composition of claim 145, wherein the guide polynucleotide is bound to a gene comprising any one of SEQ ID NOs: 29-87.
148. The composition of claim 145, wherein the gene editing system comprises any one of: a Cas endonuclease, Agrobacterium-mediated insertion of exogenous nucleic acids, a TALE-nuclease, a transposon-based nuclease, a zinc finger nuclease, a mega-nuclease, a mega-TAL, or a DNA-guided nuclease.
149. The composition of claim 129, wherein the composition is in the form of an aerosol, powder, gel, semi-gel, liquid or solid.
150. A pharmaceutical composition comprising the engineered fungal cell or an extract thereof from any one of claims 129-144.
151. The pharmaceutical composition of claim 150, wherein the pharmaceutical composition is formulated such that an effective amount of the composition for treating a health condition can be delivered to a subject in need thereof in a single dose.
152. The pharmaceutical composition of claim 151, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier.
153. The pharmaceutical composition of claim 150 or 151, wherein the pharmaceutical composition is formulated for topical, oral, inhalation or enteric delivery.
154. The pharmaceutical composition of any one of claims 151-153, wherein the health condition comprises one of depression, anxiety, post-traumatic stress, addiction, or psychological distress including cancer-related psychological distress.
155. A nutritional composition comprising an extract of the engineered fungal cell of any one of claims 129-144.
156. A supplement comprising an extract of the engineered fungal cell of any one of claims 129-144.
157. A food supplement comprising an extract of the engineered fungal cell of any one of claims 129-144.
158. A composition comprising: An engineered fungal cell comprising: a first genetic modification that results in increased expression of L-tryptophan decarboxylase in the engineered fungal cell compared to a comparable fungal cell without the first genetic modification; and and a second genetic modification that results in reduced expression of psilocybin phosphatase in the engineered fungal cell compared to a comparable fungal cell without the second genetic modification.
159. The composition of claim 158, wherein the fungal cell is from Psilocybin or Stropharia cubensis.
160. The composition of claim 158, wherein the first genetic modification comprises an exogenous nucleic acid incorporated into the engineered fungal cell, wherein the exogenous nucleic acid encodes an L-tryptophan decarboxylase.
161. The composition of claim 160, wherein the exogenous nucleic acid comprises a sequence at least 95% identical to SEQ ID NO:
90.
162. The composition of claim 160, wherein the exogenous nucleic acid further comprises a sequence that serves as a gene promoter, wherein the gene promoter comprises any one of a 35S promoter, a GPD promoter, or a CcDED1 promoter.
163. The composition of claim 160, wherein the exogenous nucleic acid comprises one or more copies of a gene selected from Table 2.
164. The composition of claim 158, wherein the second genetic modification comprises a deletion of at least a portion of an endogenous nucleic acid sequence encoding psilocybin phosphatase.
165. The composition of claim 164, wherein the endogenous nucleic acid sequence comprises a sequence at least 95% identical to SEQ ID NO:
90.
166. The composition of claim 158, wherein the second genetic modification comprises an insertion / deletion within a promoter or enhancer of a gene encoding psilocybin phosphatase.
167. The composition of claim 158, wherein the second genetic modification comprises inserting an exogenous nucleic acid sequence into the engineered fungal cell, wherein the exogenous nucleic acid sequence encodes a gene product that, when expressed, inhibits or eliminates expression of mRNA encoding psilocybin phosphatase.
168. The composition of claim 158, wherein the first genetic modification results in at least a 6-fold increase in expression of L-tryptophan decarboxylase in the engineered fungal cell compared to a comparable fungal cell not containing the first genetic modification.
169. The composition of claim 158, wherein the second genetic modification inhibits expression of psilocybin phosphatase by at least 50% compared to a comparable fungal cell without the second genetic modification.
170. The composition of claim 158, wherein the second genetic modification results in reduced expression of dephosphorylated psilocybin in the engineered fungal cell compared to a comparable fungal cell without the second genetic modification.
171. The composition of claim 158, wherein the fungal cell further comprises an exogenous nucleic acid sequence encoding a gene, wherein the gene is one of PsiM, PsiH, PsiH2, PsiK, or PsiR.
172. The composition of claim 171, wherein the gene is upregulated at least 6-fold in the engineered fungal cell compared to a comparable fungal cell without the exogenous nucleic acid sequence.
173. The composition of claim 158, wherein the composition is in the form of an aerosol, powder, gel, semi-gel, liquid or solid.
174. The composition of claim 158, wherein the first genetic modification or the second genetic modification is accomplished by contacting a fungal cell with a gene editing system.
175. The composition of claim 174, wherein the gene editing system comprises one of: a Cas endonuclease, a TALE-nuclease, Agrobacterium-mediated insertion of exogenous nucleic acids, a transposon-based nuclease, a zinc finger nuclease, a mega-nuclease, a mega-TAL, or a DNA-guided nuclease.
176. A pharmaceutical composition comprising the engineered fungal cell or extract thereof according to any one of claims 158-175.
177. The pharmaceutical composition of claim 176, wherein the composition is formulated such that an effective amount of the composition for treating a health condition can be delivered to a subject in need thereof in a single dose.
178. The pharmaceutical composition of claim 177, wherein the health condition comprises any of depression, anxiety, post-traumatic stress, addiction, or psychological distress including cancer-related psychological distress.
179. A nutritional composition comprising an extract of the engineered fungal cell of any one of claims 158-172.
180. A supplement comprising an extract of the engineered fungal cell of any one of claims 158-172.
181. A food supplement comprising an extract of the engineered fungal cell of any one of claims 158-172.
182. An engineered fungus comprising: A genetic modification that results in increased expression of an L-tryptophan decarboxylase such that the engineered fungus, or a portion thereof, changes from a first color to a second color when exposed to air, wherein the second color is visually different from the color of a corresponding portion of a comparable fungus without the genetic modification when equally exposed to air.
183. The engineered fungus of claim 182, wherein the second color reflects light having a wavelength between about 450 nanometers and 500 nanometers.
184. The engineered fungus of claim 182, wherein the genetic modification comprises an exogenous nucleic acid encoding one or more genes.
185. The engineered fungus of claim 184, wherein the one or more genes include one encoding L-tryptophan decarboxylase.
186. The engineered fungus of claim 184, wherein the one or more genes are located downstream of a gene promoter on an exogenous nucleic acid, wherein the gene promoter is one of a 35S promoter, a GPD promoter, or a CcDED1 promoter.
187. The engineered fungus of claim 184, wherein the exogenous nucleic acid comprises SEQ ID NO:
90.
188. The engineered fungus of claim 184, wherein the exogenous nucleic acid is incorporated into the engineered fungus using a vector.
189. The engineered fungus of claim 188, wherein the vector is selected from the group consisting of pGWB5, pGHGWY, and pGHGWY.
190. The engineered fungus of claim 182, wherein the engineered fungus comprises a concentration of psilocybin that is at least 10% higher than the concentration of psilocybin in a comparable fungus without the genetic modification.
191. The engineered fungus of claim 182, wherein the fungus is selected from the group consisting of Psilocybe, Conocybe, Gymnopilus, Panaeolus, Pluteus, and Stropharia.
192. The engineered fungus of claim 184, wherein the one or more transgenes are selected from the group consisting of: (i) PsiD, (ii) PsiD and PsiK, (iii) PsiD, PsiK, PsiM, and (iv) PsiD, PsiK, PsiM, PsiH.
193. The engineered fungus of claim 182, wherein the genetic modification results in a 6-fold increase in expression of L-tryptophan decarboxylase compared to a comparable fungus without the genetic modification.
194. The engineered fungus of claim 182, wherein the fungus further comprises a second modification that results in at least one of: increased tryptophan decarboxylation, increased tryptamine 4-hydroxylation, increased serotonin O-phosphorylation, increased psilocybin production via sequential N-methylation, or decreased psilocybin dephosphorylation, compared to a comparable fungus without the second modification.
195. The engineered fungus of claim 182, wherein the engineered fungus comprises a second modification that results in increased expression of a gene selected from PsiD, PsiM, PsiH, PsiK, or PsiR, compared to a comparable fungus without the second modification.
196. The engineered fungus of claim 195, wherein the second modification comprises an exogenous nucleic acid incorporated into the engineered fungus, wherein the exogenous nucleic acid comprises a sequence at least 95% identical to one of SEQ ID NOs: 1-19 or 90.
197. The engineered fungus of claim 195, wherein the gene is upregulated at least 6-fold compared to a comparable fungus without the second modification.
198. A pharmaceutical composition comprising the engineered fungus or an extract of the engineered fungus as described in any one of claims 182-197.
199. The pharmaceutical composition of claim 198, wherein the composition comprises an effective amount of the engineered fungus or an extract of the engineered fungus for treating a health condition.
200. The pharmaceutical composition of claim 200, wherein the composition is formulated such that an effective amount of the composition for treating the health condition can be delivered in a single dose.
201. A nutritional composition comprising an extract of the engineered fungus of any one of claims 182-197.
202. A food supplement comprising an extract of the engineered fungus of any one of claims 182-197.
203. The engineered fungus of any one of claims 182-197, wherein the modification is accomplished by contacting a fungal cell with a gene editing system and growing the fungal cell into a fungus.
204. A composition according to claim 203, wherein the gene editing system comprises any one of the following: Cas endonuclease, TALE-nuclease, transposon-based nuclease, Agrobacterium-mediated insertion of exogenous nucleic acid, zinc finger nuclease, mega nuclease, mega-TAL or DNA-guided nuclease.
205. A method of treatment, wherein the method comprises administering the engineered fungus or an extract of the engineered fungus of any one of claims 182-197 to a subject diagnosed with a health condition.
206. The method of claim 205, wherein the health condition comprises one of depression, anxiety, post-traumatic stress, addiction, or psychological distress including cancer-related psychological distress.
207. A method comprising: introducing an exogenous nucleic acid encoding an L-tryptophan decarboxylase into a fungal cell; growing the fungal cells into a mycelial mass; and L-tryptophan decarboxylase is expressed in the mycelial mass, wherein the presence of the exogenous nucleic acid results in an increased expression level of the L-tryptophan decarboxylase in the mycelial mass compared to a comparable wild-type mycelial mass.
208. The method of claim 207, wherein the fungal cell is a fungal protoplast.
209. The method of claim 207, wherein the fungal cell is from the phylum Basidiomycota.
210. The method of claim 207, wherein the exogenous nucleic acid comprises a sequence at least 95% identical to SEQ ID NO:
90.
211. The method of claim 207, wherein expression of L-tryptophan decarboxylase causes the mycelial mass to comprise a phenotype that is visually different from a phenotype of a comparable mycelial mass lacking the genetic modification, wherein the phenotype comprises a blue color.
212. The method of claim 207, wherein the mycelium mass reflects light at wavelengths between 450 nanometers and 500 nanometers.
213. The method of claim 207, wherein expression of L-tryptophan decarboxylase from the exogenous nucleic acid results in increased production of psilocybin in the mycelial mass compared to a comparable mycelial mass without the exogenous nucleic acid.
214. The method of claim 207, wherein the mycelial mass comprises a psilocybin concentration greater than 1.7% as measured by dry mycelial mass.
215. The method of claim 207, wherein the exogenous nucleic acid is introduced into the mycelial mass via Agrobacterium.
216. The method of claim 207, wherein the exogenous nucleic acid is introduced into the mycelial mass using a vector, wherein the vector comprises one of pGWB5, pGHGWY or pGHGWY.
217. The method of claim 207, wherein the expression of L-tryptophan decarboxylase is accomplished using a gene promoter located on the exogenous nucleic acid, wherein the gene promoter comprises one of a 35S promoter, a GPD promoter, or a CcDED1 promoter.
218. The method of claim 207, wherein the mycelial mass comprises a second genetic modification that inhibits or eliminates expression of psilocybin phosphatase in the mycelial mass compared to a comparable mycelial mass without the modification.
219. The method of claim 218, wherein the second genetic modification is achieved by deleting at least a portion of an endogenous nucleic acid sequence involved in expressing psilocybin phosphatase.
220. The method of claim 218, wherein the second genetic modification inhibits expression of psilocybin phosphatase by at least 50% compared to a comparable mycelial mass without the second genetic modification.
221. The method of claim 218, wherein the second genetic modification results in reduced expression of dephosphorylated psilocybin in the mycelial mass compared to a comparable mycelial mass without the second genetic modification.
222. The method of claim 207, further comprising expressing an exogenous nucleic acid sequence in the mycelial mass, wherein the exogenous nucleic acid sequence encodes a gene, wherein the gene is selected from PsiD, PsiM, PsiH, PsiK or PsiR.
223. The method of claim 222, wherein the gene is upregulated at least 10-fold in the mycelial mass compared to a comparable fungus without the exogenous nucleic acid sequence.
224. A method comprising: Obtaining a genetically modified organism comprising a genetic modification, wherein the genetic modification results in increased expression of L-tryptophan decarboxylase compared to a comparable organism without the genetic modification; A change from a first color to a second color is detected from tissue of the genetically modified organism when the tissue is exposed to air, wherein the second color is visually different from tissue of a comparable organism when equally exposed to air.
225. The method of claim 224, wherein the change to the second color occurs within 5 minutes.
226. The method of claim 224, wherein the second color comprises reflected light having a wavelength between 450 nanometers and 500 nanometers.
227. The method of claim 224, wherein obtaining the genetically modified organism comprises introducing an exogenous nucleic acid encoding an L-tryptophan decarboxylase into a cell of a fungus, thereby producing the genetically modified organism.
228. The method of claim 224, wherein the exogenous nucleic acid comprises a sequence at least 95% identical to SEQ ID NO:
90.
229. The method of claim 224, wherein the second color is produced due to oxidation of the tissue.
230. The method of claim 224, further comprising assessing a concentration of psilocybin in the genetically modified organism based on the second color, wherein the presence of the second color indicates a psilocybin concentration greater than 1.7% dry weight.
231. The method of claim 224, wherein the genetic modification results in at least a 6-fold increase in expression of psilocybin compared to a comparable organism without the genetic modification.
232. The method of claim 224, wherein the genetically modified organism comprises a fungus from the phylum Basidiomycota.
233. The method of claim 224, further comprising expressing an exogenous nucleic acid sequence in the genetically modified organism, wherein the exogenous nucleic acid sequence encodes a gene, wherein the gene is selected from PsiD, PsiM, PsiH, PsiK or PsiR.
234. The method of claim 233, wherein the gene is upregulated at least 6-fold in the genetically modified organism compared to a comparable fungus without the exogenous nucleic acid sequence.
235. A pharmaceutical composition comprising the composition of any preceding claim and a pharmaceutically acceptable: diluent, carrier, excipient or any combination thereof.
236. The pharmaceutical composition of claim 235, which is in unit dosage form.
237. A kit comprising the pharmaceutical composition of any preceding claim and a container.
238. A method of treating a health condition, disease or disorder in a subject, the method comprising administering to the subject a composition or pharmaceutical composition of any preceding claim in an amount effective to treat the health condition, disease or disorder in the subject.
239. The method of claim 238, wherein the subject is a subject in need thereof.
240. The method of claim 238 or claim 239, wherein the health condition, disease or disorder is a neurological health condition, disease or disorder.
241. The method of claim 240, wherein the neurological health condition, disease, or disorder is depression, anxiety, post-traumatic stress disorder (PTSD), a mental disorder, a trauma, a mood disorder, a speech disorder, a neurodegenerative disease, psychological distress, compulsion, obsessive compulsive disorder, obsessive compulsive disorder, expression of symptoms in neurodivergent individuals, cancer-related psychological distress, addiction, headache, multiple sclerosis, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, a phobia, dementia, a fear, an eating disorder, an ischemic event, or any combination thereof.
242. The composition or pharmaceutical composition of any preceding claim, further comprising a monoamine oxidase (MAO) inhibitor, a MAO A inhibitor or a MAO B inhibitor.
243. The method of any preceding claim, further comprising administering a monoamine oxidase (MAO) inhibitor, a MAO A inhibitor, or a MAO B inhibitor simultaneously or sequentially with the composition or pharmaceutical composition.
